{"companyName": "MyoKardia, Inc.", "reportNo1": {"reportType": "SC 13G/A", "url": "https://www.sec.gov/Archives/edgar/data/1364742/000021545718005613/us62857m1053_050318.txt", "dateOfReport": "2018-05-08", "htmlOfReport": " <document>\n<type>SC 13G/A\n<sequence>1\n<filename>us62857m1053_050318.txt\n<text>\nus62857m1053_050318.txt\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nSCHEDULE 13G\n\nUnder the Securities Exchange Act of 1934\n\n(Amendment No:  1)\n\nMYOKARDIA INC\n--------------------------------------------------------\n(Name of Issuer)\n\n Common Stock\n--------------------------------------------------------\n(Title of Class of Securities)\n\n62857M105\n--------------------------------------------------------\n(CUSIP Number)\n\nApril 30, 2018\n--------------------------------------------------------\n(Date of Event Which Requires Filing of this Statement)\n\nCheck the appropriate box to designate the rule pursuant to\nwhich this Schedule is filed:\n\n[X] Rule 13d-1(b)\n[ ] Rule 13d-1(c)\n[ ] Rule 13d-1(d)\n\n\n*The remainder of this cover page shall be filled out\nfor a reporting person's initial filing on this form with\nrespect to the subject class of securities, and for any\nsubsequent amendment containing information which\nwould alter the disclosures provided in a prior cover page.\n\nThe information required in the remainder of this cover\npage shall not be deemed to be \"filed\" for the purpose\nof Section 18 of the Securities Exchange Act of 1934\n(\"Act\") or otherwise subject to the liabilities of that\nsection of the Act but shall be subject to all other\nprovisions of the Act (however, see the Notes).\n\n\n\n\n\nCUSIP No.   62857M105\n\n(1)Names of reporting persons. BlackRock, Inc.\n\n\n(2) Check the appropriate box if a member of a group\n(a) [  ]\n(b) [X]\n\n\n(3) SEC use only\n\n(4) Citizenship or place of organization\n\nDelaware\n\nNumber of shares beneficially owned by each reporting person with:\n\n(5) Sole voting power\n\n 1742696\n\n(6) Shared voting power\n\n 0\n\n(7) Sole dispositive power\n\n 1786093\n\n(8) Shared dispositive power\n\n 0\n\n(9) Aggregate amount beneficially owned by each reporting person\n\n 1786093\n\n(10) Check if the aggregate amount in Row (9) excludes certain shares\n\n(11) Percent of class represented by amount in Row 9\n\n 4.97%\n\n(12) Type of reporting person\n\nHC\n\n\n\n\n\nItem 1.\n\nItem 1(a) Name of issuer:\n-----------------------------------------------------------------------\n\nMYOKARDIA INC\n\nItem 1(b) Address of issuer's principal executive offices:\n-----------------------------------------------------------------------\n\n333 ALLERTON AVENUE\nSOUTH SAN FRANCISCO CA 94080\n\n\nItem 2.\n\n\n2(a) Name of person filing:\n----------------------------------------------------------------------\nBlackRock, Inc.\n\n\n2(b) Address or principal business office or, if none, residence:\n-----------------------------------------------------------------------\nBlackRock Inc.\n55 East 52nd Street\nNew York, NY 10055\n\n\n2(c) Citizenship:\n--------------------------------------------------------------------\n See Item 4 of Cover Page\n\n\n2(d) Title of class of securities:\n-------------------------------------------------------------------\n\n Common Stock\n\n2(e) CUSIP No.:\nSee Cover Page\n\n\n\n\n\n\nItem 3.\n\nIf this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c),\ncheck whether the person filing is a:\n[ ] Broker or dealer registered under Section 15 of the Act;\n[ ] Bank as defined in Section 3(a)(6) of the Act;\n[ ] Insurance company as defined in Section 3(a)(19) of the Act;\n[ ] Investment company registered under Section 8 of the\nInvestment Company Act of 1940;\n[ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);\n[ ] An employee benefit plan or endowment fund in accordance with\n            Rule 13d-1(b)(1)(ii)(F);\n[X] A parent holding company or control person in accordance with\n            Rule 13d-1(b)(1)(ii)(G);\n[ ] A savings associations as defined in Section 3(b) of the Federal\n            Deposit Insurance Act (12 U.S.C. 1813);\n[ ] A church plan that is excluded from the definition of an\n            investment company under section 3(c)(14) of the Investment Company\n            Act of 1940;\n[ ] A non-U.S. institution in accordance with\n            Rule 240.13d-1(b)(1)(ii)(J);\n[ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing\n            as a non-U.S. institution in accordance with\n            Rule 240.13d-1(b)(1)(ii)(J), please specify the type of\n            institution:\n\n\nItem 4. Ownership\n\nProvide the following information regarding the aggregate number\nand percentage of the class of securities of the issuer identified in Item 1.\n\n\nAmount beneficially owned:\n\n  1786093\n\nPercent of class\n\n4.97%\n\nNumber of shares as to which such person has:\n\nSole power to vote or to direct the vote\n\n  1742696\n\nShared power to vote or to direct the vote\n\n  0\n\nSole power to dispose or to direct the disposition of\n\n  1786093\n\nShared power to dispose or to direct the disposition of\n\n  0\n\n\n\n\n\n\n\n\n\nItem 5.\n\nOwnership of 5 Percent or Less of a Class. If this statement is being\nfiled to report the fact that as of the date hereof the reporting person\nhas ceased to be the beneficial owner of more than 5 percent of the\nclass of securities, check the following [ X ].\n\n\nItem 6. Ownership of More than 5 Percent on Behalf of Another Person\n\n  [ N/A ]\n\nItem 7. Identification and Classification of the Subsidiary Which\nAcquired the Security Being Reported on by the Parent Holding\nCompany or Control Person.\n\n\nSee Exhibit A\n\n\nItem 8. Identification and Classification of Members of the Group\n\n\nIf a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J),\nso indicate under Item 3(j) and attach an exhibit stating the identity\nand Item 3 classification of each member of the group. If a group\nhas filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d),\nattach an exhibit stating the identity of each member of the group.\n\n\nItem 9. Notice of Dissolution of Group\n\nNotice of dissolution of a group may be furnished as an exhibit\nstating the date of the dissolution and that all further filings with\nrespect to transactions in the security reported on will be filed,\nif required, by members of the group, in their individual capacity.\n\nSee Item 5.\n\nItem 10. Certifications\nBy signing below I certify that, to the best of my knowledge and\nbelief, the securities referred to above were acquired and are\nheld in the ordinary course of business and were not acquired\nand are not held for the purpose of or with the effect of changing\nor influencing the control of the issuer of the securities and were\nnot acquired and are not held in connection with or as a participant\nin any transaction having that purpose or effect.\n\nSignature.\n\nAfter reasonable inquiry and to the best of my knowledge and\nbelief, I certify that the information set forth in this statement\nis true, complete and correct.\n\n\nDated: May 3, 2018\nBlackRock, Inc.\n\n\nSignature:  Spencer Fleming\n\n\n\n-------------------------------------------\n\nName/Title Attorney-In-Fact\n\n\nThe original statement shall be signed by each person on whose\nbehalf the statement is filed or his authorized representative.\nIf the statement is signed on behalf of a person by his authorized\nrepresentative other than an executive officer or general partner\nof the filing person, evidence of the representative's authority to\nsign on behalf of such person shall be filed with the statement,\nprovided, however, that a power of attorney for this purpose\nwhich is already on file with the Commission may be incorporated\nby reference. The name and any title of each person who\nsigns the statement shall be typed or printed beneath his signature.\n\n\n\nAttention: Intentional misstatements or omissions of fact constitute\nFederal criminal violations (see 18 U.S.C. 1001).\n\n\nExhibit A\n\n\n\nSubsidiary\n\n\n BlackRock Advisors, LLC\n BlackRock Investment Management (UK) Limited\n BlackRock Asset Management Canada Limited\n BlackRock Fund Advisors\n BlackRock Asset Management Ireland Limited\n BlackRock Institutional Trust Company, National Association\n BlackRock Financial Management, Inc.\n BlackRock Asset Management Schweiz AG\n BlackRock Investment Management, LLC\n\n\n\n*Entity beneficially owns 5% or greater of the outstanding\nshares of the security class being reported on this\nSchedule 13G.\nExhibit B\n\n\nPOWER OF ATTORNEY\n\nThe undersigned, BLACKROCK, INC., a corporation duly organized\nunder the laws of the State of Delaware, United States (the\n\"Company\"), does hereby make, constitute and appoint each of\nMatthew Mallow, Chris Meade, Howard Surloff, Dan Waltcher,\nGeorgina Fogo, Charles Park, Enda McMahon, Carsten Otto,\nCon Tzatzakis, Karen Clark, Andrew Crain, Herm Howerton,\nDavid Maryles, Daniel Ronnen, John Stelley, John Ardley,\nMaureen Gleeson and Spencer Fleming acting severally, as its\ntrue and lawful attorneys-in-fact, for the purpose of, from time to\ntime, executing in its name and on its behalf, whether the\nCompany is acting individually or as representative of others,\nany and all documents, certificates, instruments, statements, other\nfilings and amendments to the foregoing (collectively, \"documents\")\ndetermined by such person to be necessary or appropriate to\ncomply with ownership or control-person reporting requirements\nimposed by any United States or non-United States governmental\nor regulatory authority, Including without limitation Forms 3, 4, 5,\n13D, 13F, 13G and 13H and any amendments to any of the\nForegoing as may be required to be filed with the Securities and\nExchange Commission, and delivering, furnishing or filing any\nsuch documents with the appropriate governmental, regulatory\nauthority or other person, and giving and granting to each such\nattorney-in-fact power and authority to act in the premises as fully\nand to all intents and purposes as the Company might or could\ndo if personally present by one of its authorized signatories,\nhereby ratifying and confirming all that said attorney-in-fact shall\nlawfully do or cause to be done by virtue hereof. Any such\ndetermination by an attorney-in-fact named herein shall be\nconclusively evidenced by such person's execution, delivery,\nfurnishing or filing of the applicable document.\n\nThis power of attorney shall expressly revoke the power of attorney\ndated 1st day of October, 2015 in respect of the subject matter hereof,\nshall be valid from the date hereof and shall remain in full force and\neffect until either revoked in writing by the Company, or, in respect of\nany attorney-in-fact named herein, until such person ceases to be an\nemployee of the Company or one of its affiliates.\n\nIN WITNESS WHEREOF, the undersigned has caused this power of\nattorney to be executed as of this 8th day of December, 2015.\n\nBLACKROCK, INC.\n\n\nBy:_ /s/ Chris Jones\nName: Chris Jones\nTitle: Chief Investment Officer\n\n\n\n</text>\n</filename></sequence></type></document>\n"}, "reportNo2": {"reportType": "Form 4", "url": ["https://www.sec.gov/Archives/edgar/data/1413822/000089924318011725/xslF345X03/doc4.xml", "2018-05-07"], "content": {"nameOfOwner": "GIANAKAKOS ANASTASIOS", "position": "President and CEO", "dateOfReport": "2018-05-04", "transaction1": {"classOfStock": "Common Stock", "transactionDate": "2018-04-30", "amount": "578", "price": "33.15", "buyOrSell": "A", "ownershipAfterTransaction": "74968"}, "transaction2": {"classOfStock": "Common Stock", "transactionDate": "2018-05-04", "amount": "2981", "price": "1.5068", "buyOrSell": "A", "ownershipAfterTransaction": "77949"}, "transaction3": {"classOfStock": "Common Stock", "transactionDate": "2018-05-04", "amount": "1700", "price": "47.2735", "buyOrSell": "D", "ownershipAfterTransaction": "76249"}, "transaction4": {"classOfStock": "Common Stock", "transactionDate": "2018-05-04", "amount": "1300", "price": "47.95", "buyOrSell": "D", "ownershipAfterTransaction": "74949"}, "transaction5": {"classOfStock": "Stock Option (Right to Buy)", "transactionDate": "2018-05-04", "amount": "2981", "price": "0.00", "buyOrSell": "D", "ownershipAfterTransaction": "123254"}}, "dateOfReport": "2018-05-04", "htmlOfReport": " <!DOCTYPE html PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<title>SEC FORM \n            4</title>\n<style type=\"text/css\">\n              .FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;}\n              .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;}\n              .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;}\n              .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FormNumText {font-size: small; font-weight: bold; font-family: arial, helvetica, sans-serif;}\n              .FormAttention {font-size: medium; font-weight: bold; font-family: helvetica;}\n              .FormText {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTextR {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .FormTextC {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .FormEMText {font-size: medium; font-style: italic; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .FormULText {font-size: medium; text-decoration: underline; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .SmallFormTextR {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .SmallFormTextC {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .MedSmallFormText {font-size: x-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle1 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; border-top: black thick solid;}\n              .FormTitle2 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle3 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; padding-top: 2em; padding-bottom: 1em;}\n              .SectionTitle {font-size: small; text-align: left; font-family: arial, helvetica, sans-serif; \n              \t\tfont-weight: bold; border-top: gray thin solid; border-bottom: gray thin solid;}\n              .FormName {font-size: large; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .CheckBox {text-align: center; width: 5px; cell-spacing: 0; padding: 0 3 0 3; border-width: thin; border-style: solid;  border-color: black:}\n              body {background: white;}\n      </style>\n</head>\n<body>SEC Form 4 \n   <table border=\"0\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" class=\"FormName\" colspan=\"2\" valign=\"top\" width=\"20%\">FORM 4</td>\n<td align=\"center\" rowspan=\"2\" valign=\"middle\" width=\"60%\">\n<span class=\"FormTitle\">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span><br/><span class=\"MedSmallFormText\">Washington, D.C. 20549</span><br/><br/><span class=\"FormTitle\">STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP</span><br/><br/><span class=\"MedSmallFormText\">Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934</span><br/><span class=\"MedSmallFormText\">or Section 30(h) of the Investment Company Act of 1940</span>\n</td>\n<td align=\"center\" rowspan=\"2\" valign=\"top\" width=\"20%\"><table border=\"1\" summary=\"OMB Approval Status Box\" width=\"100%\">\n<tr><td class=\"FormTextC\">OMB APPROVAL</td></tr>\n<tr><td><table border=\"0\" summary=\"OMB Interior Box\" width=\"100%\">\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">OMB Number:</td>\n<td class=\"SmallFormTextR\">3235-0287</td>\n</tr>\n<tr><td class=\"SmallFormText\" colspan=\"4\">Estimated average burden</td></tr>\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">hours per response:</td>\n<td class=\"SmallFormTextR\">0.5</td>\n</tr>\n</table></td></tr>\n</table></td>\n</tr>\n<tr valign=\"middle\">\n<td><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tr><td>\u00a0\u00a0</td></tr></table></td>\n<td class=\"SmallFormText\">Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. \n         <i>See</i>\n\n         Instruction 1(b).</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td rowspan=\"3\" valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">1. Name and Address of Reporting Person<sup>*</sup></span><table border=\"0\" width=\"100%\"><tr><td><a ANASTASIOS</a></td></tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(Last)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(First)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Middle)</td>\n</tr></table>\n<table border=\"0\" width=\"100%\">\n<tr><td><span class=\"FormData\">C/O MYOKARDIA, INC.</span></td></tr>\n<tr><td><span class=\"FormData\">333 ALLERTON AVENUE</span></td></tr>\n</table>\n<hr width=\"98%\"/>\n<span class=\"MedSmallFormText\">(Street)</span><table border=\"0\" width=\"100%\"><tr>\n<td width=\"33%\"><span class=\"FormData\">SOUTH SAN FRANCISCO</span></td>\n<td width=\"33%\"><span class=\"FormData\">CA</span></td>\n<td width=\"33%\"><span class=\"FormData\">94080</span></td>\n</tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(City)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(State)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Zip)</td>\n</tr></table>\n</td>\n<td valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">2. Issuer Name <b>and</b> Ticker or Trading Symbol\n      </span><br/><a Inc</a>\n     [ <span class=\"FormData\">MYOK</span> ]\n   </td>\n<td rowspan=\"2\" valign=\"top\">\n<span class=\"MedSmallFormText\">5. Relationship of Reporting Person(s) to Issuer\n      </span><br/><span class=\"MedSmallFormText\">(Check all applicable)</span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"35%\">Director</td>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">10% Owner</td>\n</tr>\n<tr>\n<td align=\"center\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\">Officer (give title below)</td>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Other (specify below)</td>\n</tr>\n<tr><td align=\"center\" colspan=\"4\"><span class=\"FormData\">President and CEO</span></td></tr>\n</table>\n</td>\n</tr>\n<tr><td valign=\"top\">\n<span class=\"MedSmallFormText\">3. Date of Earliest Transaction\n         (Month/Day/Year)</span><br/><span class=\"FormData\">05/04/2018</span>\n</td></tr>\n<tr>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">4. If Amendment, Date of Original Filed\n         (Month/Day/Year)</span><br/>\n</td>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">6. Individual or Joint/Group Filing (Check Applicable Line)\n      </span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by One Reporting Person</td>\n</tr>\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by More than One Reporting Person</td>\n</tr>\n</table>\n</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"11\" valign=\"top\" width=\"100%\"><b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b></th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"36%\">1. Title of Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">2. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"7%\">3. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"3\" valign=\"top\" width=\"19%\">4. Securities Acquired (A) or Disposed Of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"11%\">5. \n      Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"9%\">6. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"8%\">7. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"3%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"8%\">Amount</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"5%\">(A) or (D)</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"6%\">Price</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">04/30/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">A</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">V</span></td>\n<td align=\"center\"><span class=\"FormData\">578</span></td>\n<td align=\"center\"><span class=\"FormData\">A</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">33.15</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">74,968</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">05/04/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">M</span><span class=\"FootnoteData\"><sup>(2)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">2,981</span></td>\n<td align=\"center\"><span class=\"FormData\">A</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">1.5068</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">77,949</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">05/04/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">S</span><span class=\"FootnoteData\"><sup>(2)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">1,700</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">47.2735</span><span class=\"FootnoteData\"><sup>(3)</sup></span>\n</td>\n<td align=\"center\"><span class=\"FormData\">76,249</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">05/04/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">S</span><span class=\"FootnoteData\"><sup>(2)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">1,300</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">47.95</span><span class=\"FootnoteData\"><sup>(4)</sup></span>\n</td>\n<td align=\"center\"><span class=\"FormData\">74,949</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">85,973</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Reporting Person's Trust 2</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">500,000</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Reporting Person's Trust 3</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">12,200</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Trust 1</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">12,200</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Trust 2</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">12,200</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Trust 3</span></td>\n</tr>\n</tbody>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"16\" valign=\"top\" width=\"100%\">\n<b>Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned</b><br/><b>(e.g., puts, calls, warrants, options, convertible securities)</b>\n</th></tr>\n<tr>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"13%\">1. Title of Derivative Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2. Conversion or Exercise Price of Derivative Security\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">4. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"10%\">5. \n      Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">6. Date Exercisable and Expiration Date \n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"17%\">7. Title and Amount of Securities Underlying Derivative Security (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">8. Price of Derivative Security (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">9. \n      Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">10. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"7%\">11. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(A)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(D)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">Date Exercisable</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Expiration Date</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"10%\">Title</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"7%\">Amount or Number of Shares</th>\n</tr>\n</thead>\n<tbody><tr>\n<td align=\"left\"><span class=\"SmallFormData\">Stock Option (Right to Buy)</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">1.5068</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">05/04/2018</span></td>\n<td align=\"center\"><span class=\"SmallFormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">M</span><span class=\"FootnoteData\"><sup>(2)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"SmallFormData\">2,981</span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">\n</span><span class=\"FootnoteData\"><sup>(5)</sup></span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">06/03/2025</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">2,981</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">0.00</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">123,254</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">D</span></td>\n<td align=\"left\"></td>\n</tr></tbody>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr><td class=\"MedSmallFormText\"><b>Explanation of Responses:</b></td></tr>\n<tr><td class=\"FootnoteData\">1. Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan.</td></tr>\n<tr><td class=\"FootnoteData\">2. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.</td></tr>\n<tr><td class=\"FootnoteData\">3. Represents the weighted average sale price of the shares sold ranging from $46.80 to $47.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.</td></tr>\n<tr><td class=\"FootnoteData\">4. Represents the weighted average sale price of the shares sold ranging from $47.85 to $48.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.</td></tr>\n<tr><td class=\"FootnoteData\">5. 25% of the shares subject to the option vested and became exercisable on June 4, 2016, and the remaining shares subject to this option vest and become exercisable in monthly installments through June 4, 2019, subject to the Reporting Person's continuous service to the Issuer.</td></tr>\n<tr><td class=\"FormText\"><b>Remarks:</b></td></tr>\n<tr><td class=\"FootnoteData\"></td></tr>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr>\n<td width=\"60%\"></td>\n<td width=\"20%\"><u><span class=\"FormData\">/s/Tassos Gianakakos</span></u></td>\n<td width=\"20%\"><u><span class=\"FormData\">05/07/2018</span></u></td>\n</tr>\n<tr>\n<td></td>\n<td class=\"MedSmallFormText\">** Signature of Reporting Person</td>\n<td class=\"MedSmallFormText\">Date</td>\n</tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">* If the form is filed by more than one reporting person, \n                  <i>see</i>\n\n                  Instruction \n                  4\n\n                  (b)(v).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">** Intentional misstatements or omissions of facts constitute Federal Criminal Violations \n                  <i>See</i>\n\n                  18 U.S.C. 1001 and 15 U.S.C. 78ff(a).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \n                  <i>see</i>\n\n                  Instruction 6 for procedure.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\"><b>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.</b></td></tr>\n</table>\n</body>\n</html>\n"}, "reportNo3": {"reportType": "Form 4", "url": ["https://www.sec.gov/Archives/edgar/data/1552451/000089924318011663/xslF345X03/doc4.xml", "2018-05-07"], "content": {"nameOfOwner": "Bauer Jake", "position": "Chief Business Officer", "dateOfReport": "2018-05-03", "transaction1": {"classOfStock": "Common Stock", "transactionDate": "2018-04-30", "amount": "348", "price": "33.15", "buyOrSell": "A", "ownershipAfterTransaction": "62125"}, "transaction2": {"classOfStock": "Common Stock", "transactionDate": "2018-05-03", "amount": "1519", "price": "48.95", "buyOrSell": "D", "ownershipAfterTransaction": "60606"}}, "dateOfReport": "2018-05-03", "htmlOfReport": " <!DOCTYPE html PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<title>SEC FORM \n            4</title>\n<style type=\"text/css\">\n              .FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;}\n              .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;}\n              .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;}\n              .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FormNumText {font-size: small; font-weight: bold; font-family: arial, helvetica, sans-serif;}\n              .FormAttention {font-size: medium; font-weight: bold; font-family: helvetica;}\n              .FormText {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTextR {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .FormTextC {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .FormEMText {font-size: medium; font-style: italic; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .FormULText {font-size: medium; text-decoration: underline; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .SmallFormTextR {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .SmallFormTextC {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .MedSmallFormText {font-size: x-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle1 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; border-top: black thick solid;}\n              .FormTitle2 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle3 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; padding-top: 2em; padding-bottom: 1em;}\n              .SectionTitle {font-size: small; text-align: left; font-family: arial, helvetica, sans-serif; \n              \t\tfont-weight: bold; border-top: gray thin solid; border-bottom: gray thin solid;}\n              .FormName {font-size: large; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .CheckBox {text-align: center; width: 5px; cell-spacing: 0; padding: 0 3 0 3; border-width: thin; border-style: solid;  border-color: black:}\n              body {background: white;}\n      </style>\n</head>\n<body>SEC Form 4 \n   <table border=\"0\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" class=\"FormName\" colspan=\"2\" valign=\"top\" width=\"20%\">FORM 4</td>\n<td align=\"center\" rowspan=\"2\" valign=\"middle\" width=\"60%\">\n<span class=\"FormTitle\">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span><br/><span class=\"MedSmallFormText\">Washington, D.C. 20549</span><br/><br/><span class=\"FormTitle\">STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP</span><br/><br/><span class=\"MedSmallFormText\">Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934</span><br/><span class=\"MedSmallFormText\">or Section 30(h) of the Investment Company Act of 1940</span>\n</td>\n<td align=\"center\" rowspan=\"2\" valign=\"top\" width=\"20%\"><table border=\"1\" summary=\"OMB Approval Status Box\" width=\"100%\">\n<tr><td class=\"FormTextC\">OMB APPROVAL</td></tr>\n<tr><td><table border=\"0\" summary=\"OMB Interior Box\" width=\"100%\">\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">OMB Number:</td>\n<td class=\"SmallFormTextR\">3235-0287</td>\n</tr>\n<tr><td class=\"SmallFormText\" colspan=\"4\">Estimated average burden</td></tr>\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">hours per response:</td>\n<td class=\"SmallFormTextR\">0.5</td>\n</tr>\n</table></td></tr>\n</table></td>\n</tr>\n<tr valign=\"middle\">\n<td><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tr><td>\u00a0\u00a0</td></tr></table></td>\n<td class=\"SmallFormText\">Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. \n         <i>See</i>\n\n         Instruction 1(b).</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td rowspan=\"3\" valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">1. Name and Address of Reporting Person<sup>*</sup></span><table border=\"0\" width=\"100%\"><tr><td><a Jake</a></td></tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(Last)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(First)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Middle)</td>\n</tr></table>\n<table border=\"0\" width=\"100%\">\n<tr><td><span class=\"FormData\">C/O MYOKARDIA, INC.</span></td></tr>\n<tr><td><span class=\"FormData\">333 ALLERTON AVENUE</span></td></tr>\n</table>\n<hr width=\"98%\"/>\n<span class=\"MedSmallFormText\">(Street)</span><table border=\"0\" width=\"100%\"><tr>\n<td width=\"33%\"><span class=\"FormData\">SOUTH SAN FRANCISCO</span></td>\n<td width=\"33%\"><span class=\"FormData\">CA</span></td>\n<td width=\"33%\"><span class=\"FormData\">94080</span></td>\n</tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(City)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(State)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Zip)</td>\n</tr></table>\n</td>\n<td valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">2. Issuer Name <b>and</b> Ticker or Trading Symbol\n      </span><br/><a Inc</a>\n     [ <span class=\"FormData\">MYOK</span> ]\n   </td>\n<td rowspan=\"2\" valign=\"top\">\n<span class=\"MedSmallFormText\">5. Relationship of Reporting Person(s) to Issuer\n      </span><br/><span class=\"MedSmallFormText\">(Check all applicable)</span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">Director</td>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">10% Owner</td>\n</tr>\n<tr>\n<td align=\"center\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\">Officer (give title below)</td>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Other (specify below)</td>\n</tr>\n<tr><td align=\"center\" colspan=\"4\"><span class=\"FormData\">Chief Business Officer</span></td></tr>\n</table>\n</td>\n</tr>\n<tr><td valign=\"top\">\n<span class=\"MedSmallFormText\">3. Date of Earliest Transaction\n         (Month/Day/Year)</span><br/><span class=\"FormData\">05/03/2018</span>\n</td></tr>\n<tr>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">4. If Amendment, Date of Original Filed\n         (Month/Day/Year)</span><br/>\n</td>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">6. Individual or Joint/Group Filing (Check Applicable Line)\n      </span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by One Reporting Person</td>\n</tr>\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by More than One Reporting Person</td>\n</tr>\n</table>\n</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"11\" valign=\"top\" width=\"100%\"><b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b></th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"36%\">1. Title of Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">2. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"7%\">3. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"3\" valign=\"top\" width=\"19%\">4. Securities Acquired (A) or Disposed Of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"11%\">5. \n      Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"9%\">6. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"8%\">7. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"3%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"8%\">Amount</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"5%\">(A) or (D)</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"6%\">Price</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">04/30/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">A</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">V</span></td>\n<td align=\"center\"><span class=\"FormData\">348</span></td>\n<td align=\"center\"><span class=\"FormData\">A</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">33.15</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">62,125</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">05/03/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">S</span><span class=\"FootnoteData\"><sup>(2)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">1,519</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">48.95</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">60,606</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n</tbody>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\"><thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"16\" valign=\"top\" width=\"100%\">\n<b>Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned</b><br/><b>(e.g., puts, calls, warrants, options, convertible securities)</b>\n</th></tr>\n<tr>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"13%\">1. Title of Derivative Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2. Conversion or Exercise Price of Derivative Security\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">4. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"10%\">5. \n      Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">6. Date Exercisable and Expiration Date \n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"17%\">7. Title and Amount of Securities Underlying Derivative Security (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">8. Price of Derivative Security (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">9. \n      Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">10. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"7%\">11. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(A)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(D)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">Date Exercisable</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Expiration Date</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"10%\">Title</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"7%\">Amount or Number of Shares</th>\n</tr>\n</thead></table>\n<table border=\"0\" width=\"100%\">\n<tr><td class=\"MedSmallFormText\"><b>Explanation of Responses:</b></td></tr>\n<tr><td class=\"FootnoteData\">1. Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan.</td></tr>\n<tr><td class=\"FootnoteData\">2. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.</td></tr>\n<tr><td class=\"FormText\"><b>Remarks:</b></td></tr>\n<tr><td class=\"FootnoteData\"></td></tr>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr>\n<td width=\"60%\"></td>\n<td width=\"20%\"><u><span class=\"FormData\">/s/  Jake Bauer</span></u></td>\n<td width=\"20%\"><u><span class=\"FormData\">05/07/2018</span></u></td>\n</tr>\n<tr>\n<td></td>\n<td class=\"MedSmallFormText\">** Signature of Reporting Person</td>\n<td class=\"MedSmallFormText\">Date</td>\n</tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">* If the form is filed by more than one reporting person, \n                  <i>see</i>\n\n                  Instruction \n                  4\n\n                  (b)(v).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">** Intentional misstatements or omissions of facts constitute Federal Criminal Violations \n                  <i>See</i>\n\n                  18 U.S.C. 1001 and 15 U.S.C. 78ff(a).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \n                  <i>see</i>\n\n                  Instruction 6 for procedure.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\"><b>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.</b></td></tr>\n</table>\n</body>\n</html>\n"}, "reportNo4": {"reportType": "DEFA14A", "url": "https://www.sec.gov/Archives/edgar/data/1552451/000119312518118993/d572229ddefa14a.htm", "dateOfReport": "2018-04-17", "htmlOfReport": " <document>\n<type>DEFA14A\n<sequence>1\n<filename>d572229ddefa14a.htm\n<description>DEFINITIVE ADDITIONAL MATERIALS\n<text>\n<html><head>\n<title>Definitive Additional Materials</title>\n</head>\n<body bgcolor=\"WHITE\">\n<p style=\"line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000\">\u00a0</p>\n<p style=\"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000\">\u00a0</p> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b>UNITED STATES </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Washington, D.C. 20549 </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b>SCHEDULE 14A\n</b></p> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Proxy Statement Pursuant to Section 14(a) of the </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Securities Exchange Act of 1934 </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>(Amendment No. \u00a0\u00a0\u00a0\u00a0) </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Filed by the\nRegistrant\u00a0\u00a0\u2612\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Filed by a party other than the\nRegistrant\u00a0\u00a0\u2610</p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Check the appropriate box: </p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"4%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"95%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">\u2610</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">Preliminary Proxy Statement</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">\u2610</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"><b>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</b></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">\u2610</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">Definitive Proxy Statement</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">\u2612</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">Definitive Additional Materials</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">\u2610</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">Soliciting Material Pursuant to \u00a7240.14a-12</td></tr></table> <p align=\"center\" style=\"margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman\"><b>MyoKardia,\nInc. </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>(Name of Registrant as Specified In Its Charter) </b></p> <p style=\"font-size:18pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </b></p>\n<p style=\"margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Payment of Filing Fee (Check the appropriate box): </p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"4%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"4%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"90%\"></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"16\"></td>\n<td colspan=\"4\" height=\"16\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">\u2612</td>\n<td valign=\"bottom\">\u00a0</td>\n<td colspan=\"3\" valign=\"top\">No fee required.</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"16\"></td>\n<td colspan=\"4\" height=\"16\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">\u2610</td>\n<td valign=\"bottom\">\u00a0</td>\n<td colspan=\"3\" valign=\"top\">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"16\"></td>\n<td colspan=\"2\" height=\"16\"></td>\n<td colspan=\"2\" height=\"16\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">(1)</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Title of each class of securities to which transaction applies:</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">\u00a0\u00a0\u00a0\u00a0\u00a0</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">(2)</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Aggregate number of securities to which transaction applies:</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">\u00a0\u00a0\u00a0\u00a0\u00a0</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">(3)</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing\nfee is calculated and state how it was determined):</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">\u00a0\u00a0\u00a0\u00a0\u00a0</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">(4)</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Proposed maximum aggregate value of transaction:</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">\u00a0\u00a0\u00a0\u00a0\u00a0</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">(5)</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Total fee paid:</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">\u00a0\u00a0\u00a0\u00a0\u00a0</p></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"24\"></td>\n<td colspan=\"4\" height=\"24\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">\u2610</td>\n<td valign=\"bottom\">\u00a0</td>\n<td colspan=\"3\" valign=\"top\">Fee paid previously with preliminary materials.</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"24\"></td>\n<td colspan=\"4\" height=\"24\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">\u2610</td>\n<td valign=\"bottom\">\u00a0</td>\n<td colspan=\"3\" valign=\"top\">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement\nnumber, or the Form or Schedule and the date of its filing.</td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"24\"></td>\n<td colspan=\"2\" height=\"24\"></td>\n<td colspan=\"2\" height=\"24\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">(1)</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Amount previously paid:</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">\u00a0\u00a0\u00a0\u00a0\u00a0</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">(2)</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Form, Schedule or Registration Statement No.:</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">\u00a0\u00a0\u00a0\u00a0\u00a0</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">(3)</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Filing party:</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">\u00a0\u00a0\u00a0\u00a0\u00a0</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">(4)</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Date Filed:</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">\u00a0\u00a0\u00a0\u00a0\u00a0</p></td></tr>\n</table> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000\">\u00a0</p>\n<p style=\"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000\">\u00a0</p>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<div style=\"position:relative;float:left; width:57%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Dear Shareholders, </b></p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"29%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"70%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">\n<img alt=\"LOGO\" src=\"g572229g86d21.jpg\"/>\n</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">2017 was a great year for MyoKardia. We made much progress toward our goal of bringing new medicines to patients, most notably with our mavacamten data and commitment to move forward to a pivotal study. This has everything to do\nwith our dedicated employees and the inspiration we get every day from those affected by cardiomyopathies.</td></tr>\n</table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">MyoKardia is a values-driven company and we are proud to be focused on creating new therapies to address cardiovascular\ndiseases, which continue to claim more lives than all cancers combined, worldwide. We believe deep disease focus and expertise is essential to discovering and developing game-changing therapies for patients. And were seeing the advantages in this\nfocus from the concentration of talented individuals that work at MyoKardia, to the synergies across our pipeline that are generating evidence in the clinic that we\u0092re making a dent in addressing these challenging diseases. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We reported data from our Phase 2 <font style=\"white-space:nowrap\">PIONEER-HCM</font> clinical trial of mavacamten in patients with symptomatic, obstructive\nhypertrophic cardiomyopathy (oHCM) with encouraging results. We\u0092ve seen patients on mavacamten feeling better across both quantitative and qualitative measures, including the elimination of their left ventricular outflow tract (LVOT)\nobstruction \u0096 a predictor of longer-term clinical benefits, increased ability to exercise as measured by peak VO2, improved New York Heart Association (NYHA) classification, and relief from patients\u0092 number one symptom, shortness of\nbreath. These results have enabled us to design our upcoming Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> trial. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">During 2017, we also\nconducted our first clinical study of <font style=\"white-space:nowrap\">MYK-491</font> in healthy volunteers. <font style=\"white-space:nowrap\">MYK-491</font> is designed to address the underlying cause of certain forms of dilated cardiomyopathy (DCM)\n\u0096 a disease that is responsible for most heart transplants. In the Phase 1 trial, <font style=\"white-space:nowrap\">MYK-491</font> was generally well tolerated across the range of oral doses tested. We have since started a Phase 1b study of <font style=\"white-space:nowrap\">MYK-491</font> in DCM patients where we are looking to assess safety, tolerability as well as other important clinical measurements of <font style=\"white-space:nowrap\">MYK-491\u0092s</font> activity in DCM patients. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">2017\u0092s momentum has carried into 2018, which is shaping up to be a year of continued progress across our portfolio. In the first quarter of 2018, we\ninitiated the Phase 2 <font style=\"white-space:nowrap\">MAVERICK-HCM</font> clinical trial, which is designed to expand mavacamten\u0092s potential use to an additional subtype of HCM, <font style=\"white-space:nowrap\">non-obstructed</font> HCM\n(nHCM). Our planned pivotal Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> clinical trial is on track to start in the second quarter. Later this year, we anticipate data from our Phase 1b trial of\n<font style=\"white-space:nowrap\">MYK-491</font> in patients that will inform our future clinical development plans for that program. We\u0092re also planning on sharing more details of our emerging preclinical pipeline and innovative cardiovascular\ndisease research later in 2018. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Because of the deep dedication to our science and the hard work of our employees, we have the opportunity in 2018 to get\neven closer to achieving the mission that motivates us each and every day: to change the lives of patients suffering from serious cardiovascular disease. I thank our team for their commitment, drive and energy; our clinical investigators, the\npatients and their caregivers for their willingness to go on this journey with us; and you, our shareholders, for your ongoing support. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Tassos\nGianakakos </b></p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">CEO, MyoKardia\n</p></div><div style=\"position:relative;float:left; margin-left:3%; width:40%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt\">\n<p style=\"margin-top:0pt;margin-bottom:0pt\">\n<img alt=\"LOGO\" src=\"g572229dsp035.jpg\"/>\n</p></div><div style=\"clear:both; height:0pt; font-size:0pt\">\u00a0</div>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>A PRECISION MEDICINE ADVANTAGE </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">MyoKardia was founded to apply a precision medicine approach to the discovery and development of cardiovascular medicines. Leveraging our <font style=\"white-space:nowrap\">in-depth</font> understanding of disease biology, our drug candidates target distinct biomechanical defects associated with disease. As our therapeutic candidates progress into and through clinical trials, we have\nintegrated digital health and biomarkers to further enhance the information we gain about diagnosis and treatment monitoring. Our team uses the information obtained in the clinic on patient genetics, response to therapy and disease presentation to\nrefine our understanding of the patient populations most likely to benefit from our product candidates. </p>\n<p style=\"font-size:18pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><div style=\"position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>MAVACAMTEN </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Our lead program, mavacamten, is being developed to address the hypercontractility that underlies HCM. As a result of the excessive contractility of the HCM\nheart, the left ventricle becomes abnormally thick and fibrotic, which prevents the heart from being able to relax and fill properly, and in turn, blood flow is reduced even as the heart pumps harder. Mavacamten acts by inhibiting the excessive\nmyosin-actin cross-bridge formation that underlies HCM\u0092s characteristic hypercontractility, left ventricular hypertrophy and reduced ventricular compliance. </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Mavacamten is currently in development for both HCM subtypes. We are starting a Phase 3 pivotal trial of mavacamten for the potential treatment of patients\nwith symptomatic oHCM and recently initiated a Phase 2 clinical trial of mavacamten in patients with symptomatic, <font style=\"white-space:nowrap\">non-obstructive</font> HCM.\n</p></div><div style=\"position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><font style=\"white-space:nowrap\">MYK-491</font> </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><font style=\"white-space:nowrap\">MYK-491</font> is MyoKardia\u0092s second clinical-stage program and is intended to increase the contractility of the heart.\nIn DCM, the left ventricle is distended, thin, and overexpanded, leading to improper contraction and insufficient blood being pumped by the heart. DCM is a progressive disease. Once symptoms appear, patients typically decline steadily, experiencing\nshortness of breath, fatigue, swelling in their extremities, and irregular heartbeat. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><font style=\"white-space:nowrap\">MYK-491</font> is intended to\naddress the inadequate contraction of the heart by activating the myosin-actin cross-bridge formation. <font style=\"white-space:nowrap\">MYK-491</font> is an oral, small molecule, allosteric activator of myosin designed to restore cardiac output by\ntargeting the biomechanical defects underlying disease and improving cardiac contractility. <font style=\"white-space:nowrap\">MYK-491</font> is currently being studied in a Phase 1b single-ascending dose trial in DCM patients.\n</p></div><div style=\"position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>FURTHER RESEARCH </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Beyond HCM and DCM, we are researching genetic defects that result in cardiac muscle and functional abnormalities in order to generate precision therapies for\nthose diseases. By targeting the fundamental mechanisms underlying a given cardiovascular condition, we can identify the patients most likely to benefit and then begin to explore each candidate\u0092s potential applicability to broader heart failure\npopulations. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Our most advanced preclinical candidates target protein mutations in the sarcomere in order to increase contraction, decrease contraction,\nor regulate relaxation with exquisite precision to address distinct forms and subtypes of cardiomyopathy. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">We expect to file an investigational new drug\napplication for our next product candidate in the next 12 to 18 months. </p></div><div style=\"clear:both; height:0pt; font-size:0pt\">\u00a0</div>\n<p style=\"font-size:10pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>2018 MILESTONES </b></p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><div style=\"position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>MAVACAMTEN </b></p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"6\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"20\">\u0095</td>\n<td valign=\"top\" width=\"1\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Initiate patient dosing in the Phase 3 <font style=\"white-space:nowrap\">EXPLORER-HCM</font> clinical trial of mavacamten in the second quarter of 2018 </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"6\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"20\">\u0095</td>\n<td valign=\"top\" width=\"1\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Initiate patient dosing in the long- term <font style=\"white-space:nowrap\">EXPLORER-HCM</font> extension study before the end of 2018 </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td width=\"6\">\u00a0</td>\n<td align=\"left\" valign=\"top\" width=\"20\">\u0095</td>\n<td valign=\"top\" width=\"1\">\u00a0</td>\n<td align=\"left\" valign=\"top\">Begin open-label extension study for patients who participated in the Phase 2 <font style=\"white-space:nowrap\">PIONEER-HCM</font> clinical trial of mavacamten in the second quarter of 2018\n</td></tr></table></div><div style=\"position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b><font style=\"white-space:nowrap\">MYK-491</font> </b></p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"27\">\u0095</td>\n<td align=\"left\" valign=\"top\">Report data from the Phase 1b clinical trial of <font style=\"white-space:nowrap\">MYK-491</font> in DCM patients in the second half of 2018 </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"27\">\u0095</td>\n<td align=\"left\" valign=\"top\">Begin Phase 2 clinical trial of <font style=\"white-space:nowrap\">MYK-491</font> in DCM patients in the second half of 2018\n</td></tr></table></div><div style=\"position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt\">\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>FURTHER RESEARCH </b></p> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"27\">\u0095</td>\n<td align=\"left\" valign=\"top\">Discovery-stage pipeline update in the second half of 2018 </td></tr></table></div><div style=\"clear:both; height:0pt; font-size:0pt\">\u00a0</div>\n</p></p></body></html>\n</text>\n</description></filename></sequence></type></document>\n"}, "reportNo5": {"reportType": "DEF 14A", "url": "https://www.sec.gov/Archives/edgar/data/1552451/000156459018008282/myok-def14a_20180612.htm", "dateOfReport": "2018-04-17", "content": {"ownershipTableCode": "<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Beneficial Owner (1)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Number\u00a0of\u00a0Shares</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Beneficially\u00a0Owned</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Percentage</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">of Shares</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Beneficially</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Owned</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">5% or Greater Stockholders:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Entities affiliated with Wellington Management Company (1)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">280 Congress Street, Boston, MA 02110</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,130,761</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8.7</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Entities affiliated with Fidelity (2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">245 Summer Street, Boston, MA 02210</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,506,577</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">12.5</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Entities affiliated with Sanofi (3)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">54 Rue La Boetie, 75008 Paris (France)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,018,899</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11.2</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Entities affiliated with Blackrock, Inc. (4)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">55 East 52<sup style=\"font-size:85%; vertical-align:top\">nd</sup> Street, New York, NY 10055</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,920,651</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5.3</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Named Executive Officers and Directors:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">T. Anastasios Gianakakos (5)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">984,437</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2.7</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">June Lee, M.D.(6)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">52,408</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Robert McDowell(7)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">202,982</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mark Perry (8)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">60,570</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Sunil Agarwal (9)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">32,999</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mary B. Cranston (10)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">32,541</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Wendy L. Yarno (11)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">17,907</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Kimberly Popovits (12)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">16,499</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">David P. Meeker, M.D. (13)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">16,041</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">All directors and executive officers as a group (14 persons) (14)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,722,309</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4.7</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n</table>", "content": {"280 Congress Street, Boston, MA 02110": "8.7%", "245 Summer Street, Boston, MA 02210": "12.5%", "54 Rue La Boetie, 75008 Paris (France)": "11.2%", "55 East 52nd Street, New York, NY 10055": "5.3%", "T. Anastasios Gianakakos (5)": "2.7%", "All directors and executive officers as a group (14 persons) (14)": "4.7%"}}, "htmlOfReport": " <document>\n<type>DEF 14A\n<sequence>1\n<filename>myok-def14a_20180612.htm\n<description>DEF 14A\n<text>\n<!DOCTYPE HTML PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<title>\nmyok-def14a_20180612.htm\n</title>\n</head>\n<!-- NG Converter v4.0.8.21 -->\n<body>\n<p style=\"border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">UNITED STATES </p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">SECURITIES AND EXCHANGE COMMISSION </p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Washington, D.C. 20549 </p>\n<p style=\"margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">SCHEDULE 14A INFORMATION </p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Proxy Statement Pursuant to Section 14(a) of the </p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Securities Exchange Act of 1934 (Amendment No.\u00a0\u00a0\u00a0\u00a0) </p>\n<p style=\"margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:50%;\"></td>\n<td style=\"width:50%;\"></td>\n</tr>\n<tr>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Filed by the Registrant\u00a0<font style=\"font-family:MS Mincho;\">\u2612</font> </p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Filed by a party other than the Registrant\u00a0<font style=\"font-family:MS Mincho;\">\u2610</font></p></td>\n</tr>\n</table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Check the appropriate box: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS Mincho;font-size:10pt;\"><font style=\"font-family:Times New Roman;\">Preliminary Proxy Statement</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-family:MS Mincho;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-weight:bold;font-family:MS Mincho;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:MS Mincho;font-size:10pt;\"><font style=\"font-family:Times New Roman;\">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2612</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS Mincho;font-size:10pt;\"><font style=\"font-family:Times New Roman;\">Definitive Proxy Statement</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS Mincho;font-size:10pt;\"><font style=\"font-family:Times New Roman;\">Definitive Additional Materials</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:MS Mincho;font-size:10pt;\"><font style=\"font-family:Times New Roman;\">Soliciting Material Under \u00a7240.14a-12</font></p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">MyoKardia, Inc. </p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">(Name of Registrant as Specified In Its Charter) </p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Payment of Filing Fee (Check the appropriate box): </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2612</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">No fee required.</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Title of each class of securities to which transaction applies:</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Aggregate number of securities to which transaction applies:</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Proposed maximum aggregate value of transaction:</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total fee paid:</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Fee paid previously with preliminary materials.</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:MS Mincho;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2610</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Amount previously paid:</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Form, Schedule or Registration Statement No.:</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Filing party:</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Date Filed:</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU2\"></a><img alt=\"\" src=\"g2018041701195589114084.jpg\" style=\"width:255px;height:47px;\" title=\"\"/><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font></p>\n<p style=\"text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MyoKardia, Inc. </p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">333 Allerton Avenue </p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">South San Francisco, CA 94080 </p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">To Be Held On June\u00a012, 2018 </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Dear Stockholder: </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">You are cordially invited to attend the 2018 Annual Meeting of Stockholders of MyoKardia, Inc., a Delaware corporation (the \u201cCompany\u201d). The meeting will be held on Tuesday, June\u00a012, 2018 at 9 a.m. at the DoubleTree by Hilton San Francisco Airport North, 5000 Sierra Point Parkway, Brisbane, CA 94005, for the following purposes: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1.</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">To elect two (2) Class III directors, as nominated by the Board of Directors of the Company (the \u201cBoard of Directors\u201d), to hold office until the 2021 Annual Meeting of Stockholders or until their successors are duly elected and qualified. </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2.</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December\u00a031, 2018. </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3.</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.</p></td>\n</tr>\n</table></div>\n<p style=\"margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">These items of business are more fully described in the Proxy Statement accompanying this Notice. </p>\n<p style=\"margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Proposal 1 relates solely to the election of two (2) Class III directors nominated by the Board of Directors and does not include any other matters relating to the election of directors, including without limitation, the election of directors nominated by any stockholder of the Company. </p>\n<p style=\"margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Board of Directors has fixed the close of business on Friday, April\u00a013, 2018 as the record date for the determination of stockholders entitled to notice of, and to vote at, the Annual Meeting of Stockholders, or at any adjournments of the Annual Meeting of Stockholders. </p>\n<p style=\"margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In order to ensure your representation at the Annual Meeting of Stockholders, you are requested to submit your proxy over the Internet, by telephone or by signing and dating the enclosed proxy as promptly as possible and returning it in the enclosed envelope (to which no postage need be affixed if mailed in the United States). If you attend the Annual Meeting of Stockholders and file with the Secretary of the Company an instrument revoking your proxy or a duly executed proxy bearing a later date, your proxy will not be used. </p>\n<p style=\"margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">By Order of the Board of Directors </p>\n<p style=\"margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MyoKardia, Inc.</p>\n<p style=\"margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">/s/ Tassos Gianakakos </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Tassos Gianakakos </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">President and Chief Executive Officer</p>\n<p style=\"margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">South San Francisco, California </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">April 17, 2018 </p>\n<p style=\"margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Your vote is important, whether or not you expect to attend the Annual Meeting of Stockholders. You are urged to vote either via the Internet or telephone, or vote by mail by requesting a printed copy of the proxy card, as instructed in the Important Notice Regarding the Availability of Proxy Materials that you will receive in the mail. Voting promptly will help avoid the additional expense of further solicitation to assure a quorum at the meeting. </p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU3\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">TABLE OF CONTENTS</font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">PROXY STATEMENT</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1</p></td>\n</tr>\n<tr style=\"height:6pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">PROPOSAL 1\u2014ELECTION OF DIRECTORS</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4</p></td>\n</tr>\n<tr style=\"height:6pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">PROPOSAL 2\u2014RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">18</p></td>\n</tr>\n<tr style=\"height:6pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">EXECUTIVE OFFICERS</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">19</p></td>\n</tr>\n<tr style=\"height:6pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">COMPENSATION OF EXECUTIVE OFFICERS</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">21</p></td>\n</tr>\n<tr style=\"height:6pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">26</p></td>\n</tr>\n<tr style=\"height:6pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28</p></td>\n</tr>\n<tr style=\"height:6pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">30</p></td>\n</tr>\n<tr style=\"height:6pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">AUDIT COMMITTEE REPORT</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31</p></td>\n</tr>\n<tr style=\"height:6pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">HOUSEHOLDING OF PROXY MATERIALS</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">32</p></td>\n</tr>\n<tr style=\"height:6pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a style=\"text-decoration:none;\">OTHER MATTERS</font></a></p></td>\n<td style=\"width:1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">33</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU4\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">MYOKARDIA, INC. </font></p>\n<p style=\"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"PROXY_STATEMENT\"></a><a name=\"PROXY_STATEMENT\"></a>PROXY STATEMENT </p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">FOR THE 2018 ANNUAL MEETING OF STOCKHOLDERS </p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">June\u00a012, 2018 </p>\n<p style=\"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">INFORMATION CONCERNING SOLICITATION AND VOTING </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">General </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">This proxy statement (\u201cProxy Statement\u201d) is furnished in connection with the solicitation of proxies for use prior to or at the 2018 Annual Meeting of Stockholders (the \u201cAnnual Meeting\u201d) of MyoKardia, Inc. (the \u201cCompany\u201d), a Delaware corporation, to be held at <font style=\"letter-spacing:-0.1pt;\">9 a.m. </font>local time, on Tuesday, June\u00a012, 2018 and at any adjournments or postponements thereof for the following purposes: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">To elect two (2) Class III directors, as nominated by the Board of Directors, to hold office until the 2021 Annual Meeting of Stockholders or until their successors are duly elected and qualified; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.47%;text-indent:-5.24%;font-size:6pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December\u00a031, 2018; and</p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.47%;text-indent:-5.24%;font-size:6pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. </p></td></tr></table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Annual Meeting will be held at <font style=\"letter-spacing:-0.1pt;\">the </font>DoubleTree by Hilton San Francisco Airport North, 5000 Sierra Point Parkway, Brisbane, CA 94005.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Solicitation </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">This solicitation is made on behalf of the Board of Directors. We will bear the costs of preparing, mailing, online processing and other costs of the proxy solicitation made by our Board of Directors. Certain of our officers and employees may solicit the submission of proxies authorizing the voting of shares in accordance with the Board of Directors\u2019 recommendations. Such solicitations may be made by email, telephone, facsimile transmission or personal solicitation. No additional compensation will be paid to such officers, directors or regular employees for such services. We will reimburse banks, brokerage firms and other custodians, nominees and fiduciaries for reasonable out-of-pocket expenses incurred by them in sending proxy materials to stockholders. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Important Notice Regarding the Availability of Proxy Materials </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The proxy statement and the Company\u2019s 2017 Annual Report on Form 10-K (the \u201cAnnual Report\u201d) are available electronically at www.proxyvote.com. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Voting Rights and Outstanding Shares </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Only holders of record of our common stock as of the close of business on April\u00a013, 2018 are entitled to receive notice of, and to vote at, the Annual Meeting. Each holder of common stock will be entitled to one vote for each share held on all matters to be voted upon at the Annual Meeting. At the close of business on April\u00a013, 2018, there were 35,935,980 shares of common stock issued and outstanding. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">A quorum of stockholders is necessary to take action at the Annual Meeting. Stockholders representing a majority of the outstanding shares of our common stock as of the record date (present in person or represented by proxy) will constitute a quorum. We will appoint an inspector of elections for the meeting to determine whether or not a quorum is present and to tabulate votes cast by proxy or in person at the Annual Meeting. Abstentions, withheld votes and broker non-votes (which occur when a broker, bank or other nominee holding shares for a beneficial owner does not vote on a particular matter because such broker, bank or other nominee does not have discretionary authority to vote on that matter and has not received voting instructions from the beneficial owner) are counted as present for purposes of determining the presence of a quorum for the transaction of business at the Annual Meeting. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Votes Required for Each Proposal </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">To elect our directors and approve the other proposals being considered at the Annual Meeting, the voting requirements are as follows: </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:70%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Proposal</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Vote</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Required</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Discretionary</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Voting\u00a0Permitted?</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Election of Directors</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Plurality</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">No</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Ratification of PricewaterhouseCoopers LLP</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Majority</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Yes</p></td>\n</tr>\n</table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">\u201cDiscretionary Voting Permitted\u201d<font style=\"font-style:normal;\"> means that brokers will have discretionary voting authority with respect to shares held in street name for their clients, even if the broker does not receive voting instructions from their client. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">\u201cMajority\u201d<font style=\"font-style:normal;\"> means a majority of the votes properly cast for and against such matter. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">\u201cPlurality\u201d<font style=\"font-style:normal;\"> means a plurality of the votes properly cast on such matter. For the election of directors, the three nominees receiving the plurality of votes entitled to vote and cast will be elected as directors. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The vote required and method of calculation for the proposals to be considered at the Annual Meeting are as follows: </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Proposal One\u2014Election of Directors.<font style=\"font-style:normal;\"> If a quorum is present, the director nominees receiving the highest number of votes, in person or by proxy, will be elected as directors. You may vote \u201cFOR\u201d all nominees, \u201cWITHHOLD\u201d for all nominees, or \u201cWITHHOLD\u201d for any nominee by specifying the name of the nominee on your proxy card. Proposal One is </font><font style=\"text-decoration:underline;font-style:normal;\">not</font><font style=\"font-style:normal;\"> considered to be a discretionary item, so if you do not instruct your broker how to vote with respect to this proposal, your broker may not vote on this proposal, and those votes will be counted as broker \u201cnon-votes.\u201d Withheld votes and broker non-votes will have no effect on the outcome of the election of the directors. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Proposal Two\u2014Approval of the Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm.<font style=\"font-style:normal;\"> Approval of this proposal requires the affirmative vote of a majority of the votes properly cast for and against such matter. You may vote \u201cFOR,\u201d \u201cAGAINST\u201d or \u201cABSTAIN\u201d from voting on this proposal. If you abstain from voting on this matter, your shares will not be counted as \u201cvotes cast\u201d with respect to such matter, and the abstention will have no effect on the proposal. Proposal Two is considered to be a discretionary item, and your broker will be able to vote on this proposal even if it does not receive instructions from you. Accordingly, we do not anticipate that there will be any broker non-votes on this proposal; however, any broker non-votes will not be counted as \u201cvotes cast\u201d and will therefore have no effect on the proposal. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We request that you vote your shares by proxy following the methods as instructed by the notice: over the Internet, by telephone or by mail. If you choose to vote by mail, your shares will be voted in accordance with your voting instructions if the proxy card is received prior to or at the Annual Meeting. If you sign and return your proxy card but do not give voting instructions, your shares will be voted FOR (i)\u00a0the election of each of the Company\u2019s two (2) nominees as Class III directors; (ii)\u00a0the ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending December\u00a031, 2018;\u00a0\u00a0and (iii)\u00a0as the proxy holders deem advisable, in their discretion, on other matters that may properly come before the Annual Meeting. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Voting by Proxy Over the Internet or by Telephone </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Stockholders whose shares are registered in their own names may vote by proxy by mail, over the Internet or by telephone. Instructions for voting by proxy over the Internet or by telephone are set forth on the notice of proxy materials. The Internet and telephone voting facilities will close at 11:59 p.m. Eastern Time on Monday, June\u00a011, 2018. The notice will also provide instructions on how you can elect to receive future proxy materials electronically or in printed form by mail. If you choose to receive future proxy materials electronically, you will receive an email next year with instructions containing a link to the proxy materials and a link to the proxy voting site. Your election to receive proxy materials electronically or in printed form by mail will remain in effect until you terminate such election. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU5\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If your shares are held in street name, the voting instruction form sent to you by your broker, bank or other nominee should indicate whether the institution has a process for beneficial holders to provide voting instructions over the Internet or by tel</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ephone. A number of banks and brokerage firms participate in a program that also permits stockholders whose shares are held in street name to direct their vote over the Internet or by telephone. If your bank or brokerage firm gives you this opportunity, th</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">e voting instructions from the bank or brokerage firm that accompany this Proxy Statement will tell you how to use the Internet or telephone to direct the vote of shares held in your account. If your voting instruction form does not include Internet or tel</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ephone information, please complete and return the voting instruction form in the self-addressed, postage-paid envelope provided by your broker. Stockholders who vote by proxy over the Internet or by telephone need not return a proxy card or voting instruc</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">tion form by mail, but may incur costs, such as usage charges, from telephone companies or Internet service providers. </font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Revocability of Proxies </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any proxy may be revoked at any time before it is exercised by filing an instrument revoking it with the Company\u2019s Secretary or by submitting a duly executed proxy bearing a later date prior to the time of the Annual Meeting. Stockholders who have voted by proxy over the Internet or by telephone or have executed and returned a proxy and who then attend the Annual Meeting and desire to vote in person are requested to notify the Secretary in writing prior to the time of the Annual Meeting. We request that all such written notices of revocation to the Company be addressed to Jake Bauer, Assistant Secretary, c/o MyoKardia, Inc., at the address of our principal executive offices at 333 Allerton Avenue, South San Francisco, CA 94080. Our telephone number is (650)\u00a0741-0900. Stockholders may also revoke their proxy by entering a new vote over the Internet or by telephone before these voting facilities close at 11:59 pm Eastern Time on June 11, 2018. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Stockholder Proposals to be Presented at the Next Annual Meeting </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Any stockholder who meets the requirements of the proxy rules under the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d), may submit proposals to the Board of Directors to be presented at the 2018 annual meeting. Such proposals must comply with the requirements of Rule 14a-8 under the Exchange Act and be submitted in writing by notice delivered or mailed by first-class United States mail, postage prepaid, to our Secretary at our principal executive offices at the address set forth above no later than December\u00a018, 2018 in order to be considered for inclusion in the proxy materials to be disseminated by the Board of Directors for such annual meeting. If the date of the 2019 annual meeting is moved by more than 30 days from the date contemplated at the time of the previous year\u2019s proxy statement, then notice must be received within a reasonable time before we begin to print and send proxy materials. If that happens, we will publicly announce the deadline for submitting a proposal in a press release or in a document filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d). A proposal submitted outside the requirements of Rule 14a-8 under the Exchange Act will be considered untimely if received after March\u00a03, 2019. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our Amended and Restated Bylaws (\u201cBylaws\u201d) also provide for separate notice procedures to recommend a person for nomination as a director or to propose business to be considered by stockholders at a meeting. To be considered timely under these provisions, the stockholder\u2019s notice must be received by our Assistant Secretary at our principal executive offices at the address set forth above no earlier than February\u00a012, 2019 and no later than March\u00a014, 2019. Our Bylaws also specify requirements as to the form and content of a stockholder\u2019s notice. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Board of Directors, a designated committee thereof or the chairman of the meeting may refuse to acknowledge the introduction of any stockholder proposal if it is not made in compliance with the applicable notice provisions. </p>\n<p style=\"text-align:center;margin-top:12pt; clear:both;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"PROPOSAL_1\"></a><a name=\"PROPOSAL_1\"></a>PROPOSAL 1</p>\n<p style=\"text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">ELECTION OF DIRECTORS </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">General </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our certificate of incorporation provides for a Board of Directors that is divided into three classes. The term for each class is three years, staggered over time. This year, the term of the directors in Class III expires. Our two (2) Class III directors will each stand for re-election at the Annual Meeting. Our Board of Directors is currently comprised of seven (7)\u00a0members. If each of the Class III director nominees are elected at the Annual Meeting, the composition of our Board of Directors will be as follows: Class I\u2014Ms. Kimberly Popovits and Dr.\u00a0Sunil Agarwal; Class\u00a0II\u2014 Dr. David P. Meeker, Ms. Wendy L. Yarno and Mr.\u00a0Mark Perry; and Class III\u2014Mr.\u00a0Tassos Gianakakos and Ms.\u00a0Mary\u00a0B. Cranston. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In the absence of instructions to the contrary, the persons named as proxy holders in the accompanying proxy intend to vote in favor of the election of the two (2) Class III nominees designated below to serve until the 2021 Annual Meeting of Stockholders and until their successors shall have been duly elected and qualified. Each nominee is currently a director. The Board of Directors expects that each nominee will be available to serve as a director, but if any such nominee should become unavailable or unwilling to stand for election, it is intended that the shares represented by the proxy will be voted for such substitute nominee as may be designated by the Board of Directors. The biographies of our directors and their ages as of March\u00a031, 2018 are set forth below. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Name</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Age</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.06%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Position</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.9%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Kimberly Popovits (3)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.96%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">59</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Director</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.9%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Sunil Agarwal, M.D. (2)(4)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.96%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">48</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Director</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.9%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Wendy L. Yarno (1)(2)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.96%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">63</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Director</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.9%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mark Perry (1)(2)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.96%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">62</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Director</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.9%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Tassos Gianakakos</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.96%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">45</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">President, Chief Executive Officer and Director</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.9%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mary B. Cranston (1)(3)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.96%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">70</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Director</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.9%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">David P. Meeker, M.D. (4)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.96%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">63</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.06%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Director</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1) Member of the Audit Committee. </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2) Member of the Compensation Committee. </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3) Member of the Nominating and Corporate Governance Committee. </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4) Member of the Science and Technology Committee. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Nominees for Director </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Class III: </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The persons listed below are nominated for election to Class III of the Board of Directors to serve a three-year term ending at the 2021 annual meeting of stockholders and until their successors are elected and qualified. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">The Board of Directors recommends that you vote FOR the following nominees. </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Tassos Gianakakos<font style=\"font-weight:normal;font-style:normal;\">. Mr.\u00a0Gianakakos has served as our Chief Executive Officer and President since October 2013 and has been a member of our Board of Directors since October 2013. Prior to joining us, Mr.\u00a0Gianakakos was senior vice president and chief business officer at MAP Pharmaceuticals, Inc., a biopharmaceutical company, from September 2006 to March 2013 when it was acquired by Allergan PLC. Prior to MAP Pharmaceuticals, Mr.\u00a0Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr.\u00a0Gianakakos served as president and senior vice president, business development, and global head of Codexis\u2019 Pharmaceuticals Business Unit. Before forming Codexis, Mr.\u00a0Gianakakos was director of business development at </font></p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU6\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Maxygen, a biocatalyst development company, where he led the company\u2019s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company\u2019s initial public offering. Pr</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ior to Maxygen, Mr.\u00a0Gianakakos was a process engineer in Merck\u00a0&amp; Co., Inc.\u2019s vaccine division. Mr.\u00a0Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwest</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ern University and an M.B.A. from Harvard Business School. Mr.\u00a0Gianakakos\u2019 qualifications to serve on our Board of Directors include his role as our principal executive officer and more than 15 years of management experience in the pharmaceutical industry.</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Mary B. Cranston<font style=\"font-weight:normal;font-style:normal;\">. Ms.\u00a0Cranston has served as a member of our Board of Directors since April 2016. Since December 2012 when she retired from her position as the Firm Senior Partner and Chair Emeritus of Pillsbury Winthrop Shaw Pittman LLP, an international law firm, Ms.\u00a0Cranston has served on various boards of companies and non-profits. Ms.\u00a0Cranston was the Chair and Chief Executive Officer of Pillsbury from January 1999 until April 2006, and continued to serve as Chair of the firm until December 2006. Ms.\u00a0Cranston has served as a director of Visa, Inc., a multinational financial services company since 2007, and The Chemours Company, a global chemical company since 2015. Ms.\u00a0Cranston previously served as a director of GrafTech International, Ltd. (acquired by Brookfield Asset Management), Juniper Networks, Inc., a manufacture of news networks products and infrastructure, Exponent, Inc. and International Rectifier Corporation. Ms.\u00a0Cranston holds an A.B. degree in Political Science from Stanford University, a Juris Doctor degree from Stanford Law School, and a Master of Arts degree in Educational Psychology from the University of California, Los Angeles. Ms.\u00a0Cranston is qualified to serve on our Board of Directors because during her tenure at the Pillsbury law firm, Ms.\u00a0Cranston gained a broad understanding of the business and regulation of the financial services industry as well as of the management of a global enterprise. Ms.\u00a0Cranston\u2019s qualifications to serve on our Board of Directors include her experience as a director of six other U.S. publicly-traded companies, where she has regularly reviewed corporate strategies, financial and operational risks and her management of legal risks for many public companies throughout her career. </font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Class I: Currently Serving Until the 2019 Annual Meeting</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Sunil Agarwal, M.D. <font style=\"font-weight:normal;font-style:normal;\">Dr.\u00a0Agarwal has served as a member of our Board of Directors since March 2016. Dr. Agarwal currently serves as President of Research and Development at Juno Therapeutics, Inc., a biopharmaceutical company.\u00a0\u00a0Prior to Juno, Dr. Agarwal served as partner at Sofinnova Ventures from August 2016 to April 2017. Prior to Sofinnova, Dr.\u00a0Agarwal served as the Chief Medical Officer and Senior Vice President of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, from August 2014 to August 2016. Prior to Ultragenyx, Dr.\u00a0Agarwal served in various leadership capacities at Genentech, Inc. (acquired by Roche Holdings, Inc.) for 11 years. Most recently, he held the position of Senior Vice President and Global Head of Clinical Development for OMNI (Ophthalmology, Metabolism, Neurosciences, Immunology and Infectious Diseases) from January 2013 to July 2014. Prior to that, Dr.\u00a0Agarwal held the positions of Senior VP for Immunology and Infectious Diseases, and VP for Rheumatology from July 2009 to December 2012. He also held the position of VP of Genentech Drug Safety from January 2009 to July 2009. From September 2003 to January 2009, Dr.\u00a0Agarwal held positions of increasing responsibility in Genentech\u2019s Immunology clinical organization, and was involved in the development oversight of multiple molecules including Raptiva, Rituxan, and Ocrelizumab. Dr. Agarwal currently serves on the board of directors of Calithera Biosciences, Inc., a biopharmaceutical company.\u00a0\u00a0Dr.\u00a0Agarwal obtained his Bachelor of Science in Neuro-Biology at Cornell University and then earned his medical degree from Tufts University School of Medicine. He completed his residency at Children\u2019s National Medical Center (CNMC), Washington, D.C. and subsequently joined the facility at George Washington University School of Medicine as an Assistant Clinical Professor of Pediatrics. He practiced in the Pediatric Emergency Department at CNMC. Dr.\u00a0Agarwal\u2019s qualifications to serve on our Board of Directors include his significant experience serving in professional and management positions in the biotechnology industry. </font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU7\"></a><font style=\"Background-color:#FFFFFF;\">Kimberly Popovits</font><font style=\"Background-color:#FFFFFF;font-weight:normal;font-style:normal;\">. Ms. Popovits has served as a member of our Board of Directors since March 2017. Ms.\u00a0Popovits has served as President and Chief Executive Officer of Genomic Health, Inc., a healthcare company, since January 2009, and as Chairman of the Board since March\u00a01, 2012. Prior to that, Ms.\u00a0Popovits served as President and Chief Operating Officer from February 2002 to January 2009. From November 1987 to February 2002, Ms.\u00a0Popovits served in various roles at Genentech, Inc., a biotechnology company, most recently serving as Senior Vice President, Marketing and Sales from February 2001 to February 2002, and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech, Ms.\u00a0Popovits served as Division Manager, Southeast Region, for </font></p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\"><font style=\"Background-color:#FFFFFF;font-weight:normal;font-style:normal;\">American Critical Care, a Division of American Hospital Supply, a supplier of healthcare products to hospitals. Ms.\u00a0Popovits holds a B.A. in Bus</font><font style=\"Background-color:#FFFFFF;font-weight:normal;font-style:normal;\">iness from Michigan State University. Ms. Popovits\u2019 qualifications to serve on our Board of Directors include her senior management experience in healthcare and biotechnology companies. </font><font style=\"Background-color:#FFFFFF;font-weight:normal;font-style:normal;\"> </font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Class II:  Currently Serving Until the 2020 Annual Meeting </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\"><font style=\"Background-color:#FFFFFF;\">Wendy L. Yarno</font><font style=\"Background-color:#FFFFFF;font-weight:normal;font-style:normal;\">. Ms. Yarno has served as a member of our Board of Directors since March 2017. Ms.\u00a0Yarno retired in September 2008 from Merck\u00a0&amp; Co., Inc., a pharmaceutical company, following a\u00a026-year\u00a0career there in commercial and human resource positions of increasing seniority, most recently Chief Marketing Officer before she retired. In that role, Ms.\u00a0Yarno led a global organization charged with all aspects of supporting\u00a0pre-\u00a0and post-launch</font><font style=\"font-weight:normal;font-style:normal;color:#000000;\"> </font><font style=\"Background-color:#FFFFFF;font-weight:normal;font-style:normal;\">commercialization of pharmaceuticals in more than 20 therapeutic areas. Prior to this role, she served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, and as Senior Vice President, Human Resources. After retiring from Merck, Ms.\u00a0Yarno worked part-time as the Chief Marketing Officer of HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, from September 2010 through September 2011. Ms.\u00a0Yarno has served as the\u00a0non-executive\u00a0Chairman of the Board of Aratana Therapeutics, a biopharmaceutical company developing medicines for pets, since October 2013. She also currently serves as a director of Alder Biopharmaceuticals, Inc., Global Blood Therapeutics, Inc., and Inovio Pharmaceuticals, Inc.\u00a0\u00a0She previously served as a director of St. Jude Medical, Inc., a Fortune 500 medical device company, since 2002 until January 2017, when St. Jude Medical was acquired by Abbott Laboratories; and of Medivation, Inc., a biotechnology company focused on oncology products, from April 2013 until September 2016, when Medivation was acquired by Pfizer; and of Durata Therapeutics, a pharmaceutical company, from August 2014 through November 2014 when it was acquired by Actavis W.C. Holding Inc. She also has past experience as a director for several small private company boards. Ms.\u00a0Yarno holds a B.S. in Business Administration from Portland State University and an M.B.A from Temple University. Ms. Yarno\u2019s qualifications to serve on our Board of Directors include her operational and commercial experience in biotechnology and pharmaceutical companies, as well as her experience as a director of multiple biotechnology and pharmaceutical companies.</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Mark L. Perry<font style=\"font-weight:normal;font-style:normal;\">. Mr.\u00a0Perry has served as a member of our Board of Directors since December 2012. From October 2012 to October 2013, Mr.\u00a0Perry served as an entrepreneur-in-residence at Third Rock Ventures. Since August 2011, he has served on various boards of companies and non-profit organizations. In October 2004, Mr.\u00a0Perry joined Aerovance, Inc. as a director, and he served as president and chief executive officer of Aerovance from February 2007 to October 2011. Prior to that, Mr.\u00a0Perry served as the senior business advisor of Gilead Sciences, Inc., a biopharmaceutical company, from April 2004 to February 2007 and as an executive officer from May 1994 to April 2004, during which time he served in a variety of capacities, including general counsel, chief financial officer and executive vice president of operations. Earlier in his career, Mr.\u00a0Perry served as an attorney at Cooley LLP, and was a partner of the firm from 1987 to 1994. Mr.\u00a0Perry currently serves as a director of Nvidia Corporation, a visual computing company, and Global Blood Therapeutics, Inc., a biopharmaceutical company. Mr.\u00a0Perry is also a member of the California State Bar Association and the Association of Bioscience Financial Officers, and serves on several nonprofit boards. Mr.\u00a0Perry holds a B.A. from the University of California, Berkeley, and a J.D. from the University of California, Davis. Mr.\u00a0Perry\u2019s qualifications to serve on our Board of Directors include more than 30 years of experience serving in professional and management positions in the biotechnology industry. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU8\"></a>David P. Meeker, M.D. \u00a0\u00a0<font style=\"font-weight:normal;font-style:normal;\">Dr. Meeker has served as a member of our Board of Directors since April 2017.\u00a0 Dr. Meeker was appointed Chief Executive Officer of KSQ Therapeutics, a biotechnology company that is deploying the genome-scale precision functional genomics platform it has built for drug development, in September 2017.\u00a0\u00a0He was previously executive vice president and head of Sanofi Genzyme, the specialty-care global business unit of Sanofi S.A. that focuses on rare diseases, multiple sclerosis, oncology and immunology, a position he had held since January 2016</font><font style=\"color:#1F497D;font-weight:normal;font-style:normal;\">. \u00a0</font><font style=\"font-weight:normal;font-style:normal;\">He has also served as a member of Sanofi\u2019s Executive Committee since 201</font><font style=\"color:#1F497D;font-weight:normal;font-style:normal;\">2</font><font style=\"font-weight:normal;font-style:normal;\">.\u00a0 Dr. Meeker joined Genzyme Corporation in 1994 as medical director and held positions of increasing responsibility, including vice president, medical affairs, chief operating officer and ultimately president and chief executive officer when Genzyme was acquired by Sanofi in 2011.\u00a0\u00a0Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University.\u00a0 Dr. Meeker has served as a director of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, since November 2015 and as its chairman of the board since April 2017.\u00a0 He is also chairman of the board of directors of Trevi Pharmaceuticals, a privately-held biopharmaceutical company.\u00a0\u00a0Dr. Meeker holds an M.D. degree from the </font></p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\"><font style=\"font-weight:normal;font-style:normal;\">University of Vermont Medical School and</font><font style=\"font-weight:normal;font-style:normal;\"> completed the Advanced Management Program at Harvard Business School in 2000.\u00a0He also completed his internal medicine training at Harvard University\u2019s Beth Israel Hospital and pulmonary/critical care training at Boston University.\u00a0\u00a0Dr. Meeker\u2019s qualificat</font><font style=\"font-weight:normal;font-style:normal;\">ions to serve on our Board of Directors include his previous executive management roles at Sanofi, our collaboration partner, as well as his significant experience in the clinical development and commercialization of biopharmaceutical products.</font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Board of Directors\u2019 Role in Risk Management </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including risks relating to our financial condition, development and commercialization activities, clinical and regulatory matters, operations and intellectual property. Management is responsible for the day-to-day management of risks we face, while our Board of Directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The role of our Board of Directors in overseeing the management of our risks is conducted primarily through committees of the Board of Directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. The full Board of Directors (or the appropriate board committee in the case of risks that are under the purview of a particular committee) discusses with management our major risk exposures, their potential impact on our company, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairman of the relevant committee reports on the discussion to the full Board of Directors during the committee reports portion of the next board meeting. This enables our Board of Directors and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Compensation Risk Assessment </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. This is primarily due to the fact that our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term strategic goals, in particular in connection with our pay-for-performance compensation philosophy. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on the Company. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Board of Directors and Committees of the Board </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">During 2017, the Board of Directors held a total of four meetings. All directors attended at least 75% of the total number of Board meetings.\u00a0\u00a0Except for two directors who attended 66% of the number of meetings of the Audit Committee held during the time they served on the Audit Committee, and one director who attended 25% of the number of meetings of the Compensation Committee held during the time he served on the Compensation Committee, all directors attended at least 75% of the total number of meetings of Board committees on which the director served during the time he or she served on the Board or such committees. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our Board of Directors has determined that all of our directors, except for Mr. Tassos Gianakakos, are independent, as determined in accordance with the rules of The NASDAQ Stock Market (\u201cNASDAQ\u201d) and the SEC. In making such independence determination, the Board of Directors considered the relationships that each non-employee director has with us and all other facts and circumstances that the Board of Directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. In considering the independence of the directors listed above, our Board of Directors also considered the association of our directors with the holders of more than 5% of our common stock. There are no family relationships among any of our directors or executive officers. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU9\"></a>The Board of Directors has a standing Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and Science and Technology Committee. Each of our Audit Committee, Compensation </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Committee and Nominating and Corporate Governance Committee is composed entirely of independent directors in accordance with current NASDAQ listing standards. </font><font style=\"color:#000000;\">Furthermore, our Audit Committee meets the enhanced independence standards established by the Sar</font><font style=\"color:#000000;\">banes-Oxley Act of 2002 and related rulemaking of the SEC. </font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Copies of our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee charters and our corporate governance guidelines are available, free of charge, on our websit</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">e at http://www.MyoKardia.com, under the \u201cInvestors\u00a0&amp; Media/Corporate Governance\u201d link. </font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Audit Committee </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Ms.\u00a0Cranston,\u00a0\u00a0Mr. Perry and Ms. Yarno currently serve on the Audit Committee, which is chaired by Ms.\u00a0Cranston. Our Board of Directors has determined that each of Ms.\u00a0Cranston and Mr.\u00a0Perry is an \u201cAudit Committee financial expert,\u201d as defined under the applicable rules of the SEC. The Audit Committee\u2019s responsibilities include: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">reviewing the overall internal audit plan with our independent registered public accounting firm and members of management responsible for preparing our financial statements; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">recommending, based upon the Audit Committee\u2019s review and discussions with management and our independent registered public accounting firm, whether our audited financial statements shall be included in our Annual Report on Form 10-K; </p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU12\"></a>monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">preparing the Audit Committee report required by SEC rules to be included in our annual proxy statement; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">reviewing all related person transactions for potential conflict of interest situations and approving all such transactions; and </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">reviewing quarterly earnings releases and scripts. </p></td>\n</tr>\n</table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">During 2017, the Audit Committee held six meetings. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU10\"></a><font style=\"font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Compensation C</font><font style=\"font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">ommittee </font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mr.\u00a0Perry, Dr.\u00a0Agarwal and Ms. Yarno currently serve on the Compensation Committee, which is chaired by Mr.\u00a0Perry. The Compensation Committee\u2019s responsibilities include: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">annually reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive Officer; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and determining the compensation of our Chief Executive Officer; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">reviewing and approving the compensation of our other officers; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">reviewing and establishing our overall management compensation, philosophy and policy; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">overseeing and administering our compensation and similar plans; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable NASDAQ Stock Market rules; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">retaining and approving the compensation of any compensation advisors; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">reviewing and approving our policies and procedures for the grant of equity-based awards; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">reviewing and making recommendations to our Board of Directors with respect to director compensation; and </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">reviewing and discussing with management the compensation discussion and analysis, if required, to be included in our annual proxy statement or Annual Report on Form 10-K. </p></td></tr></table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Compensation Committee is responsible for the compensation programs for our executive officers and directors and reports to the Board of Directors on its discussions, decisions and other actions. Typically, our Chief Executive Officer makes recommendations to the Compensation Committee, often attends committee meetings and is involved in the determination of compensation for the respective executive officers that report to him, except that our Chief Executive Officer does not make recommendations as to his own compensation. Our Chief Executive Officer makes recommendations to the Compensation Committee (other than with respect to himself) regarding short- and long-term compensation for all executive officers based on our results, an executive officer\u2019s individual contribution toward these results and an executive officer\u2019s performance toward individual goal achievement. The Compensation Committee then reviews the recommendations and other data and makes decisions as to total compensation for each executive officer, including the Chief Executive Officer, as well as each individual compensation component.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Pursuant to our 2015 Stock Option and Incentive Plan (the \u201c2015 Plan), the Compensation Committee may delegate to our Chief Executive Officer all or part of its authority to approve certain grants of equity awards to certain individuals, subject to certain limitations including the amount of awards that can be granted pursuant to such delegated authority. Our Compensation Committee has delegated to our Chief Executive Officer the authority to approve certain grants of awards under the 2015 Plan to certain employees below the level of Vice President in connection with their hiring or promotion.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">9</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU11\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Pursuant to its charter, the Compensation Committee has the authority to retain compensation consultants to assist in its evaluation of executive an</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">d director compensation. The Compensation Committee engaged Compensia, Inc. (\u201cCompensia\u201d) as its compensation consultant in 2017. The Compensation Committee instructed Compensia to develop a peer group of companies to assess the competitiveness of the exec</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">utive, equity and Board of Director\u2019s compensation programs and to review the Company\u2019s equity program and broader equity practices. Our Compensation Committee plans to retain one or more third-party compensation advisors to provide similar information and</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> advice in future years for consideration in establishing overall compensation for the Company\u2019s executives and directors. We do not believe the retention of, and the work performed by\u00a0\u00a0Compensia, creates any conflict of interest. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">During 2017, the Compensation Committee held four meetings. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Nominating and Corporate Governance Committee </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mses.\u00a0Cranston and Popovits currently serve on the Nominating and Corporate Governance Committee, which is chaired by Ms. Cranston. The Nominating and Corporate Governance Committee\u2019s responsibilities include:\u00a0\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">developing and recommending to the Board of Directors criteria for boar</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">d and committee membership; </font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"></p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">establishing procedures for identifying and evaluating Board of Director candidates, including nominees recommended by stockholders; </font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"></p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">reviewing the size and composition of the Board of Directors to ensure that it is composed </font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">of members containing the appropriate skills and expertise to advise us; </font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"></p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">identifying individuals qualified to become members of the Board of Directors; </font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"></p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">recommending to the Board of Directors the persons to be nominated for election as directors and to </font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">each of the Board\u2019s committees; </font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"></p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">developing and recommending to the Board of Directors a code of business conduct and ethics and a set of corporate governance guidelines; </font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"></p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">developing a mechanism by which violations of the code of business conduct and eth</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ics can be reported in a confidential manner; </font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"></p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">overseeing the evaluation of the Board of Directors and its committees; and </font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"></p></td></tr></table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.29%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.13%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">reviewing and discussing with the Board of Directors the corporate succession plans for the Chief Executive Officer and other executive officers. </p></td></tr></table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">During 2017, the Nominating and Corporate Governance Committee held one meeting. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Science and Technology Committee </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Drs.\u00a0Agarwal and Meeker currently serve on the Science and Technology Committee, which is chaired by Dr.\u00a0Agarwal. The Science and Technology Committee\u2019s responsibilities include: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">advising and recommending approval of and changes to research and development strategy to our Board of Directors; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.31%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">ensuring that appropriate metrics are established to track performance towards research and development goals; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.31%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">assisting scientific leadership in the creation and evaluation of standing advisory boards for the purpose of providing strategic input into research and development planning; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.31%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">ensuring that our investments in research and development integrate new and emerging trends in pharmaceutical science, technology and regulation;</p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">10</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU12\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">reviewing, evaluating and advising our Board of Directors regarding our progress in achieving its long-term strategic research and development goals and objectives; </font></p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.31%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU14\"></a>reviewing, evaluating and advising our Board of Directors regarding the quality, direction and competitiveness of our research and development programs; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.31%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">providing assistance to the Compensation Committee in setting any pipeline or development performance goals under our incentive compensation programs and reviewing the performance results; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.31%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">providing assistance to the Compensation Committee in assessing the capabilities of our key scientific personnel, and the depth and breadth of our scientific resources; and</p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.31%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">at the direction of the Nominating and Corporate Governance Committee, performing a periodic performance evaluation of the Committee and report to our Board of Directors on the results of such evaluation. </p></td></tr></table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">During 2017, the Science and Technology Committee held four (4) meetings. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Board Leadership </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We do not currently have a Chairman of the Board; however, we have appointed Mark L. Perry to serve as our interim non-executive chairman. We believe that the appointment of an interim non-executive chairman allows our Chief Executive Officer to focus on our day-to-day business, while allowing the interim non-executive chairman to lead our Board of Directors in its fundamental role of providing advice to and independent oversight of management. Our Board of Directors recognizes the time, effort and energy that the Chief Executive Officer is required to devote to his position in the current business environment, as well as the commitment required to serve as our lead independent director, particularly as our Board of Directors\u2019 oversight responsibilities continue to grow. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">While our Bylaws and corporate governance guidelines do not require that we appoint a separate Chairman of the Board or lead independent director and Chief Executive Officer, our Board of Directors believes that having a Chief Executive Officer and a separate interim non-executive chairman is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance.\u00a0\u00a0Our separated interim non-executive chairman and Chief Executive Officer positions are augmented by the independence of six of our seven directors, and our entirely independent Audit, Compensation and Nominating and Corporate Governance committees that provide appropriate oversight in the areas described above. At executive sessions of independent directors, these directors speak candidly on any matter of interest, without the Chief Executive Officer or other executives present. The independent directors met four times in 2017 without management present. We believe this structure provides consistent and effective oversight of our management and the Company.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU13\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Director Nominations </font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The director qualifications developed to date focus on what our Board believes to be essential competencies to effectively serve on the Board of Directors. The Nominating and Corporate Governance Committee reassesses such criteria from time to time and submits any proposed changes to the Board of Directors for approval. Presently, at a minimum, the Nominating and Corporate Governance Committee must be satisfied that each nominee it recommends (i)\u00a0has experience at a strategic or policymaking level in a business, government, non-profit or academic organization of high standing, (ii)\u00a0is highly accomplished in his or her respective field, with superior credentials and recognition, (iii)\u00a0is well regarded in the community and has a long-term reputation for high ethical and moral standards, (iv)\u00a0has sufficient time and availability to devote to the affairs of the Company, particularly in light of the number of boards of directors on which such nominee may serve, and (v)\u00a0to the extent such nominee serves or has previously served on other boards, the nominee has a demonstrated history of actively contributing at board meetings. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition to those minimum qualifications, the Nominating and Corporate Governance Committee recommends that our Board of Directors select persons for nomination to help ensure that: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">a majority of our Board is \u201cindependent\u201d in accordance with NASDAQ standards; </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.31%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">each of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee be comprised entirely of independent directors; and </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.31%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU15\"></a>at least one member of the Audit Committee shall have the experience, education and other qualifications necessary to qualify as an \u201cAudit Committee financial expert\u201d as defined by the rules of the SEC. </p></td></tr></table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition to other standards the Nominating and Corporate Governance Committee may deem appropriate from time to time for the overall structure and compensation of the Board of Directors, the Nominating and Corporate Governance Committee may consider the following factors when recommending that our Board select persons for nomination: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">whether a nominee has direct experience in the biotechnology or pharmaceuticals industry or in other fields relevant to the Company\u2019s operations; and </p></td></tr></table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10.31%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.07%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">whether the nominee, if elected, assists in achieving a mix of Board members that represents a diversity of background and experience. </p></td></tr></table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Although the Nominating and Corporate Governance Committee may consider whether nominees assist in achieving a mix of Board members that represents a diversity of background and experience, which is not only limited to race, gender or national origin, we have no formal policy regarding board diversity. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Nominating and Corporate Governance Committee adheres to the following process for identifying and evaluating nominees for the Board of Directors. First, it solicits recommendations for nominees from non-management directors, our Chief Executive Officer, other executive officers, third-party search firms or any other source it deems appropriate. The Nominating and Corporate Governance Committee then reviews and evaluates the qualifications of proposed nominees and conducts inquiries it deems appropriate; all proposed nominees are evaluated in the same manner, regardless of who initially recommended such nominee. In reviewing and evaluating proposed nominees, the Nominating and Corporate Governance Committee may consider, in addition to the minimum qualifications and other criteria for Board membership approved by our Board from time to time, all facts and circumstances that it deems appropriate or advisable, including, among other things, the skills of the proposed nominee, his or her depth and breadth of business experience or other background characteristics, his or her independence and the needs of the Board. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">12</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU14\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If the Nominating and Corporate </font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Governance Committee decides to retain a third-party search firm to identify proposed nominees, it has sole authority to retain and terminate such firm and to approve any such firm\u2019s fees and other retention terms. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Each nominee for election as director at the 2018 Annual Meeting is recommended by the Nominating and Corporate Governance Committee and is presently a director and stands for re-election by the stockholders. From time to time, the Company may pay fees to third-party search firms to assist in identifying and evaluating potential nominees, although no such fees have been paid in connection with nominations to be acted upon at the 2018 Annual Meeting. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders. Pursuant to our Bylaws, stockholders who wish to nominate persons for election to the Board of Directors at an annual meeting must be a stockholder of record at the time of giving the notice, entitled to vote at the meeting, present (in person or by proxy) at the meeting and must comply with the notice procedures in our Bylaws. A stockholder\u2019s notice of nomination to be made at an annual meeting must be delivered to our principal executive offices not less than 90 days nor more than 120 days before the anniversary date of the immediately preceding annual meeting. However, if an annual meeting is more than 30 days before or more than 60 days after such anniversary date, the notice must be delivered no later than the later of the 90th day prior to such annual meeting or the 10th day following the day on which the first public announcement of the date of such annual meeting was made. A stockholder\u2019s notice of nomination may not be made at a special meeting unless such special meeting is held in lieu of an annual meeting. The stockholder\u2019s notice must include the following information for the person making the nomination: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">name and address; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">the class and number of shares of the Company owned beneficially or of record; </p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU16\"></a>disclosure regarding any derivative, swap or other transactions which give the nominating person economic risk similar to ownership of shares of the Company or provide the opportunity to profit from an increase in the price of value of shares of the Company; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in accordance with, the Exchange Act), agreement, arrangement, understanding or relationship that confers a right to vote any shares of the Company; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">any agreement, arrangement, understanding or relationship engaged in for the purpose of acquiring, holding, disposing or voting of any shares of any class or series of capital stock of the Company; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">any rights to dividends or other distributions on the shares that are separate from the underlying shares; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">any performance-related fees that the nominating person is entitled to based on any increase or decrease in the value of any shares of the Company; </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">a description of all agreements, arrangements or understandings by and between the proposing stockholder and another person relating to the proposed business (including an identification of each party to such agreement, arrangement or understanding and the names, addresses and class and number of shares owned beneficially or of record of other stockholders known by the proposing stockholder support such proposed business); </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\"></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">13</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</font></p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">a statement whether or not the proposing stockholder will deliver a proxy statement and form of proxy to holders of, in the case of a business proposal, at least the percentage of voting power of all shares of capital stock required to approve the proposal or, in the case of director nominations, at least the percentage of voting power of all of the shares of capital stock reasonably believed by the proposing stockholder to be sufficient to elect the nominee; and </p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">any other information relating to the nominating person that would be required to be disclosed in a proxy statement filed with the SEC. </p></td>\n</tr>\n</table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">With respect to proposed director nominees, the stockholder\u2019s notice must include all information required to be disclosed in a proxy statement in connection with a contested election of directors or otherwise required pursuant to Regulation 14A under the Exchange Act (including such person\u2019s written consent to being named in the proxy statement as a nominee and to serving as a director if elected). </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">For matters other than the election of directors, the stockholder\u2019s notice must also include a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of the stockholder(s) proposing the business. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The stockholder\u2019s notice must be updated and supplemented, if necessary, so that the information required to be provided in the notice is true and correct as of the record date for the meeting and as of the date that is ten business days prior to the meeting. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Board of Directors, a designated committee thereof or the chairman of the meeting will determine if the procedures in our Bylaws have been followed, and if not, declare that the proposal or nomination be disregarded. The nominee must be willing to provide any other information reasonably requested by the Nominating and Corporate Governance Committee in connection with its evaluation of the nominee\u2019s independence. There have been no material changes to the process by which stockholders may recommend nominees to our Board of Directors. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Stockholder Communications with the Board of Directors </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Stockholders may send correspondence to the Board of Directors c/o the Chairman of the Board at our principal executive offices at the address set forth above. The Company will forward all correspondence addressed to the Board or any individual Board member. Stockholders may also communicate online with our Board of Directors as a group by accessing our website (www.MyoKardia.com) and selecting the \u201cInvestors\u00a0&amp; Media\u201d tab. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Director Attendance at Annual Meetings </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Directors are encouraged to attend the Annual Meeting. One of our directors attended the 2017 Annual Meeting of Stockholders.</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Compensation Committee Interlocks and Insider Participation </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">None of the members of the Compensation Committee is, or has at any time during the past fiscal year been, an officer or employee of the Company or had any relationship requiring disclosure under Item\u00a0404 of Regulation S-K. None of the members of the Compensation Committee has formerly been an officer of the Company. None of our executive officers serve, or in the past fiscal year, have served as a member of the Board of Directors or Compensation Committee of any other entity that has one or more executive officers serving as a member of our Board of Directors or Compensation Committee. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">14</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU15\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Director Compensation </font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In October 2015, our Board of Directors adopted a non-employee director compensation policy, which became effective upon the completion of our initial public offering in November 2015, that is designed to provide a total compensation package that enables us to attract and retain, on a long-term basis, high-caliber non-employee directors. In March 2016, the policy was amended to provide for the payment of annual cash retainers for service on the Science and Technology Committee. Under this policy, all non-employee directors are paid cash compensation for service on the Board of Directors and committees of the Board of Directors as set forth below, prorated based on days of service during a calendar year. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Board of Directors</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Annual</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Retainer</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">All non-employee members</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Additional</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Annual\u00a0Retainer</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Audit Committee:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Chairperson</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">15,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Non-Chairperson members</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,500</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Compensation Committee:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Chairperson</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">10,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Non-Chairperson members</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Nominating and Corporate Governance</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 Committee:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Chairperson</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7,500</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Non-Chairperson members</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,500</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Science and Technology Committee:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Chairperson</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">10,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.24%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Non-Chairperson members</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In addition, under the policy, as amended, each new non-employee director who is initially appointed or elected to our Board of Directors will receive an option grant to purchase 22,000 shares of our common stock, which will vest in equal monthly installments during the 48 months following the grant date, subject to the director\u2019s continued service on our Board of Directors through each vesting date. Thereafter, on the date of each annual meeting of stockholders, each continuing non-employee director will be eligible to receive an annual option grant to purchase 11,000 shares of our common stock, which will vest in equal monthly installments during the 12 months following the date of grant, subject to the director\u2019s continued service on our Board of Directors through each vesting date. All options granted to our non-employee directors pursuant to this policy, as amended, are subject to full acceleration of vesting upon the consummation of a Sale Event (as defined in the 2015 Plan). All of the foregoing options will be granted with a per share exercise price equal to the fair market value of a share of our common stock on the date of grant and will be exercisable (to the extent vested) for up to one year following the cessation of the director\u2019s service on our Board of Directors, so long as the director was not removed for cause. Our non-employee directors may also be granted such additional options in such amounts and on such dates as our Board of Directors may recommend. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We reimburse all reasonable out-of-pocket expenses incurred by our non-employee directors to attend meetings of the Board of Directors and committees thereof. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">15</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU16\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Director Compensation Table\u20142017 </font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table sets forth information with respect to the compensation earned by or paid to our non-employee directors during the fiscal year ended December\u00a031, 2017. Mr.\u00a0Gianakakos as an employee during such year and did not receive compensation for his service on the Board of Directors.\u00a0\u00a0The compensation paid to Mr.\u00a0Gianakakos during the fiscal year ended December 31, 2017 as an employee of the Company is set forth under the heading \u201cCompensation of Executive Officers\u2014Summary Compensation Table\u201d below. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:90%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.12%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Name</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Fees Earned or</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Paid in Cash</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">($)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Option</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Awards</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">($)(1)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Total</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">($)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.12%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Sunil Agarwal, M.D. (2)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">55,625</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">93,665</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">149,290</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.12%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mary Cranston (3)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">57,788</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">93,665</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">151,453</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.12%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Charles Homcy, M.D. (4)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8,111</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">-</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8,111</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.12%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">David Meeker, M.D. (5)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28,242</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">257,268</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">285,510</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.12%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mark Perry (6)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">52,500</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">93,665</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">146,165</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.12%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Kimberly Popovits (7)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">30,693</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">298,019</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">328,712</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.12%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Kevin Starr (8)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">35,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">93,665</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">128,665</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.12%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Eric Topol, M.D. (9)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28,261</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">153,016</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">181,277</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.12%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Wendy Yarno (10)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">33,764</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">298,019</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">331,783</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:4pt;\">\u00a0</p>\n<p style=\"border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards granted during the fiscal year ended December 31, 2017 computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 for stock-based compensation transactions (\u201cFASB ASC Topic 718\u201d). Such aggregate grant date fair values do not take into account any estimated forfeitures related to service-vesting conditions. Assumptions used in the calculation of these amounts are included in Note 8 to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December\u00a031, 2017. These amounts do not reflect the actual economic value that may be realized by the directors upon the exercise of the options or the sale of the common stock underlying such options.</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In September 2017, Mr. Topol\u2019s 2015 option grant was modified in order to extend its post-termination exercise period.\u00a0\u00a0The amount for Mr. Topol represents the aggregate grant date fair value of his 2017 option grant ($93,665), as well as the incremental fair value, computed as of the modification date, in accordance with FASB ASC Topic 718, with respect to the modification ($59,351).\u00a0\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Dr.\u00a0Agarwal held options to purchase an aggregate of 11,000 shares of our common stock as of December\u00a031, 2017.</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Ms.\u00a0Cranston held options to purchase an aggregate of 11,000 shares of our common stock as of December\u00a031, 2017.</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Dr. Homcy resigned from our Board of Directors in March 2017 and as a result, did not hold any outstanding equity awards as of December 31, 2017.\u00a0\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Dr. Meeker held options to purchase an aggregate of 33,000 shares of our common stock as of December\u00a031, 2017. Dr. Meeker joined our Board of Directors in April 2017.</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(6)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mr. Perry held options to purchase an aggregate of 11,000 shares of our common stock as of December\u00a031, 2017.</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(7)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Ms. Popovits held options to purchase an aggregate of 33,000 shares of our common stock as of December\u00a031, 2017. Ms. Popovits joined our Board of Directors in March 2017.</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(8)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mr. Starr held options to purchase an aggregate of 11,000 shares of our common stock as of December\u00a031, 2017. Mr. Starr resigned from our Board of Directors in March 2018.\u00a0\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(9)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Dr. Topol held options to purchase an aggregate of 11,000 shares of our common stock as of December\u00a031, 2017. Dr. Topol resigned from our Board of Directors in September 2017.</p></td>\n</tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">16</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU17\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(10)</font></p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Ms. Yarno held options to purchase an aggregate of 33,000 shares of our common stock as of December\u00a031, 2017. Ms. Yarno joined our Board of Directors in March 2017.</p></td>\n</tr>\n</table></div>\n<p style=\"margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Required Vote </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The two (2) nominees receiving the highest number of affirmative votes of all the votes properly cast shall be elected as Class III directors to serve until the 2021 Annual Meeting of Stockholders or until their successors have been duly elected and qualified. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Recommendation of the Board of Directors </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">The Board of Directors recommends that the stockholders vote FOR the election of the two (2) Class III director nominees listed above. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">17</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU18\"></a><a name=\"PROPOSAL_2\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"PROPOSAL_2\"></a>PROPO</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">SAL 2</font></p>\n<p style=\"text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Audit Committee has appointed PricewaterhouseCoopers LLP as the Company\u2019s independent registered public accounting firm for 2018. Representatives of PricewaterhouseCoopers LLP will attend the Annual Meeting and will have the opportunity to make a statement if they desire to do so. They will also be available to respond to appropriate questions. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Company\u2019s organizational documents do not require that the stockholders ratify the selection of PricewaterhouseCoopers LLP as the Company\u2019s independent registered public accounting firm, and stockholder ratification is not binding on the Company, the Board or the Audit Committee. The Company requests such ratification, however, as a matter of good corporate practice. The ratification of the selection of PricewaterhouseCoopers LLP requires the affirmative vote of a majority of the votes cast on the proposal at the Annual Meeting. Our Board, including our Audit Committee, values the opinions of our stockholders and, to the extent there is any significant vote against the ratification of the selection of PricewaterhouseCoopers LLP as disclosed in this Proxy Statement, we will consider our stockholders\u2019 concerns and evaluate what actions may be appropriate to address those concerns, although the Audit Committee, in its discretion, may still retain PricewaterhouseCoopers LLP. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table shows information about fees billed to the Company by PricewaterhouseCoopers LLP for the fiscal years ended December\u00a031, 2017 and 2016: </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.46%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Fees billed by PricewaterhouseCoopers LLP</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">2016</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.46%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Audit Fees (1)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,058,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,066,697</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.46%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Audit Related Fees</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.46%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Tax Fees</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.46%; border-bottom:solid 0.75pt transparent;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">All Other Fees</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.46%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,058,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">$</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,066,697</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:4pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Includes fees associated with the annual audit of our financial statements, the reviews of our interim financial statements and the issuance of consent and comfort letters in connection with registration statements. </p></td></tr></table></div>\n<p style=\"margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Audit Committee Pre-Approval Policies </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Audit Committee is directly responsible for the appointment, retention and termination, and for determining the compensation, of the Company\u2019s independent registered public accounting firm. The Audit Committee shall pre-approve all auditing services and the terms thereof and non-audit services (other than non-audit services prohibited under Section\u00a010A(g) of the Exchange Act or the applicable rules of the SEC or the Public Company Accounting Oversight Board), except that pre-approval is not required for the provision of non-audit services if the \u201cde minimus\u201d provisions of Section\u00a010A(i)(1)(B) of the Exchange Act are satisfied. The Audit Committee may delegate to the chairperson of the Audit Committee the authority to grant pre-approvals for audit and non-audit services, provided such approvals are presented to the Audit Committee at its next scheduled meeting. All services provided by PricewaterhouseCoopers LLP during fiscal years 2017 and 2016 were pre-approved by the Audit Committee in accordance with the pre-approval policy described above. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Required Vote </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The ratification of the selection of PricewaterhouseCoopers LLP requires the affirmative vote of a majority of the votes cast on the proposal at the Annual Meeting (meaning the number of shares voted \u201cfor\u201d the proposal must exceed the number of shares voted \u201cagainst\u201d the proposal). Abstentions are not considered votes cast for the foregoing purpose, and will have no effect on the vote for this proposal. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Recommendation of the Board of Directors </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"BOARD_DIRECTORS_RECOMMENDS_THAT_STOCKHOL\"></a>The <a name=\"BOARD_DIRECTORS_RECOMMENDS_THAT_STOCKHOL\"></a>Board of Directors recommends that the stockholders vote FOR the ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December\u00a031, 2018.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">18</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU19\"></a><a name=\"EXECUTIVE_OFFICERS\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"EXECUTIVE_OFFICERS\"></a>EX</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">ECUTIVE OFFIC</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">ERS </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The names of the executive officers of the Company, their ages as of March\u00a031, 2018, and certain other information about them are set forth below (unless set forth elsewhere in this Proxy Statement). </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Name</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.76%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.28%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Age</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.94%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.36%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Position</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Tassos Gianakakos</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.76%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.28%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">45</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.94%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.36%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">President, Chief Executive Officer and Director</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.66%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Marc Semigran, M.D.</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.76%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">61</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.94%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Chief Medical Officer</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.66%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">June Lee, M.D.</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.76%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">52</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.94%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Chief Operating Officer and Chief Development Officer</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.66%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Robert S. McDowell, Ph.D.</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.76%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">60</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.94%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Chief Scientific Officer</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.66%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Jake Bauer</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.76%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">39</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.94%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Chief Business Officer</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.66%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Taylor Harris</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.76%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">42</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.94%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Chief Financial Officer</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.66%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Joseph Lambing, Ph.D.</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.76%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">55</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.94%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Senior Vice President, Nonclinical and Pharmaceutical Development</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.66%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Cynthia J. Ladd</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.76%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.28%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">62</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.94%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.36%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">General Counsel</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Executive Officers </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The biographies of our executive officers, other than Mr.\u00a0Gianakakos, whose biography is set forth above, appear below. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Marc Semigran, M.D.<font style=\"font-weight:normal;font-style:normal;\"> Dr. Semigran has served as our Chief Medical Officer since December 2016. Dr. Semigran was Medical Director of the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program, a position he held from April 2004 through November 2016, where he was responsible for the overall direction of the care of heart failure patients, including those that needed or had undergone cardiac transplantation. Dr. Semigran also serves as an Associate Professor of Medicine at Harvard Medical School from January 2010 to present. He is a graduate of the Harvard/MIT Health Sciences and Technology Program and completed Internal Medicine Residency and Cardiology Fellowship Training at Massachusetts General Hospital. Dr. Semigran holds an M.D. from Harvard Medical School, and holds an AB and AM in Chemistry from Harvard University.</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">June Lee, M.D<font style=\"font-style:normal;\">. </font><font style=\"font-weight:normal;font-style:normal;\">Dr. Lee has served as our Chief Operating Officer since February 2017 and our Chief Development Officer since October 2017.\u00a0\u00a0Prior to joining us, and since April 2011, Dr. Lee served on the faculty of the University of California, San Francisco (\u201cUCSF\u201d), where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as well as management of staff, budget, and resource allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a medical director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis.</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Robert S. McDowell, Ph.D<font style=\"font-weight:normal;font-style:normal;\">. Dr. McDowell has served as our Chief Scientific Officer since October 2017, and prior to that as our Senior Vice President of Drug Discovery since July 2012. Prior to joining us, Dr. McDowell led drug discovery at 3-V Biosciences, Inc. from October 2008 to July 2012, advancing the company\u2019s lead program into development. Prior to 3-V Biosciences, he served as vice president of research at Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, from January 2000 to 2008, where he oversaw drug discovery, translational research and manufacturing functions. Prior to Sunesis Pharmaceuticals, Dr. McDowell led the structural chemistry group at Axys Pharmaceuticals, Inc. Before joining Axys, Dr. McDowell was a senior scientist at Genentech Inc., where he developed successful strategies for peptidomimetic design. Dr. McDowell has authored more than 40 peer-reviewed manuscripts and is an inventor on more than 20 issued U.S. patents. Dr. McDowell holds a B.S. in chemistry and physics from Butler University and a Ph.D. in chemistry from the University of California, Berkeley.</font></p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">19</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU20\"></a><font style=\"font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Jake Bauer</font><font style=\"font-weight:normal;font-style:normal;\">. Mr.\u00a0Bauer has served as our Chief Business Officer since April 2018, as our Senior Vice President, Finance and Corporate Development from July 2016 to April 2018, and prior to that as our Vice President, Business Development and Business Operations since</font><font style=\"font-weight:normal;font-style:normal;\"> July 2014. Prior to joining us, he was vice president, business operations and head of corporate development at Ablexis, LLC, a biotechnology company, from May 2011 to July 2014. At Ablexis, he led the development and implementation of the company\u2019s corpo</font><font style=\"font-weight:normal;font-style:normal;\">rate strategy and business development activities and oversaw business operations. Prior to Ablexis, Mr.\u00a0Bauer was a principal at Third Rock Ventures, where he identified, evaluated and developed new opportunities for investment, assisted with startup, cor</font><font style=\"font-weight:normal;font-style:normal;\">porate development and operations of portfolio companies, and negotiated financings from 2007 to 2011. While at Third Rock Ventures, he was actively involved in a variety of leading biopharmaceutical companies including Agios Pharmaceuticals, Inc., CytomX </font><font style=\"font-weight:normal;font-style:normal;\">Therapeutics Inc., Global Blood Therapeutics, Inc. and Zafgen, Inc., all biopharmaceutical companies. Prior to Third Rock Ventures, Mr.\u00a0Bauer served in roles in the investment group at Royalty Pharma AG and the business development group at Endo Pharmaceut</font><font style=\"font-weight:normal;font-style:normal;\">icals Inc., and was previously a management consultant at Putnam Associates. Mr.\u00a0Bauer holds a B.Sc. in biology and a B.A. in economics from Duke University and an M.B.A. from Harvard Business School. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Taylor Harris. <font style=\"font-weight:normal;font-style:normal;\">Mr. Harris has served as our Chief Financial officer since April 2018.\u00a0\u00a0Prior to joining us and from April 2016 to April 2017, he served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., a public company that markets the CoolSculpting cryolipolysis procedure. During that time, he was responsible for the global finance, accounting, tax, treasury, investor relations, and information technology functions, as well as the company\u2019s commercial operations, including customer service, product support, and inside sales. Zeltiq was acquired by Allergan plc in April 2017.\u00a0\u00a0Prior to Zeltiq, Mr. Harris served as Vice President and Chief Financial Officer at Thoratec Corporation, a public company that develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients worldwide, from October 2012 until October 2015, when the company was acquired by St. Jude Medical, Inc. Mr. Harris joined Thoratec as its Senior Director of Investor Relations and Business Development in February 2010, in which capacity he was responsible for developing and executing the company's investor relations strategy, as well as supporting the company's strategic and business development activities.\u00a0\u00a0Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase &amp; Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments. Mr.\u00a0Harris holds a B.A. in physics and economics from the University of North Carolina at Chapel Hill.</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Joseph Lambing, Ph.D<font style=\"font-weight:normal;\">.</font><font style=\"font-weight:normal;font-style:normal;\"> Dr.\u00a0Lambing has served as our Senior Vice President, Nonclinical and Pharmaceutical Development since March 2014. Prior to joining us, he was senior vice president of development for Portola Pharmaceuticals, Inc., a biopharmaceutical company, where he oversaw all preclinical and pharmaceutical development activities since the company\u2019s founding from September 2003 to January 2013. Prior to Portola Pharmaceuticals, Dr.\u00a0Lambing served as director of drug safety and disposition for Millennium Pharmaceuticals, Inc.\u2019s, a biopharmaceutical company, San Francisco site from February 2002 to November 2003, and as a scientist and then director of DMPK and toxicology at COR Therapeutics, Inc. from November 1994 to February 2002. During his career, Dr.\u00a0Lambing has contributed to numerous NDA and IND filings for more than a dozen new chemical entities, as well as numerous filings to support a variety of clinical trials in other countries. Dr.\u00a0Lambing holds a B.S. in chemistry and a Ph.D. in biochemistry from the University of Missouri, and was a postdoctoral fellow at the University of California, San Diego. </font></p>\n<p style=\"margin-bottom:6pt;margin-top:6pt;margin-left:0.16%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU24\"></a>Cynthia J. Ladd.<font style=\"font-weight:normal;font-style:normal;\"> Ms. Ladd has served as our General Counsel since January 2018.\u00a0\u00a0Prior to joining us and since June 2015, she was Senior Vice President and General Counsel of CytomX Therapeutics, an oncology-focused biopharmaceutical company.\u00a0\u00a0Prior to CytomX, Ms. Ladd was an independent consultant to biotechnology companies from February 2006 to June 2015, advising on corporate strategy, negotiations around collaborations, and clinical and regulatory issues, as well as acting as general counsel.\u00a0\u00a0Prior to that, she was president and chief executive officer of AGY Therapeutics Inc. from May 2003 to June 2005, where she guided the company through a venture round and its transition to a clinical organization. Ms. Ladd previously served as senior vice president and general counsel at Pharmacyclics. Earlier in her career, Ms. Ladd held a number of positions at Genentech, Inc., including vice president of corporate law and chief corporate counsel. She began her career as an associate with Wilson Sonsini Goodrich &amp; Rosati, P.C., and Ware &amp; Freidenrich LLP (now DLA Piper LLP (US)). Ms. Ladd holds a B.S. in animal science fr<a name=\"_AEIOULastRenderedPageBreakAEIOU24\"></a>om Penn State University, an M.S. in animal nutrition and biochemistry from Cornell University, and a J.D. from Stanford Law School.</font></p>\n<p style=\"text-align:center;margin-top:12pt; clear:both;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">20</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU21\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0</font></p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"COMPENSATION_EXECUTIVE_FICERS\"></a><a name=\"COMPENSATION_EXECUTIVE_FICERS\"></a>COMPENSATION OF EXECUTIVE OFFICERS </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Summary Compensation Table </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table presents information regarding the total compensation, for services rendered in all capacities, awarded to, earned by or paid to each individual who served as our chief executive officer at any time during the fiscal year ended December\u00a031, 2017 and our two most highly compensated executive officers who were serving as executive officers as of December\u00a031, 2017 (other than our chief executive officer). We refer to these officers in this Proxy Statement as our named executive officers. The following table also sets forth information regarding total compensation awarded to, earned by or paid to certain of our named executive officers during the fiscal year ended December\u00a031, 2016, to the extent they were our named executive officers during such fiscal year. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.46%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Name and Principal Position</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Year</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Salary</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">($)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Bonus</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">($)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Option</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Awards</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">($)(1)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Non-Equity</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Incentive Plan</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Compensation</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">($) (2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">All Other</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Compensation</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">($) (3)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Total</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">($)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.46%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Tassos Gianakakos</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">505,450</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,406,603</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">297,205</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,210,258</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.46%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">President, Chief Executive</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Officer and Director</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2016</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">459,545</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">424,306</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">220,600</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">500</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,104,951</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.46%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">June Lee, M.D.</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">352,917</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">50,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(6)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,163,430</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(7)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">183,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,750,347</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.46%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Chief Operating Officer</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.46%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Robert S. McDowell, Ph.D.</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2017</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">327,749</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">814,463</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(8)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">117,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,260,212</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.46%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Chief Scientific Officer</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> <font style=\"font-size:4pt;\"> \u00a0</font></p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">In accordance with SEC rules, this column reflects the aggregate grant date fair value of option awards granted during the fiscal years ended December 31, 2017 and December 31, 2016, as applicable, in accordance with FASB ASC Topic 718. <font style=\"Background-color:#FFFFFF;\">Such aggregate grant date fair values do not take into account any estimated forfeitures related to service-vesting conditions</font>. Assumptions used in the calculation of these amounts are included in Note 8 to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. The amounts do not reflect the actual economic value that may be realized by the named executive officers upon the exercise of the options or the sale of the common stock underlying such options.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">The amounts reported for 2017 reflect the cash incentive compensation determined by our Compensation Committee based on the Company\u2019s achievement of certain research and development, clinical, financial and operational metrics related to our 2017 corporate objectives, as specified by our Board of Directors, and individual performance. These amounts were paid in 2018.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">The amounts reported reflect the matching contributions under our 401(k) plan.(4)The amount reported represents the aggregate grant date fair value of options to purchase an aggregate of 303,500 shares of our common stock subject to time-based vesting.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Dr. Lee joined us in February 2017 and her base salary was pro-rated accordingly.\u00a0\u00a0Dr. Lee was not a named executive officer for the fiscal year ended December 31, 2016.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU25\"></a>(6)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU25\"></a>The amount reported reflects a lump-sum cash sign-on bonus of $50,000 paid to Dr. Lee in connection with her acceptance of our offer of employment.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(7)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">The amount reported represents the aggregate grant date fair value of options to purchase an aggregate of 150,000 shares of our common stock subject to time-based vesting and $0, which represents the aggregate grant date fair value of an option to purchase 25,000 shares of our common stock subject to performance-based vesting (the \u201cLee 2017 Performance-Based Option\u201d), based on the probable outcome of the applicable performance milestones.\u00a0\u00a0The aggregate grant date fair value of the Lee 2017 Performance-Based Option, assuming the achievement of the highest level of performance milestones, was $189,188.\u00a0\u00a050% of the Lee 2017 Performance-Based Option expired during 2017 because the applicable performance criteria were not met by the applicable specified dates.</p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">21</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(8)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU22\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The amount reported reflects the aggregate grant date fair value of options to purchase an aggregate of 99,850 shares of our common stock s</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ubject to time-based vesting.</font></p></td></tr></table></div>\n<p style=\"margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Narrative to Summary Compensation Table</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Base Salaries<font style=\"font-style:normal;\">. For the year ended December 31, 2017, the annual base salaries for Mr. Gianakakos, Dr. Lee and Dr. McDowell were $505,450, $385,000 and $327,749, respectively. Effective as of January 1, 2018, the annual base salaries for Mr. Gianakakos, Dr. Lee and Dr. McDowell were increased to $575,000, $414,000 and $393,000, respectively.\u00a0\u00a0</font></p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Cash Incentive Compensation.<font style=\"font-style:normal;\"> In January 2016, the Board of Directors adopted the Company\u2019s Senior Executive Cash Incentive Bonus Plan (the \u201cIncentive Plan\u201d), which applies to certain key executives of the Company (the \u201cCovered Executives\u201d), that are recommended by the Compensation Committee and selected by the Board of Directors. The Incentive Plan provides for bonus payments based upon the attainment of performance objectives established by the Compensation Committee and relate to operational and financial metrics with respect to the Company or any of its subsidiaries (the \u201cCorporate Performance Goals\u201d), which may include achievement of specified research and development, publication, clinical and/or regulatory milestones, total shareholder return, earnings before interest, taxes, depreciation and amortization, net income (loss) (either before or after interest, taxes, depreciation, stock compensation expense, restructuring charges and/or amortization), changes in the market price of the Company\u2019s common stock, economic value-added, funds from operations or similar measure, sales or revenue, acquisitions or strategic transactions, operating income (loss), cash flow (including, but not limited to, operating cash flow and free cash flow), return on capital, assets, equity, or investment, return on sales, gross or net profit levels, productivity, expense, margins, operating efficiency, customer satisfaction, working capital, earnings (loss) per share of the Company\u2019s common stock; bookings, new bookings or renewals; sales or market shares; number of customers, number of new customers or customer references; operating income and/or net annual recurring revenue. Any bonuses paid under the Incentive Plan are based upon objectively determinable bonus formulas that tie such bonuses to one or more performance targets relating to the Corporate Performance Goals. The bonus formulas will be adopted in each performance period by the Compensation Committee and communicated to each Covered Executive. No bonuses will be paid under the Incentive Plan unless and until the Compensation Committee makes a determination with respect to the attainment of the performance objectives. Notwithstanding the foregoing, the Compensation Committee may adjust bonuses payable under the Incentive Plan based on achievement of individual performance goals or pay bonuses (including, without limitation, discretionary bonuses) to Covered Executives under the Incentive Plan based on individual performance goals and/or upon such other terms and conditions as the Compensation Committee may in its discretion determine.</font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">During the fiscal year ended December\u00a031, 2017, the target annual bonus for Mr. Gianakakos was increased from 50% to 60% of his base salary.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">During the fiscal year ended December\u00a031, 2017, the target annual bonuses for Dr. Lee and Dr. McDowell were equal to 40% and 35%, respectively, of the applicable named executive officer\u2019s base salary.\u00a0\u00a0Based on the Company\u2019s achievement of certain research and development, clinical, financial and operational metrics related to our 2017 corporate objectives, the Compensation Committee determined that the Company\u2019s corporate goal achievement was 98% of target.\u00a0\u00a0The Compensation Committee also adjusted Dr. Lee and Dr. McDowell\u2019s annual bonuses for the fiscal year ended December 31, 2017 based on their individual performance during the year.</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">During the fiscal year ended December 31, 2017, Dr. Lee also received a lump-sum cash sign-on bonus equal to $50,000 in connection with her acceptance of our offer of employment. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Equity Incentive Compensation.<font style=\"font-style:normal;\"> During the fiscal year ended December\u00a031, 2017, we granted options to each of our named executive officers, as shown in more detail in the \u201cOutstanding Equity Awards at Fiscal Year-End\u201d table below. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU23\"></a>401(k) Savings Plan and Other Benefits. <font style=\"font-style:normal;\">We maintain a tax-qualified retirement plan, or the 401(k) Plan, that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to defer eligible compensation subject to applicable annual IRS limits. Employees\u2019 pre-tax or Roth contributions are allocated to each participant\u2019s individual account and are then invested in selected investment alternatives according to the participants\u2019 directions. Employees are immediately and fully vested in their </font></p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">22</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:12pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\"><font style=\"font-style:normal;\">contributions. Our 401(k) Plan i</font><font style=\"font-style:normal;\">s intended to be qualified under Section\u00a0401(a) of the Internal Revenue Code of 1986, as amended (the \u201cCode\u201d) with our 401(k) Plan\u2019s related trust intended to be tax exempt under Section\u00a0501(a) of the Code. As a tax-qualified retirement plan, contributions</font><font style=\"font-style:normal;\"> to our 401(k) Plan and earnings on those contributions are not taxable to the employees until distributed from our 401(k) Plan. In 2016, we made matching contributions under our 401(k) plan of up to $500 per year per employee and beginning in 2017, we inc</font><font style=\"font-style:normal;\">reased the matching contributions under our 401(k) plan to up to $1,000 per year per employee. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Our named executive officers are eligible to participate in all of our employee benefit plans, in each case on the same basis as other employees of the same status.\u00a0\u00a0We pay, on behalf of our employees, a portion of the premiums for health, life and disability insurance. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">Perquisites and Personal Benefits<font style=\"font-style:normal;\">.\u00a0\u00a0We generally do not provide perquisites or personal benefits to our named executive officers.</font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Outstanding Equity Awards at Fiscal Year-End </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table sets forth certain information with respect to outstanding equity awards held by each of our named executive officers as of December\u00a031, 2017. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.1%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"16\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Option Awards</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Name</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Number\u00a0of</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Securities</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Underlying</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Unexercised</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Options\u00a0(#)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Exercisable</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Number\u00a0of</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Securities</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Underlying</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Unexercised</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Options\u00a0(#)</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Unexercisable</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.08%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Equity</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Incentive\u00a0Plan</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Awards:</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Number\u00a0of</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Securities</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Underlying</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Unexercised</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Unearned</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Options</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(#)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Option</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Exercise</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Price</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">($)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Option</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Expiration</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Date</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(a)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(b)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(d)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Tassos Gianakakos</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">52,782</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1.51</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6/4/2025</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">73,174</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">78,061</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1.51</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6/4/2025</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">34,769</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">37,793</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">9.08</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2/2/2026</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">69,552</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">233,948</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">12.25</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1/18/2027</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">June Lee, M.D.</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">12,500</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11.95</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2/1/2027</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">150,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(6)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11.95</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2/1/2027</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> Robert McDowell,</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0\u00a0 Ph. D.</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">87,074</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">0.18</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">12/6/2022</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">34,864</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(7)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5,952</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(7)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">0.33</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7/24/2024</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">14,456</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8,673</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1.51</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6/4/2025</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">13,606</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1.51</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6/4/2025</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">13,038</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">14,173</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">9.08</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2/2/2026</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">18,298</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">61,552</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">12.25</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1/18/2027</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.1%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.66%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">20,000</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(8)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%;\" valign=\"top\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">13.90</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">7/20/2027</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:4pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">The shares underlying the options are fully vested. The options for Mr. Gianakakos were granted under our 2012 Equity Incentive Plan (the \u201c2012 Plan\u201d).\u00a0\u00a0The options for Dr. McDowell were granted under our 2015 Equity Incentive Plan (the \u201c2015 Plan\u201d).</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU27\"></a><a name=\"_AEIOULastRenderedPageBreakAEIOU27\"></a>25% of the shares underlying the options vested on June\u00a04, 2016, while the remaining 75% of shares underlying the options vest in equal monthly installments over three years from June\u00a04, 2016 to June\u00a04, 2019, subject to the applicable named executive officer\u2019s continued employment with the Company through each applicable vesting date. These options were granted under our 2012 Plan.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">1/48<font style=\"font-size:8.5pt;\">th</font> of the shares underlying the options vest in equal monthly installments over four years from January 1, 2016 to January 1, 2020, subject to the applicable named executive officer\u2019s continued employment with the Company through each applicable vesting date.\u00a0\u00a0These options were granted under our 2015 Plan.</p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">23</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU24\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1/48</font><font style=\"font-size:8.5pt;\">th</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"> of the sha</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">res underlying the options vest in equal monthly installments over four years from January 1, 2017 to January 1, 2021, subject to the applicable named executive officer\u2019s continued employment with the Company through each applicable vesting date.\u00a0\u00a0These op</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">tions were granted under our 2015 Plan.</font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">The shares underlying the options vest with respect to 25% of the underlying shares upon the Company\u2019s achievement of each of four (4) specified regulatory and clinical milestones on or before certain specified dates, as determined by the Board of Directors, subject to the applicable named executive officer\u2019s continued employment with the Company through each applicable vesting date. As of December 31, 2017, 50% of the underlying shares subject to the options have expired, since two of the applicable performance milestones were not met by the applicable specified dates.\u00a0\u00a0These options were granted under our 2015 Plan.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(6)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">25% of the shares underlying the options vest on January 31, 2018, while the remaining 75% of shares underlying the options vest in equal monthly installments over three years from January 31, 2018 to January 31, 2021, subject to the applicable named executive officer\u2019s continued employment with the Company through each applicable vesting date. These options were granted under our 2015 Plan.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(7)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">25% of the shares underlying this option vested on July\u00a01, 2015, while the remaining 75% of shares underlying this option vest in equal monthly installments over three years from July 1, 2015 to July\u00a01, 2018, subject to the applicable named executive officer\u2019s continued employment with the Company through each applicable vesting date. These options were granted under our 2015 Plan.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(8)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">50% of the shares underlying the option vest on July 20, 2018 and 50% vest on July 20, 2019, subject to the applicable named executive officer\u2019s continued employment with the Company through each applicable vesting date. This option was granted under our 2015 Plan.</p></td></tr></table></div>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Employment Arrangements with Our Named Executive Officers </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Change in Control Policy </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We consider it essential to the best interests of our stockholders to foster the continuous employment of our key management personnel. In this regard, we recognize that the possibility that a change in control of the Company may occur and the uncertainty and questions that a change in control may raise among management could result in the departure or distraction of management personnel to the detriment of the Company and our stockholders. In order to reinforce and encourage the continued attention and dedication of certain key members of management, in October 2015, our Board of Directors adopted a Change in Control Policy (the \u201cPolicy\u201d). Pursuant to the Policy, in the event the employment of any of our named executive officers is terminated by us or our acquirer or successor without Cause (as such term is defined in the 2015 Plan) within one year after the consummation of a Sale Event (as such term is defined in the 2015 Plan), he or she will be entitled to receive the following payments and benefits, subject to his or her execution and non-revocation of a severance agreement within 60 days following the date of such termination, including a general release of claims: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">a lump sum cash payment equal to 12 months (or 18 months in the case of Mr.\u00a0Gianakakos as our Chief Executive Officer) of the named executive officer\u2019s then-current base salary; </p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">payment of the named executive officer\u2019s target annual incentive compensation; </p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">if the named executive officer elects to continue his or her group healthcare benefits, payment of an amount equal to the monthly employer contribution we would have made to provide the named executive officer with health insurance if he or she had remained employed by us until the earlier of (i)\u00a012 months (or 18 months in the case of Mr.\u00a0Gianakakos as our Chief Executive Officer) following the date of termination or (ii)\u00a0the end of the named executive officer\u2019s COBRA health continuation period; and </p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">all stock options and other stock-based awards with time-based vesting conditions granted to the named executive officer will become fully exercisable and non-forfeitable as of the date of the named executive officer\u2019s termination. </p></td>\n</tr>\n</table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU25\"></a>In addition, upon a Sale Event, to the extent Sections\u00a0280G and 4999 of the Code are applicable, each named executive officer who is then employed with us will be entitled to receive the better treatment of: (i)\u00a0payment of the full amounts set forth above to which the named executive officer is entitled or (ii)\u00a0payment of such lesser amount that does not trigger excise taxes under Section\u00a04999 of the Code.\u00a0\u00a0 We have also entered into a written employment </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">24</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">agreement with each of our named executive officers that provides for other compensation and benefits, as described b</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">elow. </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Tassos Gianakakos </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We entered into an employment offer letter agreement with Mr.\u00a0Gianakakos in September 2013, pursuant to which he began serving as, and continues to serve as, our President and Chief Executive Officer in October 2013. The letter agreement entitled Mr.\u00a0Gianakakos to an initial annual base salary of $375,000, subject to adjustment pursuant to our employee compensation policies in effect from time to time, and Mr.\u00a0Gianakakos\u2019 annual base salary in 2017 was $505,450, which was increased to 575,000 effective as of January 1, 2018. Pursuant to the terms of his letter agreement and the Incentive Plan, Mr.\u00a0Gianakakos is considered annually for a bonus target representing a percentage of his annual base salary, as determined by our Board of Directors based on a combination of our achievement of certain performance goals and Mr.\u00a0Gianakakos\u2019 achievement of certain individual goals.\u00a0\u00a0During the fiscal year ended December\u00a031, 2017, the target annual bonus for Mr. Gianakakos was increased from 50% to 60% of his base salary. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mr.\u00a0Gianakakos is also eligible to receive certain post-termination compensation and benefits in accordance with the Policy described above. </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">June Lee, M.D.</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We entered into an employment offer letter agreement with Dr.\u00a0Lee in February 2017, pursuant to which she assumed the role of our Chief Operating Officer. The agreement entitled Dr.\u00a0Lee to an initial annual base salary of $385,000, subject to adjustment pursuant to our employee compensation policies in effect from time to time.\u00a0\u00a0Pursuant to the terms of her agreement and the Incentive Plan, Dr.\u00a0Lee is considered annually for a bonus target of 40% of her annual base salary, as determined by the Board of Directors based on a combination of our achievement of certain performance goals and Dr.\u00a0Lee\u2019s achievement of certain individual performance goals. Dr.\u00a0<font style=\"color:#000000;\">Lee\u2019s annual base salary in 2017 was $385,000, which was increased</font> to <font style=\"color:#000000;\">$414,000 effective as</font> of <font style=\"color:#000000;\">January 1, 2018. </font>Pursuant to the terms of her agreement, Dr.\u00a0Lee was paid a lump-sum sign-on bonus of $50,000 within 60 days of her start date.\u00a0\u00a0Pursuant to the terms of her agreement, Dr. Lee was also issued an option to purchase 150,000 shares of our common stock on February 1, 2017 with time-based vesting, and an option to purchase 25,000 shares of our common stock on February 1, 2017 with performance-based vesting, both of which were granted pursuant to the terms of the 2015 Plan and option award agreements thereunder. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Dr.\u00a0Lee is also eligible to receive certain post-termination compensation and benefits in accordance with the Policy described above. </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Robert McDowell, M.D.</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We entered into an employment offer letter agreement with <font style=\"color:#000000;\">Dr.\u00a0McDowell </font>in<font style=\"color:#000000;\"> June 2012</font>, pursuant to which he assumed the role of Vice President<font style=\"color:#000000;\"> of Drug Discovery in July 2012. Dr. McDowell</font> currently serves as our <font style=\"color:#000000;\">Chief Scientific Officer.\u00a0\u00a0</font>The agreement <font style=\"color:#000000;\">entitled Dr.\u00a0McDowell </font>to an initial annual base salary of $260,000, subject to adjustment pursuant to our employee compensation policies in effect from time to time<font style=\"color:#000000;\">.\u00a0\u00a0Dr.\u00a0McDowell\u2019s</font> annual base salary <font style=\"color:#000000;\">in 2017 was $327,749 which was increased to $393,000 effective as of January 1, 2018. </font>Pursuant to the terms of his agreement and the Incentive Plan, <font style=\"color:#000000;\">Dr.\u00a0McDowell </font>is considered annually for a bonus target of 35% of his annual base salary, as determined by the Board of Directors, based on a combination of our achievement of certain performance goals and <font style=\"color:#000000;\">Dr.\u00a0McDowell\u2019s </font>achievement of individual performance goals.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">25</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU26\"></a><font style=\"color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Dr.\u00a0McDowell </font><font style=\"color:#000000;\">is also eligible to receive certain post-termination c</font><font style=\"color:#000000;\">ompensation and benefits in accordance with the Policy described above.</font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Securities Authorized for Issuance under Equity Compensation Plans </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table sets forth information as of December 31, 2017 regarding shares of common stock that may be issued under our equity compensation plans, consisting of our 2012 Plan, our 2015 Plan and our 2015 Employee Stock Purchase Plan (the \"ESPP\").</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:80%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Plan Category</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.32%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Number\u00a0of\u00a0Securities\u00a0to\u00a0be</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Issued upon Exercise\u00a0of Outstanding</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Options, Warrants and</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Rights\u00a0(#)(a)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.32%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Weighted\u00a0Average</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Exercise Price</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">of\u00a0Outstanding\u00a0Options,</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Warrants</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">and\u00a0Rights\u00a0($)\u00a0(b)(1)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.22%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Number\u00a0of\u00a0Securities</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Remaining Available</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">for Future\u00a0Issuance\u00a0under</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Equity Compensation\u00a0Plans</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">(Excluding\u00a0Securities\u00a0Reflected</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">in\u00a0Column\u00a0(a))(c)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Equity compensation plans</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">approved by securityholders (2)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.32%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,964,549</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.32%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11.54</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.22%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,312,982</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Equity compensation plans</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">not approved by securityholders</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.32%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.32%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2014</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Total</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.32%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2,964,549</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.32%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.22%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,312,982</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The weighted average exercise price is calculated based solely on outstanding stock options.</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Includes the 2012 Plan, the 2015 Plan and the ESPP.</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Does not include purchase rights accruing under the ESPP because the purchase right (and therefore the number of shares to be purchased) will not be determined until the end of the purchase period.</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</p></td>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU30\"></a>Includes 863,538 shares of common stock remaining available for issuance under the 2015 Plan and 449,444 shares of common stock remaining available for issuance under the ESPP as of December 31, 2017. Our 2015 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2017, by the lesser of (i) 4% of the number of outstanding shares of the Company\u2019s common stock on the immediately preceding December 31, and (ii) an amount as determined by the compensation committee of the Company\u2019s Board of Directors. The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning with January 1, 2017 and ending on January 1, 2025, by the lesser of: (i) 3,000,000 shares of common stock, (ii) 1% of the number of outstanding shares of common stock on the immediately preceding December 31 or (iii) such lesser amount of shares as determined by the compensation committee of the Company\u2019s Board of Directors. On January 1, 2018, the number of shares available for issuance under our 2015 Plan and our ESPP increased by 358,127 shares and 314,289 shares, respectively, pursuant to these provisions.\u00a0\u00a0These increases are not reflected in the table above.\u00a0\u00a0We no longer grant new awards under our 2012 Plan, and any awards previously granted under such plan prior to our initial public offering that are forfeited, canceled, reacquired by us prior to vesting satisfied without the issuance of stock or otherwise terminated (other than by exercise) are added to shares available for issuance under the 2015 Plan.</p></td>\n</tr>\n</table></div>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"CERTAIN_RELATIONSHIPS_RELATED_PARTY_TRA\"></a><a name=\"CERTAIN_RELATIONSHIPS_RELATED_PARTY_TRA\"></a>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Other than the compensation agreements and other arrangements described under \u201cCompensation of Executive Officers\u201d and the transactions described below, since January\u00a01, 2017, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">26</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU27\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Transactions with Sanofi S.A.</font></p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Until June 2017, Dr. David P. Meeker, a member of our Board of Directors, was an Executive Vice President and an executive officer of Sanofi S.A. (\u201cSanofi\u201d), our strategic collaboration partner and a holder of more than five percent of our outstanding common stock.\u00a0\u00a0Set forth below are descriptions of transactions with Sanofi (or its affiliated entities) to which we are or were a party.</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Payments under Collaboration Agreement</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We are party to a license and collaboration agreement (the \u201cCollaboration Agreement\u201d) entered into in August 2014 with Aventis Inc., a wholly-owned subsidiary of Sanofi, for the research, development and potential commercialization of pharmaceutical products for the treatment, prevention and diagnosis of HCM and DCM, as well as potential additional indications.\u00a0\u00a0Pursuant to the Collaboration Agreement, in November 2016, Sanofi paid to us a $25.0 million milestone-based payment in connection with our submission of an investigational new drug application for MYK-491 to the U.S. Food and Drug Administration.\u00a0\u00a0Additionally, in December 2016, Sanofi provided notice to us of its election to continue the collaboration through December 31, 2018 pursuant to the terms of the Collaboration Agreement.\u00a0\u00a0In connection with Sanofi\u2019s decision to continue the collaboration, we received a $45.0 million milestone payment in January 2017.</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Participation in Follow-On Offering</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In\u00a0\u00a0August 2017, Sanofi (through its wholly-owned subsidiary, Aventis Inc.) purchased an aggregate of 350,000 shares of our common stock in our follow-on public offering at the public offering price and on the same terms as the other purchasers in the offering, which included the following purchase in an amount that exceeded $120,000: </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:70%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Beneficial Owner</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Shares Purchased</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">in Offering</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Aggregate</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Purchase</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Price ($)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Sanofi</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.58%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">350,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">12,425,000</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n</table></div>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Executive Officer and Director Compensation </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Employment Agreements </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We have entered into offer letters or employment agreements with each of our named executive officers and certain of our other executive officers. For more information regarding these arrangements, see \u201cCompensation of Executive Officers\u2014Employment Arrangements with Our Named Executive Officers.\u201d </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;\">Stock Option Awards </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">For information regarding stock option awards granted to our named executive officers and directors, see \u201cElection of Directors\u2014Director Compensation\u201d and \u201cCompensation of Executive Officers.\u201d </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Indemnification Agreements </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We have entered into agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys\u2019 fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person\u2019s status as a member of our Board of Directors to the maximum extent allowed under Delaware law. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Procedures for Approval of Related Person Transactions </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Audit Committee conducts an appropriate review of all related party transactions for potential conflict of interest situations on an ongoing basis, and the approval of the Audit Committee is required for all such transactions. The Audit Committee follows the policies and procedures set forth in our Related Person Transaction Policy in order to facilitate such review. The Related Person Transaction Policy is written. </p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">27</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU28\"></a><a name=\"SECURITY_OWNERSHIP_CERTAIN_BENEFICIAL_OW\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"SECURITY_OWNERSHIP_CERTAIN_BENEFICIAL_OW\"></a>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS </font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </font></p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The following table sets forth the beneficial ownership information of our common stock by: </p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">each person known to us to be the beneficial owner of more than 5% of our common stock as of March\u00a031, 2018; </p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">each named executive officer; </p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">each of our directors; and </p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></td>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u2022</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">all of our executive officers and directors as a group. </p></td></tr></table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We have based our calculation of the percentage of beneficial ownership of 35,928,038 shares of common stock outstanding on March\u00a031, 2018. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Each individual or entity shown in the table has furnished information with respect to beneficial ownership. The information with respect to our executive officers and directors is as of March\u00a031, 2018 unless otherwise noted. The information with respect to certain significant stockholders is based on filings by the beneficial owners with the SEC pursuant to section 13(d) and 13(g) of the Exchange Act. We have determined beneficial ownership in accordance with the SEC\u2019s rules. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options that are either immediately exercisable or exercisable on or before May\u00a030, 2018, which is 60 days after March\u00a031, 2018. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Beneficial Owner (1)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Number\u00a0of\u00a0Shares</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Beneficially\u00a0Owned</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Percentage</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">of Shares</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Beneficially</p>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">Owned</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">5% or Greater Stockholders:</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Entities affiliated with Wellington Management Company (1)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">280 Congress Street, Boston, MA 02110</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">3,130,761</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">8.7</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Entities affiliated with Fidelity (2)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">245 Summer Street, Boston, MA 02210</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,506,577</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">12.5</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Entities affiliated with Sanofi (3)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">54 Rue La Boetie, 75008 Paris (France)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4,018,899</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">11.2</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Entities affiliated with Blackrock, Inc. (4)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">55 East 52<sup style=\"font-size:85%; vertical-align:top\">nd</sup> Street, New York, NY 10055</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,920,651</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">5.3</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Named Executive Officers and Directors:</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">T. Anastasios Gianakakos (5)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">984,437</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">2.7</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">June Lee, M.D.(6)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">52,408</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Robert McDowell(7)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">202,982</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mark Perry (8)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">60,570</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Sunil Agarwal (9)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">32,999</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Mary B. Cranston (10)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">32,541</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Wendy L. Yarno (11)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">17,907</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Kimberly Popovits (12)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">16,499</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">David P. Meeker, M.D. (13)</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">16,041</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#CFF0FC\" colspan=\"2\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</p></td>\n<td bgcolor=\"#CFF0FC\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">All directors and executive officers as a group (14 persons) (14)</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1,722,309</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;\" valign=\"bottom\">\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">4.7</p></td>\n<td bgcolor=\"#FFFFFF\" style=\"padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;\" valign=\"bottom\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">%</p></td>\n</tr>\n</table></div>\n<p style=\"border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">*</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Represents beneficial ownership of less than 1% of the shares of common stock. </p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">28</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(1)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU29\"></a><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Based on Schedule 13G/A filed on February 8, 2018 and consists of 3,130,761 shares of common stock owned of record by clients of one or more investment advisers identified in Exhibit A thereto directly or indirectly owned by Wellington Management Group LLP</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">. The address of the beneficial owner is c/o Wellington Management Company LLP, 280 Congress Street, Boston, MA 02210. </font></p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(2)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Based solely on a report on Schedule 13G/A filed with the SEC on February\u00a012, 2018, which indicates that (i)\u00a0FMR, LLC has sole dispositive power over 4,506,577 shares of common stock and (ii)\u00a0Abigail P. Johnson had sole dispositive power over 4,506,577 shares of common stock and. Abigail P. Johnson is a Director, the Vice Chairman, and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders\u2019 voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders\u2019 voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act (\u201cFidelity Funds\u201d) advised by Fidelity Management\u00a0&amp; Research Company (\u201cFMR Co\u201d), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds\u2019 Boards of Trustees. Fidelity Management\u00a0&amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds\u2019 Boards of Trustees. </p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(3)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Based solely on a report on Schedule 13G/A filed with the SEC on February\u00a013, 2018, which indicates that Sanofi has sole voting power and sole dispositive power with respect to 4,018,899 shares of common stock. </p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(4)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Based solely on a report on Schedule 13G filed with the SEC on February\u00a01, 2018, which indicates that Black Rock, Inc. has sole voting power with respect to 1,870,257 shares of common stock and sole dispositive power with respect to 1,920,651 shares of common stock</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(5)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Consists of: (i)\u00a0622,573 shares of common stock held by trusts, (ii)\u00a074,390 shares of common stock, of which 0 shares are subject to our right of repurchase as of March\u00a031, 2018, held by Mr.\u00a0Gianakakos and (iii)\u00a0options to purchase 287,474 shares of common stock that are exercisable within 60 days of March\u00a031, 2018, held by Mr.\u00a0Gianakakos. </p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(6)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Consists of options to purchase 52,408 shares of common stock that are exercisable within 60 days of March 31, 2018 held by Ms. Lee.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(7)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Consists of options to purchase 202,982 shares of common stock that are exercisable within 60 days of March 31, 2018 held by Mr. McDowell.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(8)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Consists of: (i) 25,408 shares of common stock held by Mr.\u00a0Perry and (ii) options to purchase 35,162 shares of common stock that are exercisable within 60 days of March\u00a031, 2018 held by Mr.\u00a0Perry.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(9)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Consists of options to purchase 32,999shares of common stock that are exercisable within 60 days of March\u00a031, 2018 held by Dr.\u00a0Agarwal. </p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(10)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Consists of options to purchase 32,541 shares of common stock that are exercisable within 60 days of March\u00a031, 2018 held by Ms. Cranston.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(11)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Consists of: (i) 1,408 shares of common stock held by Ms.\u00a0Yarno and (ii) options to purchase 16,499 shares of common stock that are exercisable within 60 days of March\u00a031, 2018 held by Ms.\u00a0Yarno.</p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(12)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU33\"></a>Consists of options to purchase 16,499 shares of common stock that are exercisable within 60 days of March\u00a031, 2018 held by Ms. Popovits. </p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(13)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\">Consists of options to purchase 16,041 shares of common stock that are exercisable within 60 days of March\u00a031, 2018 held by Dr. Meeker. </p></td></tr></table></div>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">(14)</font></p></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU30\"></a>Includes the number of shares beneficially owned by the named executive officers and directors listed in the above table, as well as (i) 93,546 shares of common stock, of which 10,629 shares are subject to our right of repurchase as of March\u00a031, 2018 and options to purchase 39,909 shares of common stock that are exercisable within 60 days of March\u00a031, 2018, held by Joseph Lambing, (ii) 61,777 shares of common stock, of which </p></td></tr></table></div>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">29</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<div align=\"left\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:100%;\">\n<tr>\n<td style=\"width:5.24%;white-space:nowrap\" valign=\"top\"></td>\n<td valign=\"top\">\n<p style=\"margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;\"><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">6,803 shares are subject to our right of repurchase as of March\u00a031, 2018 and optio</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">ns to purchase 46,064 shares of common stock that are exercisable within 60 days of March\u00a031, 2018, held by Jake Bauer, (iii) options to purchase 64,629 shares of common stock that are exercisable within 60 days of March\u00a031, 2018, held by Marc Semigran, (i</font><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">v) options to purchase 0 shares of common stock that are exercisable within 60 days of March 31, 2018 held by Cynthia Ladd, and (v) options to purchase 0 shares of common stock that are exercisable within 60 days of March 31, 2018 held by Taylor Harris.</font></p></td></tr></table></div>\n<p style=\"margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"SECTION_16A_BENEFICIAL_OWNERSHIP_REPORTI\"></a><a name=\"SECTION_16A_BENEFICIAL_OWNERSHIP_REPORTI\"></a>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Section\u00a016(a) of the Exchange Act requires our officers and directors, and persons who own more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership (Forms 3, 4 and 5) with the SEC. Officers, directors and greater than 10% stockholders are required to furnish us with copies of all such forms which they file. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">To our knowledge, based solely on our review of such reports or written representations from certain reporting persons, we believe that all of the filing requirements applicable to our officers, directors, greater than 10% beneficial owners and other persons subject to Section 16 of the Exchange Act were complied with during the year ended December 31, 2017, except that one transaction involving the partial exercise of an option to purchase common stock by Mr. Gianakakos, was reported late on a Form 5 due to administrative error. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;\">The following Audit Committee Report is not considered proxy solicitation material and is not deemed filed with the Securities and Exchange Commission. Notwithstanding anything to the contrary set forth in any of the Company\u2019s filings made under the Securities Act of 1933 or the Exchange Act that might incorporate filings made by the Company under those statutes, the Audit Committee Report shall not be incorporated by reference into any prior filings or into any future filings made by the Company under those statutes. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">30</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU31\"></a><a name=\"AUDIT_COMMITTEE_REPORT\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"AUDIT_COMMITTEE_REPORT\"></a>AUDIT COMMIT</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">TEE REPORT </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Audit Committee of the Board of Directors (the \u201cAudit Committee\u201d) has furnished this report concerning the independent audit of the Company\u2019s financial statements. Each member of the Audit Committee meets the enhanced independence standards established by the Sarbanes-Oxley Act of 2002 and rulemaking of the Securities and Exchange Commission (the \u201cSEC\u201d) and the NASDAQ Stock Market regulations. A copy of the Audit Committee Charter is available on the Company\u2019s website at http://www.MyoKardia.com. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Audit Committee\u2019s responsibilities include assisting the Board of Directors regarding the oversight of the integrity of the Company\u2019s financial statements, the Company\u2019s compliance with legal and regulatory requirements, the independent registered public accounting firm\u2019s qualifications and independence, and the performance of the Company\u2019s internal audit function and the independent registered public accounting firm. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">In fulfilling its oversight responsibilities, the Audit Committee reviewed and discussed the Company\u2019s financial statements for the fiscal year ended December\u00a031, 2017 with the Company\u2019s management and PricewaterhouseCoopers LLP. In addition, the Audit Committee has discussed with PricewaterhouseCoopers LLP, with and without management present, their evaluation of the Company\u2019s internal accounting controls and overall quality of the Company\u2019s financial reporting. The Audit Committee also discussed with PricewaterhouseCoopers LLP the matters required to be discussed by Statement on Auditing Standards No.\u00a0114 (formerly SAS 61), as amended (AICPA, <font style=\"font-style:italic;\">Professional Standards</font>, Vol. 1 AU section 380), as adopted by the Public Company Accounting Oversight Board in Rule 3200T. The Audit Committee also received the written disclosures and the letter from PricewaterhouseCoopers LLP required by the Public Company Accounting Oversight Board Rule 3526 and the Audit Committee discussed the independence of PricewaterhouseCoopers LLP with that firm. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Based on the Audit Committee\u2019s review and discussions noted above, the Audit Committee recommended to the Board of Directors, and the Board of Directors approved, that the audited financial statements be included in the Company\u2019s Annual Report for the fiscal year ended December\u00a031, 2017. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">The Audit Committee and the Board of Directors have recommended the selection of PricewaterhouseCoopers LLP as the Company\u2019s independent registered public accounting firm for the year ending December\u00a031, 2018. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">AUDIT COMMITTEE</p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">MARY CRANSTON, CHAIRPERSON</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">MARK PERRY </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">WENDY L. YARNO</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">31</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU32\"></a><a name=\"HOUSEHOLDING_PROXY_MATERIALS\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"HOUSEHOLDING_PROXY_MATERIALS\"></a>HOUSEHOLDING OF P</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">ROXY MATERIALS </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We have made available a procedure approved by the SEC known as \u201chouseholding.\u201d This procedure allows multiple stockholders residing at the same address the convenience of receiving a single copy of our Notice, Annual Report on Form 10-K and proxy materials, as applicable. This allows us to save money by reducing the number of documents we must print and mail, and helps protect the environment as well. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Householding is available to both registered stockholders (i.e., those stockholders with certificates registered in their name) and streetname holders (i.e., those stockholders who hold their shares through a brokerage). </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Registered Stockholders </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">If you are a registered stockholder and would like to consent to a mailing of proxy materials and other stockholder information only to one account in your household, as identified by you, we will deliver or mail a single copy of our Annual Report and proxy materials for all registered stockholders residing at the same address. Your consent will be perpetual unless you revoke it, which you may do at any time by contacting the Householding Department of Broadridge Corporate Issuer Solutions, Inc. (\u201cBroadridge\u201d), at 1717 Arch Street, Suite 1300, Philadelphia, PA 19103. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Registered stockholders who have not consented to householding will continue to receive copies of Annual Reports and proxy materials for each registered stockholder residing at the same address. As a registered stockholder, you may elect to participate in householding and receive only a single copy of Annual Reports or proxy statements for all registered stockholders residing at the same address by contacting Broadridge as outlined above. </p>\n<p style=\"margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">Street Name Holders </p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Stockholders who hold their shares through a brokerage may elect to participate in householding or revoke their consent to participate in householding by contacting their respective brokers. </p>\n<p style=\"margin-bottom:6pt;margin-top:6pt;margin-left:0.16%;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">32</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU38\"></a><a name=\"_AEIOULastRenderedPageBreakAEIOU33\"></a><a name=\"OR_MATTERS\"></a><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"OR_MATTERS\"></a>OTHER MA</font><font style=\"font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;\">TTERS </font></p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">We are not aware of any matters that may come before the meeting other than those referred to in the notice. If any other matter shall properly come before the Annual Meeting, however, the persons named in the accompanying proxy intend to vote all proxies in accordance with their best judgment. </p>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">Accompanying this Proxy Statement is our Annual Report. Copies of our Annual Report are available free of charge on our website at www.MyoKardia.com or you can request a copy free of charge by calling Investor Relations at (650)\u00a0351-4705 or sending an e-mail request to IR@myokardia.com. Please include your contact information with the request. </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p>\n<div align=\"right\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse; width:45%;\">\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">By Order of the Board of Directors,</p></td>\n</tr>\n<tr style=\"height:12pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">MyoKardia, Inc.</p></td>\n</tr>\n<tr style=\"height:12pt;\">\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45%;\" valign=\"middle\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">\u00a0</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">/s/ T. Anastasios Gianakakos</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">T. Anastasios Gianakakos</p></td>\n</tr>\n<tr>\n<td style=\"padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45%;\" valign=\"top\">\n<p style=\"margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">President and Chief Executive Officer</p></td>\n</tr>\n</table></div>\n<p style=\"margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">April\u00a017, 2018</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">33</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU34\"></a><img alt=\"\" src=\"g2018041701200089114085.jpg\" style=\"width:623px;height:802px;\" title=\"\"/><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">1 1\u00a0\u00a012345678\u00a0\u00a012345678\u00a0\u00a012345678\u00a0\u00a012345678\u00a0\u00a012345678\u00a0\u00a012345678\u00a0\u00a012345678\u00a0\u00a012345678\u00a0\u00a0NAME\u00a0\u00a0THE COMPANY NAME INC. - COMMON 123,456,789,012.12345\u00a0\u00a0THE COMPANY NAME INC. - CLASS A 123,456,789,012.12345\u00a0\u00a0THE COMPANY NAME INC. - CLASS B 123,456,789,012.12345\u00a0\u00a0THE COMPANY NAME INC. - CLASS C 123,456,789,012.12345\u00a0\u00a0THE COMPANY NAME INC. - CLASS D 123,456,789,012.12345\u00a0\u00a0THE COMPANY NAME INC. - CLASS E 123,456,789,012.12345\u00a0\u00a0THE COMPANY NAME INC. - CLASS F 123,456,789,012.12345\u00a0\u00a0THE COMPANY NAME INC. - 401 K 123,456,789,012.12345\u00a0\u00a0.\u00a0\u00a0x\u00a0\u00a002 0000000000\u00a0\u00a0JOB #\u00a0\u00a01 OF 2\u00a0\u00a01 OF 2 PAGE\u00a0\u00a0SHARES\u00a0\u00a0CUSIP #\u00a0\u00a0SEQUENCE #\u00a0\u00a0THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.\u00a0\u00a0KEEP THIS PORTION FOR YOUR RECORDS\u00a0\u00a0DETACH AND RETURN THIS PORTION ONLY\u00a0\u00a0TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:\u00a0\u00a0Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date\u00a0\u00a0CONTROL #\u00a0\u00a0SHARES\u00a0\u00a0To withhold authority to vote for any\u00a0\u00a0individual nominee(s), mark \u201cFor All\u00a0\u00a0Except\u201d and write the number(s) of the\u00a0\u00a0nominee(s) on the line below.\u00a0\u00a00 0 0\u00a0\u00a00 0 0\u00a0\u00a00000377673_1 R1.0.1.17\u00a0\u00a0For Withhold For All\u00a0\u00a0All All Except\u00a0\u00a0The Board of Directors recommends you vote FOR\u00a0\u00a0the following:\u00a0\u00a01. To elect the two Class III directors\u00a0\u00a0Nominees\u00a0\u00a001 Tassos Gianakakos 02 Mary B. Cranston\u00a0\u00a0MYOKARDIA, INC.\u00a0\u00a0333 ALLERTON AVE.\u00a0\u00a0SOUTH SAN FRANCISCO, CA 94080\u00a0\u00a0Investor Address Line 1\u00a0\u00a0Investor Address Line 2\u00a0\u00a0Investor Address Line 3\u00a0\u00a0Investor Address Line 4\u00a0\u00a0Investor Address Line 5\u00a0\u00a0John Sample\u00a0\u00a01234 ANYWHERE STREET\u00a0\u00a0ANY CITY, ON A1A 1A1\u00a0\u00a0Investor Address Line 1\u00a0\u00a0Investor Address Line 2\u00a0\u00a0Investor Address Line 3\u00a0\u00a0Investor Address Line 4\u00a0\u00a0Investor Address Line 5\u00a0\u00a0John Sample\u00a0\u00a01234 ANYWHERE STREET\u00a0\u00a0ANY CITY, ON A1A 1A1\u00a0\u00a0VOTE BY INTERNET - www.proxyvote.com\u00a0\u00a0Use the Internet to transmit your voting instructions and for electronic delivery of\u00a0\u00a0information. Vote by 11:59 P.M. ET on 06/11/2018. Have your proxy card in hand when\u00a0\u00a0you access the web site and follow the instructions to obtain your records and to create\u00a0\u00a0an electronic voting instruction form.\u00a0\u00a0ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS\u00a0\u00a0If you would like to reduce the costs incurred by our company in mailing proxy materials,\u00a0\u00a0you may consent to receive all future proxy statements, proxy cards and annual reports\u00a0\u00a0electronically via e-mail or the Internet. To sign up for electronic delivery, please follow\u00a0\u00a0the instructions above to vote using the Internet and, when prompted, indicate that you\u00a0\u00a0agree to receive or access proxy materials electronically in the future.\u00a0\u00a0VOTE BY PHONE - 1-800-690-6903\u00a0\u00a0Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET\u00a0\u00a0on 06/11/2018. Have your proxy card in hand when you call and then follow the\u00a0\u00a0instructions.\u00a0\u00a0VOTE BY MAIL\u00a0\u00a0Mark, sign and date your proxy card and return it in the postage-paid envelope we have\u00a0\u00a0provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood,\u00a0\u00a0NY 11717.\u00a0\u00a0The Board of Directors recommends you vote FOR the following: For Against Abstain\u00a0\u00a02 To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm\u00a0\u00a0of the Company for its fiscal year ending December 31, 2018.\u00a0\u00a0NOTE: To transact such other business as may properly come before the meeting or any adjournment or postponement\u00a0\u00a0thereof.\u00a0\u00a0In their discretion, the proxies are authorized to vote upon such other business as may properly\u00a0\u00a0come before the Annual Meeting. This proxy, when properly executed, will be voted as directed herein by the\u00a0\u00a0undersigned Stockholder. If no direction is made, this proxy will be voted \"FOR ALL NOMINEES\" in Proposal 1 and\u00a0\u00a0\"FOR\" Proposal 2.\u00a0\u00a0Please sign exactly as your name(s) appear(s) hereon. When signing as\u00a0\u00a0attorney, executor, administrator, or other fiduciary, please give full\u00a0\u00a0title as such. Joint owners should each sign personally. All holders must\u00a0\u00a0sign. If a corporation or partnership, please sign in full corporate or\u00a0\u00a0partnership name by authorized officer.</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<hr style=\"page-break-after:always;width:100%;\"/>\n<p style=\"text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"><a name=\"_AEIOULastRenderedPageBreakAEIOU35\"></a><img alt=\"\" src=\"g2018041701200092214086.jpg\" style=\"width:623px;height:810px;\" title=\"\"/><font style=\"font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\"></font></p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;\">0000377673_2 R1.0.1.17\u00a0\u00a0Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:\u00a0\u00a0The Proxy Statement and Annual Report on Form 10-K are available at www.proxyvote.com.\u00a0\u00a0Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Proxy Statement and Annual Report on Form\u00a0\u00a010-K are available at www.proxyvote.com\u00a0\u00a0MYOKARDIA, INC.\u00a0\u00a0Proxy for Annual Meeting of Stockholders on June 12, 2018\u00a0\u00a0Solicited on Behalf of the Board of Directors\u00a0\u00a0The undersigned hereby appoints Tassos Gianakakos and Jacob Bauer as proxies, each with the power to\u00a0\u00a0appoint his substitute, and hereby authorizes such proxies to represent and vote, as designated on the reverse\u00a0\u00a0side hereof, all the shares of common stock of MyoKardia, Inc. held of record by the undersigned at the close of\u00a0\u00a0business on April 13, 2018 at the Annual Meeting of Stockholders to be held June 12, 2018 at 9:00AM Pacific\u00a0\u00a0Time at the DoubleTree by Hilton San Francisco Airport North, 5000 Sierra Point Parkway, Brisbane, CA 94005,\u00a0\u00a0and at any adjournment thereof.\u00a0\u00a0(Continued and to be signed on reverse side) </p>\n<p style=\"margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p>\n<p style=\"text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;\">\u00a0</p></body>\n</html>\n</text>\n</description></filename></sequence></type></document>\n"}, "reportNo6": {"reportType": "Form 4", "url": ["https://www.sec.gov/Archives/edgar/data/1552451/000089924318010091/xslF345X03/doc4.xml", "2018-04-12"], "content": {"nameOfOwner": "Bauer Jake", "position": "See Remarks", "dateOfReport": "2018-04-11", "transaction1": {"classOfStock": "Common Stock", "transactionDate": "2018-04-11", "amount": "5000", "price": "12.25", "buyOrSell": "A", "ownershipAfterTransaction": "66777"}, "transaction2": {"classOfStock": "Common Stock", "transactionDate": "2018-04-11", "amount": "5000", "price": "50.00", "buyOrSell": "D", "ownershipAfterTransaction": "61777"}, "transaction3": {"classOfStock": "Stock Option (Right to Buy)", "transactionDate": "2018-04-11", "amount": "5000", "price": "0.00", "buyOrSell": "D", "ownershipAfterTransaction": "49850"}}, "dateOfReport": "2018-04-11", "htmlOfReport": " <!DOCTYPE html PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<title>SEC FORM \n            4</title>\n<style type=\"text/css\">\n              .FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;}\n              .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;}\n              .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;}\n              .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FormNumText {font-size: small; font-weight: bold; font-family: arial, helvetica, sans-serif;}\n              .FormAttention {font-size: medium; font-weight: bold; font-family: helvetica;}\n              .FormText {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTextR {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .FormTextC {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .FormEMText {font-size: medium; font-style: italic; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .FormULText {font-size: medium; text-decoration: underline; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .SmallFormTextR {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .SmallFormTextC {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .MedSmallFormText {font-size: x-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle1 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; border-top: black thick solid;}\n              .FormTitle2 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle3 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; padding-top: 2em; padding-bottom: 1em;}\n              .SectionTitle {font-size: small; text-align: left; font-family: arial, helvetica, sans-serif; \n              \t\tfont-weight: bold; border-top: gray thin solid; border-bottom: gray thin solid;}\n              .FormName {font-size: large; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .CheckBox {text-align: center; width: 5px; cell-spacing: 0; padding: 0 3 0 3; border-width: thin; border-style: solid;  border-color: black:}\n              body {background: white;}\n      </style>\n</head>\n<body>SEC Form 4 \n   <table border=\"0\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" class=\"FormName\" colspan=\"2\" valign=\"top\" width=\"20%\">FORM 4</td>\n<td align=\"center\" rowspan=\"2\" valign=\"middle\" width=\"60%\">\n<span class=\"FormTitle\">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span><br/><span class=\"MedSmallFormText\">Washington, D.C. 20549</span><br/><br/><span class=\"FormTitle\">STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP</span><br/><br/><span class=\"MedSmallFormText\">Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934</span><br/><span class=\"MedSmallFormText\">or Section 30(h) of the Investment Company Act of 1940</span>\n</td>\n<td align=\"center\" rowspan=\"2\" valign=\"top\" width=\"20%\"><table border=\"1\" summary=\"OMB Approval Status Box\" width=\"100%\">\n<tr><td class=\"FormTextC\">OMB APPROVAL</td></tr>\n<tr><td><table border=\"0\" summary=\"OMB Interior Box\" width=\"100%\">\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">OMB Number:</td>\n<td class=\"SmallFormTextR\">3235-0287</td>\n</tr>\n<tr><td class=\"SmallFormText\" colspan=\"4\">Estimated average burden</td></tr>\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">hours per response:</td>\n<td class=\"SmallFormTextR\">0.5</td>\n</tr>\n</table></td></tr>\n</table></td>\n</tr>\n<tr valign=\"middle\">\n<td><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tr><td>\u00a0\u00a0</td></tr></table></td>\n<td class=\"SmallFormText\">Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. \n         <i>See</i>\n\n         Instruction 1(b).</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td rowspan=\"3\" valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">1. Name and Address of Reporting Person<sup>*</sup></span><table border=\"0\" width=\"100%\"><tr><td><a Jake</a></td></tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(Last)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(First)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Middle)</td>\n</tr></table>\n<table border=\"0\" width=\"100%\">\n<tr><td><span class=\"FormData\">C/O MYOKARDIA, INC.</span></td></tr>\n<tr><td><span class=\"FormData\">333 ALLERTON AVENUE</span></td></tr>\n</table>\n<hr width=\"98%\"/>\n<span class=\"MedSmallFormText\">(Street)</span><table border=\"0\" width=\"100%\"><tr>\n<td width=\"33%\"><span class=\"FormData\">SOUTH SAN FRANCISCO</span></td>\n<td width=\"33%\"><span class=\"FormData\">CA</span></td>\n<td width=\"33%\"><span class=\"FormData\">94080</span></td>\n</tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(City)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(State)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Zip)</td>\n</tr></table>\n</td>\n<td valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">2. Issuer Name <b>and</b> Ticker or Trading Symbol\n      </span><br/><a Inc</a>\n     [ <span class=\"FormData\">MYOK</span> ]\n   </td>\n<td rowspan=\"2\" valign=\"top\">\n<span class=\"MedSmallFormText\">5. Relationship of Reporting Person(s) to Issuer\n      </span><br/><span class=\"MedSmallFormText\">(Check all applicable)</span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">Director</td>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">10% Owner</td>\n</tr>\n<tr>\n<td align=\"center\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\">Officer (give title below)</td>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Other (specify below)</td>\n</tr>\n<tr><td align=\"center\" colspan=\"4\"><span class=\"FormData\">See Remarks</span></td></tr>\n</table>\n</td>\n</tr>\n<tr><td valign=\"top\">\n<span class=\"MedSmallFormText\">3. Date of Earliest Transaction\n         (Month/Day/Year)</span><br/><span class=\"FormData\">04/11/2018</span>\n</td></tr>\n<tr>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">4. If Amendment, Date of Original Filed\n         (Month/Day/Year)</span><br/>\n</td>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">6. Individual or Joint/Group Filing (Check Applicable Line)\n      </span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by One Reporting Person</td>\n</tr>\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by More than One Reporting Person</td>\n</tr>\n</table>\n</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"11\" valign=\"top\" width=\"100%\"><b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b></th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"36%\">1. Title of Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">2. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"7%\">3. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"3\" valign=\"top\" width=\"19%\">4. Securities Acquired (A) or Disposed Of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"11%\">5. \n      Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"9%\">6. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"8%\">7. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"3%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"8%\">Amount</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"5%\">(A) or (D)</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"6%\">Price</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">04/11/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">M</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">5,000</span></td>\n<td align=\"center\"><span class=\"FormData\">A</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">12.25</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">66,777</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">04/11/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">S</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">5,000</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">50</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">61,777</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n</tbody>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"16\" valign=\"top\" width=\"100%\">\n<b>Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned</b><br/><b>(e.g., puts, calls, warrants, options, convertible securities)</b>\n</th></tr>\n<tr>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"13%\">1. Title of Derivative Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2. Conversion or Exercise Price of Derivative Security\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">4. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"10%\">5. \n      Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">6. Date Exercisable and Expiration Date \n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"17%\">7. Title and Amount of Securities Underlying Derivative Security (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">8. Price of Derivative Security (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">9. \n      Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">10. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"7%\">11. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(A)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(D)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">Date Exercisable</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Expiration Date</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"10%\">Title</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"7%\">Amount or Number of Shares</th>\n</tr>\n</thead>\n<tbody><tr>\n<td align=\"left\"><span class=\"SmallFormData\">Stock Option (Right to Buy)</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">12.25</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">04/11/2018</span></td>\n<td align=\"center\"><span class=\"SmallFormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">M</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"SmallFormData\">5,000</span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">\n</span><span class=\"FootnoteData\"><sup>(2)</sup></span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">01/17/2027</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">5,000</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">0.00</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">49,850</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">D</span></td>\n<td align=\"left\"></td>\n</tr></tbody>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr><td class=\"MedSmallFormText\"><b>Explanation of Responses:</b></td></tr>\n<tr><td class=\"FootnoteData\">1. This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.</td></tr>\n<tr><td class=\"FootnoteData\">2. The shares subject to this option vest and become exercisable in 48 equal monthly installments from January 1, 2017, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.</td></tr>\n<tr><td class=\"FormText\"><b>Remarks:</b></td></tr>\n<tr><td class=\"FootnoteData\">Chief Business Officer</td></tr>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr>\n<td width=\"60%\"></td>\n<td width=\"20%\"><u><span class=\"FormData\">/s/ Jake Bauer</span></u></td>\n<td width=\"20%\"><u><span class=\"FormData\">04/12/2018</span></u></td>\n</tr>\n<tr>\n<td></td>\n<td class=\"MedSmallFormText\">** Signature of Reporting Person</td>\n<td class=\"MedSmallFormText\">Date</td>\n</tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">* If the form is filed by more than one reporting person, \n                  <i>see</i>\n\n                  Instruction \n                  4\n\n                  (b)(v).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">** Intentional misstatements or omissions of facts constitute Federal Criminal Violations \n                  <i>See</i>\n\n                  18 U.S.C. 1001 and 15 U.S.C. 78ff(a).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \n                  <i>see</i>\n\n                  Instruction 6 for procedure.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\"><b>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.</b></td></tr>\n</table>\n</body>\n</html>\n"}, "reportNo7": {"reportType": "Form 4", "url": ["https://www.sec.gov/Archives/edgar/data/1413822/000089924318009605/xslF345X03/doc4.xml", "2018-04-05"], "content": {"nameOfOwner": "GIANAKAKOS ANASTASIOS", "position": "President and CEO", "dateOfReport": "2018-04-04", "transaction1": {"classOfStock": "Common Stock", "transactionDate": "2018-04-04", "amount": "3000", "price": "1.5068", "buyOrSell": "A", "ownershipAfterTransaction": "77390"}, "transaction2": {"classOfStock": "Common Stock", "transactionDate": "2018-04-04", "amount": "1775", "price": "47.62", "buyOrSell": "D", "ownershipAfterTransaction": "75615"}, "transaction3": {"classOfStock": "Common Stock", "transactionDate": "2018-04-04", "amount": "1225", "price": "48.4389", "buyOrSell": "D", "ownershipAfterTransaction": "74390"}, "transaction4": {"classOfStock": "Stock Option (Right to Buy)", "transactionDate": "2018-04-04", "amount": "3000", "price": "0.00", "buyOrSell": "D", "ownershipAfterTransaction": "126235"}}, "dateOfReport": "2018-04-04", "htmlOfReport": " <!DOCTYPE html PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<title>SEC FORM \n            4</title>\n<style type=\"text/css\">\n              .FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;}\n              .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;}\n              .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;}\n              .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FormNumText {font-size: small; font-weight: bold; font-family: arial, helvetica, sans-serif;}\n              .FormAttention {font-size: medium; font-weight: bold; font-family: helvetica;}\n              .FormText {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTextR {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .FormTextC {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .FormEMText {font-size: medium; font-style: italic; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .FormULText {font-size: medium; text-decoration: underline; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .SmallFormTextR {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .SmallFormTextC {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .MedSmallFormText {font-size: x-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle1 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; border-top: black thick solid;}\n              .FormTitle2 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle3 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; padding-top: 2em; padding-bottom: 1em;}\n              .SectionTitle {font-size: small; text-align: left; font-family: arial, helvetica, sans-serif; \n              \t\tfont-weight: bold; border-top: gray thin solid; border-bottom: gray thin solid;}\n              .FormName {font-size: large; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .CheckBox {text-align: center; width: 5px; cell-spacing: 0; padding: 0 3 0 3; border-width: thin; border-style: solid;  border-color: black:}\n              body {background: white;}\n      </style>\n</head>\n<body>SEC Form 4 \n   <table border=\"0\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" class=\"FormName\" colspan=\"2\" valign=\"top\" width=\"20%\">FORM 4</td>\n<td align=\"center\" rowspan=\"2\" valign=\"middle\" width=\"60%\">\n<span class=\"FormTitle\">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span><br/><span class=\"MedSmallFormText\">Washington, D.C. 20549</span><br/><br/><span class=\"FormTitle\">STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP</span><br/><br/><span class=\"MedSmallFormText\">Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934</span><br/><span class=\"MedSmallFormText\">or Section 30(h) of the Investment Company Act of 1940</span>\n</td>\n<td align=\"center\" rowspan=\"2\" valign=\"top\" width=\"20%\"><table border=\"1\" summary=\"OMB Approval Status Box\" width=\"100%\">\n<tr><td class=\"FormTextC\">OMB APPROVAL</td></tr>\n<tr><td><table border=\"0\" summary=\"OMB Interior Box\" width=\"100%\">\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">OMB Number:</td>\n<td class=\"SmallFormTextR\">3235-0287</td>\n</tr>\n<tr><td class=\"SmallFormText\" colspan=\"4\">Estimated average burden</td></tr>\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">hours per response:</td>\n<td class=\"SmallFormTextR\">0.5</td>\n</tr>\n</table></td></tr>\n</table></td>\n</tr>\n<tr valign=\"middle\">\n<td><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tr><td>\u00a0\u00a0</td></tr></table></td>\n<td class=\"SmallFormText\">Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. \n         <i>See</i>\n\n         Instruction 1(b).</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td rowspan=\"3\" valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">1. Name and Address of Reporting Person<sup>*</sup></span><table border=\"0\" width=\"100%\"><tr><td><a ANASTASIOS</a></td></tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(Last)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(First)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Middle)</td>\n</tr></table>\n<table border=\"0\" width=\"100%\">\n<tr><td><span class=\"FormData\">C/O MYOKARDIA, INC.</span></td></tr>\n<tr><td><span class=\"FormData\">333 ALLERTON AVENUE</span></td></tr>\n</table>\n<hr width=\"98%\"/>\n<span class=\"MedSmallFormText\">(Street)</span><table border=\"0\" width=\"100%\"><tr>\n<td width=\"33%\"><span class=\"FormData\">SOUTH SAN FRANCISCO</span></td>\n<td width=\"33%\"><span class=\"FormData\">CA</span></td>\n<td width=\"33%\"><span class=\"FormData\">94080</span></td>\n</tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(City)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(State)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Zip)</td>\n</tr></table>\n</td>\n<td valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">2. Issuer Name <b>and</b> Ticker or Trading Symbol\n      </span><br/><a Inc</a>\n     [ <span class=\"FormData\">MYOK</span> ]\n   </td>\n<td rowspan=\"2\" valign=\"top\">\n<span class=\"MedSmallFormText\">5. Relationship of Reporting Person(s) to Issuer\n      </span><br/><span class=\"MedSmallFormText\">(Check all applicable)</span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"35%\">Director</td>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">10% Owner</td>\n</tr>\n<tr>\n<td align=\"center\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\">Officer (give title below)</td>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Other (specify below)</td>\n</tr>\n<tr><td align=\"center\" colspan=\"4\"><span class=\"FormData\">President and CEO</span></td></tr>\n</table>\n</td>\n</tr>\n<tr><td valign=\"top\">\n<span class=\"MedSmallFormText\">3. Date of Earliest Transaction\n         (Month/Day/Year)</span><br/><span class=\"FormData\">04/04/2018</span>\n</td></tr>\n<tr>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">4. If Amendment, Date of Original Filed\n         (Month/Day/Year)</span><br/>\n</td>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">6. Individual or Joint/Group Filing (Check Applicable Line)\n      </span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by One Reporting Person</td>\n</tr>\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by More than One Reporting Person</td>\n</tr>\n</table>\n</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"11\" valign=\"top\" width=\"100%\"><b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b></th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"36%\">1. Title of Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">2. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"7%\">3. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"3\" valign=\"top\" width=\"19%\">4. Securities Acquired (A) or Disposed Of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"11%\">5. \n      Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"9%\">6. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"8%\">7. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"3%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"8%\">Amount</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"5%\">(A) or (D)</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"6%\">Price</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">04/04/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">M</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">3,000</span></td>\n<td align=\"center\"><span class=\"FormData\">A</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">1.5068</span>\n</td>\n<td align=\"center\"><span class=\"FormData\">77,390</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">04/04/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">S</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">1,775</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">47.62</span><span class=\"FootnoteData\"><sup>(2)</sup></span>\n</td>\n<td align=\"center\"><span class=\"FormData\">75,615</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">04/04/2018</span></td>\n<td align=\"center\"><span class=\"FormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">S</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">1,225</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"center\">\n<span class=\"FormText\">$</span><span class=\"FormData\">48.4389</span><span class=\"FootnoteData\"><sup>(3)</sup></span>\n</td>\n<td align=\"center\"><span class=\"FormData\">74,390</span></td>\n<td align=\"center\"><span class=\"FormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">85,973</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Reporting Person's Trust 2</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">500,000</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Reporting Person's Trust 3</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">12,200</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Trust 1</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">12,200</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Trust 2</span></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"FormData\">Common Stock</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"FormData\">12,200</span></td>\n<td align=\"center\"><span class=\"FormData\">I</span></td>\n<td align=\"left\"><span class=\"FormData\">By Trust 3</span></td>\n</tr>\n</tbody>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"16\" valign=\"top\" width=\"100%\">\n<b>Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned</b><br/><b>(e.g., puts, calls, warrants, options, convertible securities)</b>\n</th></tr>\n<tr>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"13%\">1. Title of Derivative Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2. Conversion or Exercise Price of Derivative Security\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">4. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"10%\">5. \n      Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">6. Date Exercisable and Expiration Date \n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"17%\">7. Title and Amount of Securities Underlying Derivative Security (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">8. Price of Derivative Security (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">9. \n      Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">10. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"7%\">11. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(A)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(D)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">Date Exercisable</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Expiration Date</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"10%\">Title</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"7%\">Amount or Number of Shares</th>\n</tr>\n</thead>\n<tbody><tr>\n<td align=\"left\"><span class=\"SmallFormData\">Stock Option (Right to Buy)</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">1.5068</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">04/04/2018</span></td>\n<td align=\"center\"><span class=\"SmallFormData\"></span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">M</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"SmallFormData\">3,000</span></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">\n</span><span class=\"FootnoteData\"><sup>(4)</sup></span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">06/03/2025</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">3,000</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">0.00</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">126,235</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">D</span></td>\n<td align=\"left\"></td>\n</tr></tbody>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr><td class=\"MedSmallFormText\"><b>Explanation of Responses:</b></td></tr>\n<tr><td class=\"FootnoteData\">1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.</td></tr>\n<tr><td class=\"FootnoteData\">2. The sale price reported in column 4 of Table 1 represents the average sale price of the shares sold ranging from $47.05 to $48.00 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.</td></tr>\n<tr><td class=\"FootnoteData\">3. The sale price reported in column 4 of Table 1 represents the average sale price of the shares sold ranging from $48.05 to $48.70 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.</td></tr>\n<tr><td class=\"FootnoteData\">4. 25% of the shares subject to the option vested and became exercisable on June 4, 2016, and the remaining shares subject to this option vest and become exercisable in monthly installments through June 4, 2019.</td></tr>\n<tr><td class=\"FormText\"><b>Remarks:</b></td></tr>\n<tr><td class=\"FootnoteData\"></td></tr>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr>\n<td width=\"60%\"></td>\n<td width=\"20%\"><u><span class=\"FormData\">/s/ Jake Bauer, Attorney-in-Fact</span></u></td>\n<td width=\"20%\"><u><span class=\"FormData\">04/05/2018</span></u></td>\n</tr>\n<tr>\n<td></td>\n<td class=\"MedSmallFormText\">** Signature of Reporting Person</td>\n<td class=\"MedSmallFormText\">Date</td>\n</tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">* If the form is filed by more than one reporting person, \n                  <i>see</i>\n\n                  Instruction \n                  4\n\n                  (b)(v).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">** Intentional misstatements or omissions of facts constitute Federal Criminal Violations \n                  <i>See</i>\n\n                  18 U.S.C. 1001 and 15 U.S.C. 78ff(a).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \n                  <i>see</i>\n\n                  Instruction 6 for procedure.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\"><b>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.</b></td></tr>\n</table>\n</body>\n</html>\n"}, "reportNo8": {"reportType": "Form 4", "url": ["https://www.sec.gov/Archives/edgar/data/1552451/000089924318009603/xslF345X03/doc4.xml", "2018-04-05"], "content": {"nameOfOwner": "Harris Taylor C.", "position": "Chief Financial Officer", "dateOfReport": "2018-04-04", "transaction1": {"classOfStock": "Stock Option (Right to Buy)", "transactionDate": "2018-04-04", "amount": "100000", "price": "0.00", "buyOrSell": "A", "ownershipAfterTransaction": "100000"}, "transaction2": {"classOfStock": "Restricted Stock Units", "transactionDate": "2018-04-04", "amount": "15000", "price": "0.00", "buyOrSell": "A", "ownershipAfterTransaction": "15000"}}, "dateOfReport": "2018-04-04", "htmlOfReport": " <!DOCTYPE html PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<title>SEC FORM \n            4</title>\n<style type=\"text/css\">\n              .FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;}\n              .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;}\n              .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;}\n              .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FormNumText {font-size: small; font-weight: bold; font-family: arial, helvetica, sans-serif;}\n              .FormAttention {font-size: medium; font-weight: bold; font-family: helvetica;}\n              .FormText {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTextR {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .FormTextC {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .FormEMText {font-size: medium; font-style: italic; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .FormULText {font-size: medium; text-decoration: underline; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .SmallFormTextR {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .SmallFormTextC {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .MedSmallFormText {font-size: x-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle1 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; border-top: black thick solid;}\n              .FormTitle2 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle3 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; padding-top: 2em; padding-bottom: 1em;}\n              .SectionTitle {font-size: small; text-align: left; font-family: arial, helvetica, sans-serif; \n              \t\tfont-weight: bold; border-top: gray thin solid; border-bottom: gray thin solid;}\n              .FormName {font-size: large; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .CheckBox {text-align: center; width: 5px; cell-spacing: 0; padding: 0 3 0 3; border-width: thin; border-style: solid;  border-color: black:}\n              body {background: white;}\n      </style>\n</head>\n<body>SEC Form 4 \n   <table border=\"0\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" class=\"FormName\" colspan=\"2\" valign=\"top\" width=\"20%\">FORM 4</td>\n<td align=\"center\" rowspan=\"2\" valign=\"middle\" width=\"60%\">\n<span class=\"FormTitle\">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span><br/><span class=\"MedSmallFormText\">Washington, D.C. 20549</span><br/><br/><span class=\"FormTitle\">STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP</span><br/><br/><span class=\"MedSmallFormText\">Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934</span><br/><span class=\"MedSmallFormText\">or Section 30(h) of the Investment Company Act of 1940</span>\n</td>\n<td align=\"center\" rowspan=\"2\" valign=\"top\" width=\"20%\"><table border=\"1\" summary=\"OMB Approval Status Box\" width=\"100%\">\n<tr><td class=\"FormTextC\">OMB APPROVAL</td></tr>\n<tr><td><table border=\"0\" summary=\"OMB Interior Box\" width=\"100%\">\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">OMB Number:</td>\n<td class=\"SmallFormTextR\">3235-0287</td>\n</tr>\n<tr><td class=\"SmallFormText\" colspan=\"4\">Estimated average burden</td></tr>\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">hours per response:</td>\n<td class=\"SmallFormTextR\">0.5</td>\n</tr>\n</table></td></tr>\n</table></td>\n</tr>\n<tr valign=\"middle\">\n<td><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"><tr><td>\u00a0\u00a0</td></tr></table></td>\n<td class=\"SmallFormText\">Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. \n         <i>See</i>\n\n         Instruction 1(b).</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td rowspan=\"3\" valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">1. Name and Address of Reporting Person<sup>*</sup></span><table border=\"0\" width=\"100%\"><tr><td><a Taylor C.</a></td></tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(Last)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(First)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Middle)</td>\n</tr></table>\n<table border=\"0\" width=\"100%\">\n<tr><td><span class=\"FormData\">C/O MYOKARDIA, INC.</span></td></tr>\n<tr><td><span class=\"FormData\">333 ALLERTON AVENUE</span></td></tr>\n</table>\n<hr width=\"98%\"/>\n<span class=\"MedSmallFormText\">(Street)</span><table border=\"0\" width=\"100%\"><tr>\n<td width=\"33%\"><span class=\"FormData\">SOUTH SAN FRANCISCO</span></td>\n<td width=\"33%\"><span class=\"FormData\">CA</span></td>\n<td width=\"33%\"><span class=\"FormData\">94080</span></td>\n</tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(City)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(State)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Zip)</td>\n</tr></table>\n</td>\n<td valign=\"top\" width=\"35%\">\n<span class=\"MedSmallFormText\">2. Issuer Name <b>and</b> Ticker or Trading Symbol\n      </span><br/><a Inc</a>\n     [ <span class=\"FormData\">MYOK</span> ]\n   </td>\n<td rowspan=\"2\" valign=\"top\">\n<span class=\"MedSmallFormText\">5. Relationship of Reporting Person(s) to Issuer\n      </span><br/><span class=\"MedSmallFormText\">(Check all applicable)</span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">Director</td>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">10% Owner</td>\n</tr>\n<tr>\n<td align=\"center\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\">Officer (give title below)</td>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Other (specify below)</td>\n</tr>\n<tr><td align=\"center\" colspan=\"4\"><span class=\"FormData\">Chief Financial Officer</span></td></tr>\n</table>\n</td>\n</tr>\n<tr><td valign=\"top\">\n<span class=\"MedSmallFormText\">3. Date of Earliest Transaction\n         (Month/Day/Year)</span><br/><span class=\"FormData\">04/04/2018</span>\n</td></tr>\n<tr>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">4. If Amendment, Date of Original Filed\n         (Month/Day/Year)</span><br/>\n</td>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">6. Individual or Joint/Group Filing (Check Applicable Line)\n      </span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by One Reporting Person</td>\n</tr>\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by More than One Reporting Person</td>\n</tr>\n</table>\n</td>\n</tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\"><thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"11\" valign=\"top\" width=\"100%\"><b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b></th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"36%\">1. Title of Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">2. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"7%\">3. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"3\" valign=\"top\" width=\"19%\">4. Securities Acquired (A) or Disposed Of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"11%\">5. \n      Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"9%\">6. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"8%\">7. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"3%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"8%\">Amount</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"5%\">(A) or (D)</th>\n<th align=\"center\" class=\"SmallFormText\" width=\"6%\">Price</th>\n</tr>\n</thead></table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"16\" valign=\"top\" width=\"100%\">\n<b>Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned</b><br/><b>(e.g., puts, calls, warrants, options, convertible securities)</b>\n</th></tr>\n<tr>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"13%\">1. Title of Derivative Security (Instr. \n      3)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">2. Conversion or Exercise Price of Derivative Security\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3. Transaction Date\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"5%\">3A. Deemed Execution Date, if any\n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">4. Transaction Code (Instr. \n      8)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"10%\">5. \n      Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. \n      3, 4 and 5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">6. Date Exercisable and Expiration Date \n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"SmallFormText\" colspan=\"2\" valign=\"top\" width=\"17%\">7. Title and Amount of Securities Underlying Derivative Security (Instr. \n      3 and 4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">8. Price of Derivative Security (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">9. \n      Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"6%\">10. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"SmallFormText\" rowspan=\"2\" valign=\"top\" width=\"7%\">11. Nature of Indirect Beneficial Ownership (Instr. \n      4)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Code</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">V</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(A)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">(D)</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"5%\">Date Exercisable</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"4%\">Expiration Date</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"10%\">Title</th>\n<th align=\"center\" class=\"SmallFormText\" valign=\"bottom\" width=\"7%\">Amount or Number of Shares</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td align=\"left\"><span class=\"SmallFormData\">Stock Option (Right to Buy)</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">48.5</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">04/04/2018</span></td>\n<td align=\"center\"><span class=\"SmallFormData\"></span></td>\n<td align=\"center\"><span class=\"SmallFormData\">A</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"SmallFormData\">100,000</span></td>\n<td align=\"center\"></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">\n</span><span class=\"FootnoteData\"><sup>(1)</sup></span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">04/03/2028</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">100,000</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">0.00</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">100,000</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n<tr>\n<td align=\"left\"><span class=\"SmallFormData\">Restricted Stock Units</span></td>\n<td align=\"center\"><span class=\"FootnoteData\"><sup>(2)</sup></span></td>\n<td align=\"center\"><span class=\"SmallFormData\">04/04/2018</span></td>\n<td align=\"center\"><span class=\"SmallFormData\"></span></td>\n<td align=\"center\"><span class=\"SmallFormData\">A</span></td>\n<td align=\"center\"></td>\n<td align=\"center\"><span class=\"SmallFormData\">15,000</span></td>\n<td align=\"center\"></td>\n<td align=\"center\">\n<span class=\"SmallFormData\">\n</span><span class=\"FootnoteData\"><sup>(2)</sup></span>\n</td>\n<td align=\"center\">\n<span class=\"SmallFormData\">\n</span><span class=\"FootnoteData\"><sup>(2)</sup></span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">Common Stock</span></td>\n<td align=\"center\"><span class=\"FormData\">15,000</span></td>\n<td align=\"center\">\n<span class=\"SmallFormText\">$</span><span class=\"SmallFormData\">0.00</span>\n</td>\n<td align=\"center\"><span class=\"SmallFormData\">15,000</span></td>\n<td align=\"center\"><span class=\"SmallFormData\">D</span></td>\n<td align=\"left\"></td>\n</tr>\n</tbody>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr><td class=\"MedSmallFormText\"><b>Explanation of Responses:</b></td></tr>\n<tr><td class=\"FootnoteData\">1. The shares underlying the option shall vest and become exercisable as to 25% of the shares on April 4, 2019, and as to the remainder of the shares in 36 equal monthly installments thereafter, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.</td></tr>\n<tr><td class=\"FootnoteData\">2. Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The units vest in equal annual installments over 4 years from April 4, 2018, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer.</td></tr>\n<tr><td class=\"FormText\"><b>Remarks:</b></td></tr>\n<tr><td class=\"FootnoteData\"></td></tr>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr>\n<td width=\"60%\"></td>\n<td width=\"20%\"><u><span class=\"FormData\">/s/ Taylor Harris</span></u></td>\n<td width=\"20%\"><u><span class=\"FormData\">04/05/2018</span></u></td>\n</tr>\n<tr>\n<td></td>\n<td class=\"MedSmallFormText\">** Signature of Reporting Person</td>\n<td class=\"MedSmallFormText\">Date</td>\n</tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">* If the form is filed by more than one reporting person, \n                  <i>see</i>\n\n                  Instruction \n                  4\n\n                  (b)(v).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">** Intentional misstatements or omissions of facts constitute Federal Criminal Violations \n                  <i>See</i>\n\n                  18 U.S.C. 1001 and 15 U.S.C. 78ff(a).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \n                  <i>see</i>\n\n                  Instruction 6 for procedure.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\"><b>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.</b></td></tr>\n</table>\n</body>\n</html>\n"}, "reportNo9": {"reportType": "Form 3", "url": "https://www.sec.gov/Archives/edgar/data/1552451/000089924318009598/xslF345X02/doc3.xml", "dateOfReport": "2018-04-05", "htmlOfReport": " <!DOCTYPE html PUBLIC \"-//W3C//DTD HTML 4.01 Transitional//EN\" \"http://www.w3.org/TR/html4/loose.dtd\">\n\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<title>SEC FORM \n            3</title>\n<style type=\"text/css\">\n              .FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;}\n              .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;}\n              .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;}\n              .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;}\n              .FormNumText {font-size: small; font-weight: bold; font-family: arial, helvetica, sans-serif;}\n              .FormAttention {font-size: medium; font-weight: bold; font-family: helvetica;}\n              .FormText {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTextR {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .FormTextC {font-size: small; font-weight: normal; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .FormEMText {font-size: medium; font-style: italic; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .FormULText {font-size: medium; text-decoration: underline; font-weight: normal; font-family: arial, helvetica, sans-serif;}\n              .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .SmallFormTextR {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: right;}\n              .SmallFormTextC {font-size: xx-small; font-family: arial, helvetica, sans-serif; text-align: center;}\n              .MedSmallFormText {font-size: x-small; font-family: arial, helvetica, sans-serif; text-align: left;}\n              .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle1 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; border-top: black thick solid;}\n              .FormTitle2 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .FormTitle3 {font-size: small; font-family: arial, helvetica, sans-serif; font-weight: bold; padding-top: 2em; padding-bottom: 1em;}\n              .SectionTitle {font-size: small; text-align: left; font-family: arial, helvetica, sans-serif; \n              \t\tfont-weight: bold; border-top: gray thin solid; border-bottom: gray thin solid;}\n              .FormName {font-size: large; font-family: arial, helvetica, sans-serif; font-weight: bold;}\n              .CheckBox {text-align: center; width: 5px; cell-spacing: 0; padding: 0 3 0 3; border-width: thin; border-style: solid;  border-color: black:}\n              body {background: white;}\n      </style>\n</head>\n<body>SEC Form 3 \n   <table border=\"0\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\"><tr>\n<td align=\"center\" class=\"FormName\" colspan=\"2\" valign=\"top\" width=\"20%\">FORM 3</td>\n<td align=\"center\" rowspan=\"1\" valign=\"middle\" width=\"60%\">\n<span class=\"FormTitle\">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span><br/><span class=\"MedSmallFormText\">Washington, D.C. 20549</span><br/><br/><span class=\"FormTitle\">INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES</span><br/><br/><span class=\"MedSmallFormText\">Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934</span><br/><span class=\"MedSmallFormText\">or Section 30(h) of the Investment Company Act of 1940</span>\n</td>\n<td align=\"center\" rowspan=\"1\" valign=\"top\" width=\"20%\"><table border=\"1\" summary=\"OMB Approval Status Box\" width=\"100%\">\n<tr><td class=\"FormTextC\">OMB APPROVAL</td></tr>\n<tr><td><table border=\"0\" summary=\"OMB Interior Box\" width=\"100%\">\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">OMB Number:</td>\n<td class=\"SmallFormTextR\">3235-0104</td>\n</tr>\n<tr><td class=\"SmallFormText\" colspan=\"4\">Estimated average burden</td></tr>\n<tr>\n<td class=\"SmallFormText\" colspan=\"3\">hours per response:</td>\n<td class=\"SmallFormTextR\">0.5</td>\n</tr>\n</table></td></tr>\n</table></td>\n</tr></table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\">\n<tr>\n<td rowspan=\"3\" valign=\"top\" width=\"30%\">\n<span class=\"MedSmallFormText\">1. Name and Address of Reporting Person<sup>*</sup></span><table border=\"0\" width=\"100%\"><tr><td><a Taylor C.</a></td></tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(Last)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(First)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Middle)</td>\n</tr></table>\n<table border=\"0\" width=\"100%\">\n<tr><td><span class=\"FormData\">C/O MYOKARDIA, INC.</span></td></tr>\n<tr><td><span class=\"FormData\">333 ALLERTON AVENUE</span></td></tr>\n</table>\n<hr width=\"98%\"/>\n<span class=\"MedSmallFormText\">(Street)</span><table border=\"0\" width=\"100%\"><tr>\n<td width=\"33%\"><span class=\"FormData\">SOUTH SAN FRANCISCO</span></td>\n<td width=\"33%\"><span class=\"FormData\">CA</span></td>\n<td width=\"33%\"><span class=\"FormData\">94080</span></td>\n</tr></table>\n<hr width=\"98%\"/>\n<table border=\"0\" width=\"100%\"><tr>\n<td class=\"MedSmallFormText\" width=\"33%\">(City)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(State)</td>\n<td class=\"MedSmallFormText\" width=\"33%\">(Zip)</td>\n</tr></table>\n</td>\n<td rowspan=\"3\" valign=\"top\" width=\"15%\">\n<span class=\"MedSmallFormText\">2. Date of Event Requiring Statement\n         (Month/Day/Year)</span><br/><span class=\"FormData\">04/04/2018</span>\n</td>\n<td colspan=\"2\" valign=\"top\">\n<span class=\"MedSmallFormText\">3. Issuer Name <b>and</b> Ticker or Trading Symbol\n      </span><br/><a Inc</a>\n     [ <span class=\"FormData\">MYOK</span> ]\n   </td>\n</tr>\n<tr>\n<td rowspan=\"2\" valign=\"top\" width=\"30%\">\n<span class=\"MedSmallFormText\">4. Relationship of Reporting Person(s) to Issuer\n      </span><br/><span class=\"MedSmallFormText\">(Check all applicable)</span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">Director</td>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"35%\">10% Owner</td>\n</tr>\n<tr>\n<td align=\"center\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\">Officer (give title below)</td>\n<td align=\"center\"></td>\n<td class=\"MedSmallFormText\">Other (specify below)</td>\n</tr>\n<tr><td align=\"center\" colspan=\"4\"><span class=\"FormData\">Chief Financial Officer</span></td></tr>\n</table>\n</td>\n<td valign=\"top\">\n<span class=\"MedSmallFormText\">5. If Amendment, Date of Original Filed\n         (Month/Day/Year)</span><br/>\n</td>\n</tr>\n<tr><td valign=\"top\">\n<span class=\"MedSmallFormText\">6. Individual or Joint/Group Filing (Check Applicable Line)\n      </span><table border=\"0\" width=\"100%\">\n<tr>\n<td align=\"center\" width=\"15%\"><span class=\"FormData\">X</span></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by One Reporting Person</td>\n</tr>\n<tr>\n<td align=\"center\" width=\"15%\"></td>\n<td class=\"MedSmallFormText\" width=\"85%\">Form filed by More than One Reporting Person</td>\n</tr>\n</table>\n</td></tr>\n</table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\"><thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"4\" valign=\"top\" width=\"100%\"><b>Table I - Non-Derivative Securities Beneficially Owned</b></th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" valign=\"top\" width=\"44%\">1. Title of Security (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"MedSmallFormText\" valign=\"top\" width=\"19%\">2. \n      Amount of Securities Beneficially Owned (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"MedSmallFormText\" valign=\"top\" width=\"11%\">3. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"MedSmallFormText\" valign=\"top\" width=\"26%\">4. Nature of Indirect Beneficial Ownership (Instr. \n      5)\n   </th>\n</tr>\n</thead></table>\n<table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" width=\"100%\"><thead>\n<tr><th align=\"center\" class=\"FormTextC\" colspan=\"8\" valign=\"top\" width=\"100%\">\n<b>Table II - Derivative Securities Beneficially Owned</b><br/><b>(e.g., puts, calls, warrants, options, convertible securities)</b>\n</th></tr>\n<tr>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"35%\">1. Title of Derivative Security (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"MedSmallFormText\" colspan=\"2\" valign=\"top\" width=\"9%\">2. Date Exercisable and Expiration Date \n      (Month/Day/Year)</th>\n<th align=\"left\" class=\"MedSmallFormText\" colspan=\"2\" valign=\"top\" width=\"26%\">3. Title and Amount of Securities Underlying Derivative Security (Instr. \n      4)\n   </th>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"7%\">4. Conversion or Exercise Price of Derivative Security\n   </th>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"8%\">5. Ownership Form: Direct (D) or Indirect (I) (Instr. \n      5)\n   </th>\n<th align=\"left\" class=\"MedSmallFormText\" rowspan=\"2\" valign=\"top\" width=\"15%\">6. Nature of Indirect Beneficial Ownership (Instr. \n      5)\n   </th>\n</tr>\n<tr>\n<th align=\"center\" class=\"MedSmallFormText\" valign=\"bottom\" width=\"4%\">Date Exercisable</th>\n<th align=\"center\" class=\"MedSmallFormText\" valign=\"bottom\" width=\"5%\">Expiration Date</th>\n<th align=\"center\" class=\"MedSmallFormText\" valign=\"bottom\" width=\"20%\">Title</th>\n<th align=\"center\" class=\"MedSmallFormText\" valign=\"bottom\" width=\"6%\">Amount or Number of Shares</th>\n</tr>\n</thead></table>\n<table border=\"0\" width=\"100%\">\n<tr><td class=\"MedSmallFormText\"><b>Explanation of Responses:</b></td></tr>\n<tr><td class=\"FormText\"><b>Remarks:</b></td></tr>\n<tr><td class=\"FootnoteData\">Exhibit List: Exhibit 24.1 - Power of Attorney</td></tr>\n<tr><td class=\"MedSmallFormText\"><b>No securities are beneficially owned.</b></td></tr>\n</table>\n<table border=\"0\" width=\"100%\">\n<tr>\n<td width=\"60%\"></td>\n<td width=\"20%\"><u><span class=\"FormData\">/s/ Taylor Harris</span></u></td>\n<td width=\"20%\"><u><span class=\"FormData\">04/05/2018</span></u></td>\n</tr>\n<tr>\n<td></td>\n<td class=\"MedSmallFormText\">** Signature of Reporting Person</td>\n<td class=\"MedSmallFormText\">Date</td>\n</tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">* If the form is filed by more than one reporting person, \n                  <i>see</i>\n\n                  Instruction \n                  5\n\n                  (b)(v).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">** Intentional misstatements or omissions of facts constitute Federal Criminal Violations \n                  <i>See</i>\n\n                  18 U.S.C. 1001 and 15 U.S.C. 78ff(a).</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\">Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \n                  <i>see</i>\n\n                  Instruction 6 for procedure.</td></tr>\n<tr><td class=\"MedSmallFormText\" colspan=\"3\"><b>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.</b></td></tr>\n</table>\n</body>\n</html>\n"}, "reportNo10": {"reportType": "8-K", "url": "https://www.sec.gov/Archives/edgar/data/1552451/000119312518106937/d562620d8k.htm", "dateOfReport": "2018-04-04", "content": "(c) Effective on April4, 2018, the Board of Directors of MyoKardia, Inc. (the \u0093Company\u0094) appointed Taylor Harris as the Company\u0092s chief\nfinancial officer. Prior to joining the Company and from April 2016 to April 2017, Mr.Harris, age 42, served as Senior Vice President and Chief\nFinancial Officer of Zeltiq Aesthetics, Inc., a public company that markets the CoolSculpting cryolipolysis procedure. During that time, he was responsible for the global finance, accounting, tax, treasury, investor relations, and information\ntechnology functions, as well as the company\u0092s commercial operations, including customer service, product support, and inside sales. Zeltiq was acquired by Allergan plc in April 2017. Prior to Zeltiq, Mr.Harris served as Vice President\nand Chief Financial Officer at Thoratec Corporation, a public company that develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients worldwide, from October\n2012 until October 2015, when the company was acquired by St. Jude Medical, Inc. Mr.Harris joined Thoratec as its Senior Director of Investor Relations and Business Development in February 2010, in which capacity he was responsible for\ndeveloping and executing the company\u0092s investor relations strategy, as well as supporting the company\u0092s strategic and business development activities. Prior to joining Thoratec, Mr.Harris worked at JPMorgan Chase& Co. for\nover a decade in several capacities, including as a Vice President in the firm\u0092s Healthcare Investment Banking and Equity Research departments. Mr.Harris holds a B.A. in physics and economics from the University of North Carolina at\nChapel Hill. There are no understandings or arrangements between Mr.Harris and any other person pursuant to which he was appointed as chief\nfinancial officer of the Company, and Mr.Harris has no material interest in any transaction or proposed transaction in which the Company is or is to be a party. Mr.Harris has no family relationship with any director or executive officer\nof the Company. The Company entered into an at-will employment offer letter agreement with Mr.Harris, dated\nMarch26, 2018 (the \u0093Employment Agreement\u0094), pursuant to which Mr.Harris would become employed as Chief Financial Officer of the Company. A copy of the Employment Agreement is filed as Exhibit 10.1 to this report on Form8-K. Effective on his start date of April4, 2018 (the \u0093Employment Start Date\u0094), in his position as Chief Financial Officer, Mr.Harris is entitled to receive an annual base salary of\n$415,000 and is eligible to receive an annual performance bonus, with a target bonus amount of 40% of his annual base salary. Mr.Harris\u0092 base salary is subject to adjustment pursuant to the Company\u0092s employee compensation policies in\neffect from time to time. Pursuant to the Employment Agreement, the Company agreed to grant Mr.Harris an option to purchase 100,000shares of\nthe Company\u0092s common stock under the Company\u0092s 2015 Stock Option and Incentive Plan (the \u0093Plan\u0094). 25% of the option shares will vest on the first anniversary of the Employment Start Date and the balance will vest in equal monthly\ninstallments over the next 36 months, subject to Mr.Harris\u0092 continued service to the Company through each vesting date. Also pursuant to the Employment Agreement, the Company agreed to grant Mr.Harris Restricted Stock Units\n(\u0093RSUs\u0094) for 15,000 shares of the Company\u0092s common stock under the Plan. 25% of the RSUs will vest on the first anniversary of the Employment Start Date and the balance will vest in equal annual installments over the next three years,\nsubject to Mr.Harris\u0092 continued service to the Company through each vesting date. In addition, Mr.Harris is eligible to participate in\nthe Company\u0092s Change in Control Policy as in effect from time to time. In accordance with the policy\u0092s terms, if Mr.Harris\u0092 employment is terminated without Cause (as defined in the Plan) within one year after the closing of a\nSale Event (as defined in the Plan), then, subject to his execution of a severance agreement and a general release of claims, Mr.Harris will receive the following benefits: (a)full acceleration of vesting of his outstanding equity awards\nunder the Plan (as set forth in the Plan); (b) a lump sum equal to twelve months of his then-current base salary; (c)a lump sum equal to his then-current target bonus; and (d)if he is participating in the Company group health plan\nimmediately prior to termination and elects COBRA, a monthly cash payment for twelve months equal to the Company\u0092s monthly premium contribution. \n\nThe foregoing summary of the Employment Agreement does not purport to be complete and is qualified in its\nentirety by reference to the complete Employment Agreement, which is attached as Exhibit 10.1 and incorporated herein by reference.  (b) \nOn April4, 2018, the Company\u0092s Board of Directors also appointed Mr.Harris as the Company\u0092s principal financial officer and principal\naccounting officer, replacing Jacob Bauer in these positions, and appointed Mr.Bauer as the Company\u0092s Chief Business Officer.  \n\n\nItem7.01\nRegulation FD Disclosure  On April4, 2018, the Company issued a press release announcing\nMr.Harris\u0092 appointment as chief financial officer of the Company. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K. \nThe information in this Item7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed \u0093filed\u0094 for purposes of\nSection18 of the Securities Exchange Act of 1934 (the \u0093Exchange Act\u0094) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the\nExchange Act, except as expressly set forth by specific reference in such filing.  \n\n\nThe foregoing summary of the Employment Agreement does not purport to be complete and is qualified in its\nentirety by reference to the complete Employment Agreement, which is attached as Exhibit 10.1 and incorporated herein by reference. (b) On April4, 2018, the Company\u0092s Board of Directors also appointed Mr.Harris as the Company\u0092s principal financial officer and principal\naccounting officer, replacing Jacob Bauer in these positions, and appointed Mr.Bauer as the Company\u0092s Chief Business Officer. On April4, 2018, the Company issued a press release announcing\nMr.Harris\u0092 appointment as chief financial officer of the Company. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K. The information in this Item7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed \u0093filed\u0094 for purposes of\nSection18 of the Securities Exchange Act of 1934 (the \u0093Exchange Act\u0094) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the\nExchange Act, except as expressly set forth by specific reference in such filing. ", "htmlOfReport": " <document>\n<type>8-K\n<sequence>1\n<filename>d562620d8k.htm\n<description>8-K\n<text>\n<html><head>\n<title>8-K</title>\n</head>\n<body bgcolor=\"WHITE\">\n<p style=\"line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000\">\u00a0</p>\n<p style=\"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000\">\u00a0</p> <p align=\"center\" style=\"margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b>UNITED STATES </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Washington, D.C. 20549 </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman\"><b><font style=\"white-space:nowrap\">FORM\u00a08-K</font> </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>CURRENT\nREPORT </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Pursuant to Section\u00a013 or 15(d) </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>of the Securities Exchange Act of 1934 </b></p>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman\"><b>Date of Report (Date of earliest event reported): April\u00a04, 2018 </b></p>\n<p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center> <p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman\"><b>MYOKARDIA, INC. </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>(Exact\nname of registrant as specified in its charter) </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt\" width=\"100%\">\n<tr>\n<td width=\"34%\"></td>\n<td valign=\"bottom\"></td>\n<td width=\"32%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"32%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td align=\"center\" valign=\"top\"><b>Delaware</b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"><b><font style=\"white-space:nowrap\">001-37609</font></b></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"><b><font style=\"white-space:nowrap\">44-5500552</font></b></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td align=\"center\" valign=\"top\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(State or other jurisdiction</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>of incorporation)</b></p></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Commission</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>File Number)</b></p></td>\n<td valign=\"bottom\">\u00a0</td>\n<td align=\"center\" valign=\"top\"> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(I.R.S. Employer</b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman\"><b>Identification No.)</b></p></td></tr>\n</table> <p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>333 Allerton Ave. </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>South San Francisco, CA 94080 </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Address of principal executive offices, including zip code) </b></p>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>(650) <font style=\"white-space:nowrap\">741-0900</font> </b></p>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Registrant\u0092s telephone number, including area code) </b></p>\n<p align=\"center\" style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Not Applicable </b></p> <p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman\"><b>(Former\nName or Former Address, if Changed Since Last Report) </b></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p><center>\n<p style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%\">\u00a0</p></center> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Check the appropriate box below\nif the <font style=\"white-space:nowrap\">Form\u00a08-K</font> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\">Written communications pursuant to Rule\u00a0425 under the Securities Act (17 CFR 230.425) </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\">Soliciting material pursuant to <font style=\"white-space:nowrap\">Rule\u00a014a-12</font> under the Exchange Act (17 CFR <font style=\"white-space:nowrap\">240.14a-12)</font> </td></tr></table>\n<p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\"><font style=\"white-space:nowrap\">Pre-commencement</font> communications pursuant to <font style=\"white-space:nowrap\">Rule\u00a014d-2(b)</font> under the Exchange Act (17 CFR\n<font style=\"white-space:nowrap\">240.14d-2(b))</font> </td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">\u2610</td>\n<td align=\"left\" valign=\"top\"><font style=\"white-space:nowrap\">Pre-commencement</font> communications pursuant to <font style=\"white-space:nowrap\">Rule\u00a013e-4(c)</font> under the Exchange Act (17 CFR\n<font style=\"white-space:nowrap\">240.13e-4(c))</font> </td></tr></table> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Indicate by check mark whether the registrant is an emerging growth company as\ndefined in Rule 405 of the Securities Act of 1933 (\u00a7\u00a0230.405 of this chapter) or Rule <font style=\"white-space:nowrap\">12b-2</font> of the Securities Exchange Act of 1934 <font style=\"white-space:nowrap\">(\u00a7\u00a0240.12b-2</font> of\nthis chapter). </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Emerging growth company\u00a0\u00a0\u2612 </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or\nrevised financial accounting standards provided pursuant to Section\u00a013(a) of the Exchange Act.\u00a0\u00a0\u2612 </p> <p style=\"font-size:10pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<p style=\"line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000\">\u00a0</p> <p style=\"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000\">\u00a0</p>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>Item\u00a05.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain\nOfficers; Compensatory Arrangements of Certain Officers. </b></p> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>(c)</b> </p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Effective on April\u00a04, 2018, the Board of Directors of MyoKardia, Inc. (the \u0093Company\u0094) appointed Taylor Harris as the Company\u0092s chief\nfinancial officer. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Prior to joining the Company and from April 2016 to April 2017, Mr.\u00a0Harris, age 42, served as Senior Vice President and Chief\nFinancial Officer of Zeltiq Aesthetics, Inc., a public company that markets the CoolSculpting cryolipolysis procedure. During that time, he was responsible for the global finance, accounting, tax, treasury, investor relations, and information\ntechnology functions, as well as the company\u0092s commercial operations, including customer service, product support, and inside sales. Zeltiq was acquired by Allergan plc in April 2017. Prior to Zeltiq, Mr.\u00a0Harris served as Vice President\nand Chief Financial Officer at Thoratec Corporation, a public company that develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients worldwide, from October\n2012 until October 2015, when the company was acquired by St. Jude Medical, Inc. Mr.\u00a0Harris joined Thoratec as its Senior Director of Investor Relations and Business Development in February 2010, in which capacity he was responsible for\ndeveloping and executing the company\u0092s investor relations strategy, as well as supporting the company\u0092s strategic and business development activities. Prior to joining Thoratec, Mr.\u00a0Harris worked at JPMorgan Chase\u00a0&amp; Co. for\nover a decade in several capacities, including as a Vice President in the firm\u0092s Healthcare Investment Banking and Equity Research departments. Mr.\u00a0Harris holds a B.A. in physics and economics from the University of North Carolina at\nChapel Hill. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">There are no understandings or arrangements between Mr.\u00a0Harris and any other person pursuant to which he was appointed as chief\nfinancial officer of the Company, and Mr.\u00a0Harris has no material interest in any transaction or proposed transaction in which the Company is or is to be a party. Mr.\u00a0Harris has no family relationship with any director or executive officer\nof the Company. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The Company entered into an <font style=\"white-space:nowrap\">at-will</font> employment offer letter agreement with Mr.\u00a0Harris, dated\nMarch\u00a026, 2018 (the \u0093Employment Agreement\u0094), pursuant to which Mr.\u00a0Harris would become employed as Chief Financial Officer of the Company. A copy of the Employment Agreement is filed as Exhibit 10.1 to this report on <font style=\"white-space:nowrap\">Form\u00a08-K.</font> Effective on his start date of April\u00a04, 2018 (the \u0093Employment Start Date\u0094), in his position as Chief Financial Officer, Mr.\u00a0Harris is entitled to receive an annual base salary of\n$415,000 and is eligible to receive an annual performance bonus, with a target bonus amount of 40% of his annual base salary. Mr.\u00a0Harris\u0092 base salary is subject to adjustment pursuant to the Company\u0092s employee compensation policies in\neffect from time to time. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Pursuant to the Employment Agreement, the Company agreed to grant Mr.\u00a0Harris an option to purchase 100,000\u00a0shares of\nthe Company\u0092s common stock under the Company\u0092s 2015 Stock Option and Incentive Plan (the \u0093Plan\u0094). 25% of the option shares will vest on the first anniversary of the Employment Start Date and the balance will vest in equal monthly\ninstallments over the next 36 months, subject to Mr.\u00a0Harris\u0092 continued service to the Company through each vesting date. Also pursuant to the Employment Agreement, the Company agreed to grant Mr.\u00a0Harris Restricted Stock Units\n(\u0093RSUs\u0094) for 15,000 shares of the Company\u0092s common stock under the Plan. 25% of the RSUs will vest on the first anniversary of the Employment Start Date and the balance will vest in equal annual installments over the next three years,\nsubject to Mr.\u00a0Harris\u0092 continued service to the Company through each vesting date. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">In addition, Mr.\u00a0Harris is eligible to participate in\nthe Company\u0092s Change in Control Policy as in effect from time to time. In accordance with the policy\u0092s terms, if Mr.\u00a0Harris\u0092 employment is terminated without Cause (as defined in the Plan) within one year after the closing of a\nSale Event (as defined in the Plan), then, subject to his execution of a severance agreement and a general release of claims, Mr.\u00a0Harris will receive the following benefits: (a)\u00a0full acceleration of vesting of his outstanding equity awards\nunder the Plan (as set forth in the Plan); (b) a lump sum equal to twelve months of his then-current base salary; (c)\u00a0a lump sum equal to his then-current target bonus; and (d)\u00a0if he is participating in the Company group health plan\nimmediately prior to termination and elects COBRA, a monthly cash payment for twelve months equal to the Company\u0092s monthly premium contribution. </p>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The foregoing summary of the Employment Agreement does not purport to be complete and is qualified in its\nentirety by reference to the complete Employment Agreement, which is attached as Exhibit 10.1 and incorporated herein by reference. </p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>(b) </b></p>\n<p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">On April\u00a04, 2018, the Company\u0092s Board of Directors also appointed Mr.\u00a0Harris as the Company\u0092s principal financial officer and principal\naccounting officer, replacing Jacob Bauer in these positions, and appointed Mr.\u00a0Bauer as the Company\u0092s Chief Business Officer. </p> <p style=\"font-size:18pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"12%\"><b>Item\u00a07.01</b></td>\n<td align=\"left\" valign=\"top\"><b>Regulation FD Disclosure </b></td></tr></table> <p style=\"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">On April\u00a04, 2018, the Company issued a press release announcing\nMr.\u00a0Harris\u0092 appointment as chief financial officer of the Company. A copy of this press release is furnished as Exhibit 99.1 to this report on Form <font style=\"white-space:nowrap\">8-K.</font> </p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">The information in this Item\u00a07.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed \u0093filed\u0094 for purposes of\nSection\u00a018 of the Securities Exchange Act of 1934 (the \u0093Exchange Act\u0094) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the\nExchange Act, except as expressly set forth by specific reference in such filing. </p> <p style=\"font-size:18pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"12%\"><b>Item\u00a09.01</b></td>\n<td align=\"left\" valign=\"top\"><b>Financial Statements and Exhibits </b></td></tr></table> <p style=\"font-size:6pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr style=\"page-break-inside:avoid\">\n<td align=\"left\" valign=\"top\" width=\"4%\">(d)</td>\n<td align=\"left\" valign=\"top\">Exhibits. </td></tr></table> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table align=\"center\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td></td>\n<td valign=\"bottom\" width=\"5%\"></td>\n<td width=\"92%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td align=\"center\" nowrap=\"\" style=\"border-bottom:1.00pt solid #000000\" valign=\"bottom\"><b>Exhibit</b><br/><b>No.</b></td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td nowrap=\"\" valign=\"bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; \"><b>Description</b></p></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">10.1</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\"><a Letter by and between MyoKardia, Inc. and Taylor Harris, dated March\u00a026, 2018 </a></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"8\"></td>\n<td colspan=\"2\" height=\"8\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td nowrap=\"\" valign=\"top\">99.1</td>\n<td valign=\"bottom\">\u00a0\u00a0</td>\n<td valign=\"top\"><a Release issued by MyoKardia, Inc. on April\u00a04, 2018, furnished herewith </a></td></tr>\n</table>\n<p style=\"page-break-before:always\">\n<hr align=\"CENTER\" size=\"3\" style=\"COLOR:#999999\" width=\"100%\"/>\n<p align=\"center\" style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\"><b>SIGNATURES </b></p>\n<p style=\"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman\">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized. </p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">\u00a0</p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt\" width=\"100%\">\n<tr>\n<td width=\"46%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"4%\"></td>\n<td valign=\"bottom\"></td>\n<td width=\"2%\"></td>\n<td valign=\"bottom\" width=\"1%\"></td>\n<td width=\"45%\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\">Date: April\u00a04, 2018</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td colspan=\"3\" valign=\"bottom\"><b>MyoKardia, Inc.</b></td></tr>\n<tr style=\"font-size:1pt\">\n<td height=\"16\"></td>\n<td colspan=\"2\" height=\"16\"></td>\n<td colspan=\"2\" height=\"16\"></td>\n<td colspan=\"2\" height=\"16\"></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"top\">By:</td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"> <p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ Cynthia Ladd</p></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">Cynthia Ladd</td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td valign=\"top\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\"></td>\n<td valign=\"bottom\">\u00a0</td>\n<td valign=\"bottom\">General Counsel</td></tr>\n</table>\n</p></p></p></body></html>\n</text>\n</description></filename></sequence></type></document>\n"}, "companyProfile": "MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.", "stockSymbol": "MYOK", "float": "33.6M", "instOwn": "89.66%", "shortFloat": "9.61%", "sharesOutstanding": "40115401", "going concern": false, "companyAddress": "SOUTH SAN FRANCISCO 650-741-0900 CA 333 ALLERTON AVENUE 94080"}